

Annual Report 年報 2024



天大藥業有限公司

TIANDA PHARMACEUTICALS LIMITED

股份代號 Stock Code: 00455 (於開曼群島註冊成立之公司)
(Incorporated in the Cayman Islands with limited liability)

CONTENTS

目錄

2	Corporate Information	公司資料
5	Corporate Structure	企業架構
8	Biographical Details of Directors	董事簡歷
11	Report of the Chairman	董事長報告
13	Management Discussion and Analysis	管理層討論與分析
22	Corporate Governance Report	企業管治報告
44	Report of the Directors	董事會報告
57	Independent Auditor's Report	獨立核數師報告
64	Consolidated Statement of Profit or Loss and Other Comprehensive Income	綜合損益及其它全面收益表
66	Consolidated Statement of Financial Position	綜合財務狀況表
68	Consolidated Statement of Changes in Equity	綜合權益變動表
69	Consolidated Statement of Cash Flows	綜合現金流量表
71	Notes to the Consolidated Financial Statements	綜合財務報表附註
176	Financial Summary	財務摘要

CORPORATE INFORMATION

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. Fang Wen Quan
(Chairman and Managing Director)
Mr. Lui Man Sang

Non-Executive Directors

Mr. Feng Quanming
Mr. Zhong Tao

Independent Non-Executive Directors

Mr. Lam Yat Fai
Mr. Chiu Sung Hong
Dr. Xian Yanfang

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27th Floor, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

HONG KONG LEGAL ADVISER

Woo, Kwan, Lee & Lo
25th Floor, Jardine House
1 Connaught Place, Central
Hong Kong

COMPANY SECRETARY

Mr. Lo Tai On

董事會

執行董事

方文權先生
(董事長兼董事總經理)
呂文生先生

非執行董事

馮全明先生
鍾濤先生

獨立非執行董事

林日輝先生
趙崇康先生
冼彥芳博士

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

香港法律顧問

胡關李羅律師行
香港
中環康樂廣場1號
怡和大廈25樓

公司秘書

羅泰安先生

CORPORATE INFORMATION

公司資料

AUDIT COMMITTEE

Mr. Lam Yat Fai (*Chairman*)
Mr. Chiu Sung Hong
Dr. Xian Yanfang
Mr. Zhong Tao

REMUNERATION COMMITTEE

Mr. Chiu Sung Hong (*Chairman*)
Mr. Fang Wen Quan
Mr. Lam Yat Fai
Dr. Xian Yanfang

NOMINATION COMMITTEE

Mr. Fang Wen Quan (*Chairman*)
Mr. Lam Yat Fai
Mr. Chiu Sung Hong

RISK MANAGEMENT COMMITTEE

Mr. Chiu Sung Hong (*Chairman*)
Mr. Fang Wen Quan
Mr. Lam Yat Fai

PRINCIPAL BANKERS

Agricultural Bank of China
Bank of China
Bank of Communications
China Citic Bank
China Merchants Bank
Industrial and Commercial Bank of China

REGISTERED OFFICE

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman
KY1-1111
Cayman Islands

審核委員會

林日輝先生 (*主席*)
趙崇康先生
冼彥芳博士
鍾濤先生

薪酬委員會

趙崇康先生 (*主席*)
方文權先生
林日輝先生
冼彥芳博士

提名委員會

方文權先生 (*主席*)
林日輝先生
趙崇康先生

風險管理委員會

趙崇康先生 (*主席*)
方文權先生
林日輝先生

主要往來銀行

中國農業銀行
中國銀行
交通銀行
中信銀行
招商銀行
中國工商銀行

註冊辦事處

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman
KY1-1111
Cayman Islands

CORPORATE INFORMATION

公司資料

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS

Suites 2405-2410, 24th Floor
CITIC Tower
No. 1 Tim Mei Avenue
Central
Hong Kong

HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Secretaries Limited
17/F,
Far East Finance Centre
16 Harcourt Road
Hong Kong

PLACE OF LISTING

The Stock Exchange of Hong Kong Limited

STOCK CODE

00455

CORPORATE WEBSITE

www.tiandapharma.com

總辦事處及主要營業地點

香港
中環
添美道1號
中信大廈
24樓2405-2410室

香港股份過戶及轉讓登記處

卓佳秘書商務有限公司
香港
夏慤道16號
遠東金融中心
17樓

上市地點

香港聯合交易所有限公司

股份代號

00455

公司網站

www.tiandapharma.com

以下為天大藥業有限公司(本公司)及其附屬公司(本集團)於2024年12月31日之架構圖:



- (1) Incorporated in Australia with limited liability
於澳大利亞註冊成立之有限公司
- (2) Incorporated in the British Virgin Islands with limited liability
於英屬維爾京群島註冊成立之有限公司
- (3) Incorporated in Hong Kong with limited liability
於香港註冊成立之有限公司
- (4) Incorporated in Macau with limited liability
於澳門註冊成立之有限公司
- (5) Incorporated in the PRC with limited liability
於中國註冊成立之有限公司

* For identification purpose only
* 僅供識別

您的健康是天大的事! Tianda for Health!

Award & Certificate 獎項與證書

Tianda Pharmaceuticals was awarded the status of Happy Company under the “Happiness-at-Work Promotional Scheme” by the Promoting Happiness Index Foundation. 天大藥業獲香港提升快樂指數基金嘉許為「開心工作間」計劃下之開心企業。



HAPPY 開心企業
COMPANY



Tianda Pharmaceuticals was awarded the “Caring Company” logo by the Hong Kong Council of Social Service for the fourth consecutive year. 天大藥業連續第四年獲香港社會服務聯會頒發的「商界展關懷」嘉許標誌。

Tianda Pharmaceutical (Zhuhai) Ltd was awarded the “Caring Enterprise in Biomedical Charity” awards. 天大藥業(珠海)有限公司榮獲「珠海市生物醫藥公益事業愛心企業」殊榮。



Tianda Pharmaceuticals (Yunnan) Ltd has been granted the drug registration approval of “Nicorandil for Injection” by the National Medical Products Administration of the People's Republic of China. 天大藥業(雲南)有限公司獲得中華人民共和國國家藥品監督管理局簽發的關於「注射用尼可地爾」的藥品註冊證書。

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. has been granted the drug registration approval of “Ibuprofen suspension” by the National Medical Products Administration of the People's Republic of China. 天大醫藥科技(珠海)有限公司獲得中華人民共和國國家藥品監督管理局簽發的關於「布洛芬混懸液」的藥品註冊證書。

Our Products 公司產品



R&D and Production Base 研發及生產基地



New R&D and Production Base (Jinwan District, Zhuhai) 新研發及製藥基地 (珠海金灣)



R&D and Production Base (Kunming, China) 研發及製藥基地 (昆明)

Chinese Medicine Clinic 新型中醫館



Zhuhai TDMall 珠海天大館



TDMall (Jordan) 天大館 (佐敦)



TDMall (Causeway Bay) 天大館 (銅鑼灣)



TDMall (Sydney) 悉尼天大館



Shenzhen TDMall 深圳天大館

BIOGRAPHICAL DETAILS OF DIRECTORS

董事簡歷

Mr. FANG Wen Quan, aged 55, has been appointed as an Executive Director since 6 October 2003. He is currently Chairman, Managing Director, chairman of the nomination committee and a member of the remuneration committee and the risk management committee of the Company, and a director of the Group's certain subsidiaries. Mr. Fang is the founder, chairman and beneficial owner of Tianda Group Limited (Tianda Group) (the controlling shareholder of the Company holding 56.72% equity interest in the Company). Mr. Fang is the chairman of the board of directors, general manager and authorized representative of Tianda Culture Holdings (China) Limited* (listed on the National Equities Exchange and Quotations, company code: 837889, and delisted on 3 April 2024). Mr. Fang studied International Relations at the University of Sydney and Tsinghua University. He has ample experience in corporate strategy and management. He also established a non-profit strategic studies think tank named "Tianda Institute". With the mission of "Caring for a Better World", Mr. Fang has all along provided financial support to communities in need, including donations to the poor, education and talent development, medical and healthcare, scientific research and environmental protection, culture and arts, and so on.

Mr. LUI Man Sang, aged 60, has been appointed as an Executive Director of the Company since 30 September 2013 and is a director of the Group's certain subsidiaries. Mr. Lui joined Tianda Group, the controlling shareholder of the Company in 2007 and is the deputy general manager of Tianda Group. He is responsible for the financial management of Tianda Group and the Company. Mr. Lui is a director of Tianda Culture Holdings (China) Limited* (listed on the National Equities Exchange and Quotations, company code: 837889, and delisted on 3 April 2024). Mr. Lui possesses enriched financial management experience covering a variety of industries including auditing in one of the big four accounting firms in Hong Kong and overseeing the finance department of a Hong Kong listed company. He holds an Executive MBA granted by City University of Hong Kong. He is a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants.

方文權先生，55歲，自2003年10月6日起獲委任為執行董事。方先生現任本公司董事長、董事總經理、提名委員會主席、薪酬委員會及風險管理委員會成員，以及本集團若干附屬公司之董事。方先生乃天大集團有限公司（天大集團）（本公司之控股股東，持有本公司56.72%股權）創始人、董事長及實益擁有人。方先生乃天大文化控股（中國）股份有限公司（在全國中小企業股份轉讓系統掛牌，公司代號：837889，及於2024年4月3日退市）董事長、總經理及法定代表人。方先生先後於悉尼大學和清華大學學習國際關係專業，彼具有豐富企業戰略及管理方面之經驗，並創辦了公益性戰略研究智庫「天大研究院」。一直以來，方先生秉承「關心社會，共同發展」的使命，熱誠資助社會公益事業，包括捐助扶貧、教育和人才發展、醫療衛生、科學研究和環境保護、文化藝術等。

呂文生先生，60歲，自2013年9月30日起獲委任為本公司之執行董事，以及為本集團若干附屬公司之董事。呂先生於2007年加入本公司控股股東天大集團，現為天大集團副總經理，全面負責天大集團及本公司的財務管理。呂先生亦為天大文化控股（中國）股份有限公司（在全國中小企股份轉讓系統掛牌，股份代號：837889，及於2024年4月3日退市）之董事。呂先生擁有豐富財務管理經驗，涵蓋不同行業，當中曾在香港四大會計師事務所之一擔任審核工作以及管理一間香港上市公司的財務部門。呂先生持有香港城市大學行政人員工商管理碩士學位，目前為英國特許公認會計師公會及香港會計師公會資深會員。

* For identification purpose only

* 僅供參考

BIOGRAPHICAL DETAILS OF DIRECTORS

董事簡歷

Mr. ZHONG Tao, aged 52, has been appointed as a Non-executive Director and a member of the audit committee of the Company since 29 August 2023. He is the vice president, board secretary and joint company secretary of Shanghai Pharmaceuticals Holding Co., Ltd. (a company listed on the Shanghai Stock Exchange with stock code 601607, and The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange") with stock code 02607, which holds 13.05% equity interest in the Company). Mr. Zhong previously served as an executive director and a vice president of Shanghai Industrial Urban Development Group Limited (a company listed on Hong Kong Stock Exchange with stock code 00563); and held several management positions in other companies including Shanghai Industrial Management (Shanghai) Company Limited., Shanghai Galaxy Digital Investment Company Limited., and Shanghai Industrial Real Property Group (Shanghai) Company Limited. etc. Mr. Zhong holds a master's degree in Business Management from Fudan University.

Mr. FENG Quanming, aged 48, has been appointed as a Non-executive Director since 23 March 2016. Mr. Feng is the deputy general manager of Hongta Tobacco (Group) Limited (Hongta), which holds 9.66% equity interest in the Company. He has extensive experience in corporate financial accounting and asset management. Mr. Feng joined Hongta in July 2001. During the period from August 2007 to January 2022, he took various positions in the finance department of Hongta, including deputy head of industrial finance division, head and deputy head of asset management division, head of general management division and head of the finance department. He was also the head of financial planning division of Yunnan Hongta Group Co., Ltd*, a wholly-owned subsidiary of Hongta, during the period from June 2013 to August 2014. Mr. Feng obtained his bachelor degree in accounting at Southwestern University of Finance and Economics in 2001 and master in business administration at Renmin University of China in 2009. Mr. Feng possesses the qualification of practising certified public accountant in mainland China.

Mr. LAM Yat Fai, aged 59, has been appointed as an Independent Non-executive Director, a member of the remuneration committee and a member of audit committee of the Company since 2004. On 26 November 2013, he was appointed as the chairman of the audit committee. He was appointed as a member of nomination committee and risk management committee on 22 July 2009. He is a Certified Public Accountant (Practising). He is also a fellow member of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. Mr. Lam has accumulated rich experience in auditing, taxation, corporate finance and accounting over the years. Mr. Lam is an independent non-executive director of Oriental Enterprise Holdings Limited (stock code: 0018), which is listed on the Main Board of the Hong Kong Stock Exchange.

鍾濤先生，52歲，自2023年8月29日起獲委任為本公司之非執行董事及審核委員會成員。彼為上海醫藥集團股份有限公司（一家於上海證券交易所（股份代號：601607）及香港聯合交易所有限公司（「香港聯交所」，股份代號：02607）上市的公司，其持有本公司的13.05%權益）副總裁、董事會秘書及聯席公司秘書。鍾先生曾任上海實業城市開發集團有限公司（一家於香港聯交所上市的公司（股份代號：00563））執行董事及副總裁，並曾於上實管理（上海）有限公司、上海星河數碼投資有限公司及上實置業集團（上海）有限公司等公司擔任不同管理職位。鍾先生持有復旦大學企業管理碩士學位。

馮全明先生，48歲，自2016年3月23日起獲委任為非執行董事。馮先生現任紅塔煙草（集團）有限責任公司（紅塔，持有本公司9.66%股權之股東）副總經理。彼於企業財務會計和資產管理擁有豐富的工作經驗。馮先生於2001年7月加入紅塔，並曾於2007年8月至2022年1月期間於紅塔財務部擔任多個職位，包括工業財務科副科長、資產管理科副科長、資產管理科科長、綜合管理科科長和財務部部長，以及於2013年6月至2014年8月，擔任紅塔全資子公司雲南紅塔集團有限公司財務部計劃財務科科長。馮先生於2001年獲西南財經大學會計學學士學位，以及於2009年獲中國人民大學工商管理學碩士學位。馮先生具備中國註冊會計師執業資格。

林日輝先生，59歲，自2004年起獲委任為本公司之獨立非執行董事、薪酬委員會成員及審核委員會成員。彼於2013年11月26日獲委任為審核委員會主席。彼於2009年7月22日獲委任為提名委員會及風險管理委員會成員。彼現為執業會計師，亦為香港會計師公會及英國特許公認會計師公會資深會員。林先生於審計、稅務、企業融資及會計等方面累積多年經驗。林先生為香港聯交所主板上市之東方企控集團有限公司（股份代號：0018）之獨立非執行董事。

* For identification purpose only

* 僅供參考

BIOGRAPHICAL DETAILS OF DIRECTORS

董事簡歷

Mr. CHIU Sung Hong, aged 77, was appointed as an Independent Non-executive Director, the chairman of the audit committee of the Company with effect from 10 April 2008. Mr. Chiu ceased to act as the chairman of the audit committee and remained as a member of the committee on 26 November 2013. Mr. Chiu was appointed as the chairman of risk management committee on 22 July 2009. On 1 April 2012, he was appointed as the chairman of the remuneration committee and a member of the nomination committee. He received an LL.B. degree from the University of Sydney. He was admitted as a solicitor of the Supreme Court of New South Wales and the High Court of Australia. He has over 40 years of experience in legal practice. Mr. Chiu is the founding member of the Board of Trustees of the Australian Nursing Home Foundation and a senior research fellow of Centre for Law & Globalization of Renmin University of China. He also served as the General Secretary of Australian Chinese Community Association of New South Wales. Mr. Chiu is an independent non-executive director of CNOOC Limited (a company listed on the Shanghai Stock Exchange with stock code 600938, and Hong Kong Stock Exchange with stock code 0883), which is listed on the Main Board of the Hong Kong Stock Exchange and Bank of China (Australia) Limited.

Dr. XIAN Yanfang, aged 43, has been appointed as an Independent Non-executive Director and a member of the audit committee and remuneration committee of the Company since 27 June 2023. Dr. Xian is an assistant professor of School of Chinese Medicine, The Chinese University of Hong Kong. She has extensive research experience in the field of pharmacology of Chinese medicines, herb-drug interactions of Chinese and western medicines and quality control of Chinese medicines. Dr. Xian is currently a project review expert of National Natural Science Foundation of China, the general secretary of Hong Kong Association of Chinese Herbal Pharmacology, a member of technical support team in Pharmacology and Toxicology of The Hong Kong Government Chinese Medicines Testing Institute, the committee member of Deficiency Syndrome and Geriatrics Professional Committee of China Association of Integrative Medicine, and a member of Branch of Integrative Traditional Chinese and Western Medicine of the China Association of Gerontology and Geriatrics. Dr. Xian holds a Ph. D degree in Chinese Medicine from The Chinese University of Hong Kong, and a master's degree and a bachelor's degree in Science of Chinese Materia Medica from Guangzhou University of Chinese Medicine.

趙崇康先生，77歲，於2008年4月10日獲委任為本公司之獨立非執行董事及審核委員會主席。趙先生於2013年11月26日不再擔任審核委員會主席，惟仍留任該委員會之成員。趙先生於2009年7月22日獲委任為風險管理委員會主席。於2012年4月1日，彼獲委任為薪酬委員會主席及提名委員會成員。趙先生擁有悉尼大學法學學士學位，曾擔任澳大利亞新南威爾斯高等法院律師和澳大利亞高等法院律師。趙先生在法律行業累積逾40年經驗。趙先生乃澳華療養院基金信託委員會創始會員及中國人民大學法律與全球化研究中心高級研究員。彼亦曾擔任澳大利亞新南威爾斯中國社區協會秘書長。趙先生現為於香港聯交所主板上市之中國海洋石油有限公司（一家於上海證券交易所（股份代號：600938）及香港聯交所（股份代號：0883）上市的公司）之獨立非執行董事及中國銀行（澳大利亞）有限公司之獨立非執行董事。

冼彥芳博士，43歲，自2023年6月27日起獲委任為本公司之獨立非執行董事、審核委員會及薪酬委員會成員。冼博士現任香港中文大學中醫學院助理教授。冼博士在中藥藥理學、中西草藥相互作用和中藥質量控制領域擁有豐富研究經驗。冼博士現任國家自然科學基金項目評審專家、香港中藥藥理學會秘書長、香港政府中藥檢測中心諮詢委員會技術支援小組藥理及毒理學成員、中國中西醫結合學會虛證與老年醫學專業委員會委員、及中國老年學和老年醫學學會中西醫結合分會委員。冼博士持有香港中文大學中醫哲學博士學位，及廣州中醫藥大學中藥學碩士學位及學士學位。

Note: The Group's businesses are under the direct responsibility of the above executive directors who are the senior management of the Company.

附註：本集團之業務由上述執行董事（即本公司的高級管理人員）直接負責。

REPORT OF THE CHAIRMAN

董事長報告

In 2024, global economic uncertainty increased, and the market environment of China's pharmaceutical industry remained unfavorable. This was due to multiple factors, including shrinking market demand following the pandemic, stricter control and supervision of medical insurance, anti-corruption measures in centralized procurement, and intensified industry involution. The pharmaceutical market exhibited characteristics of "overall pressure with partial differentiation". In particular, respiratory infection and antihypertensive drugs struggled to grow in 2024, as hospitals, pharmacies, and households all focused on clearing inventories stocked up during the pandemic. Despite these challenges, the Group remains committed in advancing the "Three Developments" strategy (development of Chinese medicine business as foundation, development of innovative drugs and medical technologies, as well as the development of quality medical and healthcare services). The Group aims to consolidate core products, enrich its pipelines, expand sales channels, and further develop the traditional Chinese medicine ("TCM") industry chain. The Group actively adapts to market changes, aligns with national policies promoting drug innovation, and continues to invest in research and development ("R&D"), which is expected to yield fruitful results with new product launches, aiming to create new profit growth drivers and striving to find opportunities amidst adversity.

The Group's pharmaceutical production and R&D focuses primarily on cardiovascular and cerebrovascular chronic diseases, respiratory infections, and pediatric diseases, which developed rapidly after the pandemic, by continuously strengthening the construction of an integrated pharmaceutical industrial chain that combines TCM and western medicines, and synergizes bulk drugs and preparations. By increasing innovation, the Group is upgrading its product pipelines, with three new products expected to launch in 2025. In the future, the Group will continue to increase the R&D, introduction, and acquisition of innovative drugs, specialized varieties, and consumer healthcare products with synergistic effects. It will enhance its business layout across multiple product pipelines, business models, terminals, and channels, with a focus on exploring the county-level grassroots markets and online and offline markets outside the hospital. Meanwhile, leveraging its production capacity and R&D advantages, the Group's CDMO/CMO business also recorded rapid growth. Not only has the number of customers continued to rise, but revenue has more than doubled compared to the Previous Financial Period, providing new momentum for current revenue and profit growth.

For the Chinese medicine business segment, leveraging on the established TCM industrial chain build-up, the Group focused on domestic and overseas trading of Chinese medicinal materials, production and sales, and distribution of TCM decoction pieces. During the year, the business was affected by the domestic and international economic environment, leading to a decline in demand of end-users.

2024 年全球經濟不確定性加劇，中國醫藥產業市場環境不佳，受到疫情後市場需求萎縮、醫保稽查管控趨嚴、集采反腐及行業內卷加劇等多重影響，醫藥市場呈現「整體承壓 局部分化」的特徵，尤其是呼吸感染及降壓類藥物在2024年無論醫院藥店還是百姓家中全部都在清理疫情期備貨導致增長乏力，儘管如此，本集團仍堅定推進「三個發展戰略」（以發展中醫藥產業為基礎，發展創新藥物和醫療科技，發展優質醫療和保健服務），鞏固核心產品、豐富管線、拓展銷售管道及深化中醫藥產業鏈佈局。本集團積極應對市場變化，順應國家加大藥物創新扶持政策，持續投入研發即將迎來收穫期，新產品將密集上市，為後續發展創造新的利潤增長點，力求在逆境中尋找機遇。

本集團藥物生產及研發主要聚焦於疫情後快速發展的心腦血管慢病領域、呼吸感染及兒科領域，不斷強化中藥西藥並舉及原料製劑協同的醫藥產業鏈建設，不斷加大創新推動產品管線升級，2025年預計將有三個新品種上市，未來將持續加大研發、引進、併購具有協同效應的創新藥、特色專科品種和消費醫療產品，加大多產線、多業態、多終端、多管道的產業佈局，尤其重視縣區基層市場及院外線上線下市場開拓力度。同時，自身的產能及研發優勢推動了本集團CDMO/CMO業務獲得快速增長，不僅客戶數持續增加，而且收入規模較上一個財政期間增長逾一倍，為目前應收及利潤增長提供新的動能。

本集團中醫藥業務板塊依託已形成的全產業鏈佈局，重點發展中藥材國內外貿易、中藥飲片生產、銷售及配送等，本年業務受累於國內外經濟環境影響，導致終端需求下降。2025年本集團將在強化品種開發、豐富品種供應、加大市場開拓的同時

REPORT OF THE CHAIRMAN

董事長報告

In 2025, while strengthening variety development, enriching variety supply and expanding market reach, the Group will emphasize on the implementation of decoction pieces large varieties, actively align with the nation's policies on centralized procurement for decoction pieces by establishing supply bases, and respond to nation's push in supporting the development of TCM clinics by creating a supply reserve for commonly used and essential decoction pieces for TCM clinics. Furthermore, it will continue to enhance the development and management of fine and precious medicinal materials, improve its TCM health products series, fully leveraging the advantages and diverse values of TCM to realize the leapfrog development of the Chinese medicine business.

For the Medical and healthcare business segment, the Group achieved steady growth. The Group's sixth TDMall in the world and fifth TDMall in the Guangdong-Hong Kong-Macao Greater Bay Area – Jordan TDMall was opened in Hong Kong in October 2024, with the introduction of a renowned medical expert as shareholder. The Group is planning to establish it as the oncology treatment center with the aim to build up an operating model of a chain of conglomerate Chinese medicine clinics.

As the economy gradually recovers and national policies supporting the pharmaceutical industry continue to increase and improve, the future market demand will gradually improve. The Group will remain committed to building core brands of innovative drugs and medical technologies, increasing the introduction of specialized varieties, and focusing on a market-oriented, patient-centered approach to optimize the big health industry. Meanwhile, the Group will leverage the opportunities arising from favorable TCM policies to advance the high-quality development of the Chinese medicine business and promote a collaborative development model of "drugs + medical services".

Finally, I would like to express sincere gratitude to the shareholders, customers, employees, and business partners for their years of support, contributions, and trust and would like to extend my appreciation to the members of the Board for their efforts and dedication to the development of the Group.

Fang Wen Quan
Chairman

Hong Kong, 28 March 2025

著重實施飲片大品種群戰略，積極順應國家飲片集採建立集采飲片供應基地，積極回應國家大力扶持中醫館發展的政策建立中醫館常用必備飲片供給庫，並持續加大貴細藥材品種開發經營，完善中醫藥健康產品系列，充分發揮中醫藥特色優勢和多元價值，推動中醫藥業務更好實現跨越式發展。

本集團醫療和保健業務板塊獲得穩健增長，2024年10月份投資的全球第六家、粵港澳大灣區第五家天大館——佐敦天大館，引入名醫專家作為股東，於香港開業，籌劃建立成為腫瘤治療中心，這將持續打造連鎖中醫館集團化經營模式。

隨著經濟的逐步恢復和國家醫藥產業配套及扶持政策不斷完善，相信未來市場需求將逐漸好轉。本集團將繼續致力於打造創新藥物和醫療科技的核心品牌，加大特色專科品種引進，注重以市場為導向以患者為中心完善大健康產業佈局。同時，把握中醫藥政策紅利搶抓機遇期，推動中醫藥業務的高品質發展，推動「藥物+醫療服務」的協同發展模式。

最後，謹此感謝股東、客戶、員工及業務合作夥伴多年來的支援、貢獻及信任，以及董事會成員為本集團發展所做的努力和付出。

方文權
董事長

香港，2025年3月28日

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

BUSINESS REVIEW

In 2024, through a series of measures such as consolidating core products, enriching product pipeline, expanding sales channels and further developing the TCM industrial chain, the Group continued to improve the operation management in its three major business segments: pharmaceuticals and medical technologies, Chinese medicine and medical and healthcare services.

As the aftershocks of the pandemic subsided and the demand for medicines returned to normal, the demand for the "Four Types of Medicines" (antipyretic, cough suppressant, antibiotic and antiviral) dropped sharply, and there was a significant drop in the demand for the Group's pediatric drugs, Tuoen®Ibuprofen. Nonetheless, the Tuoen still ranked the second in Mainland China in terms of market share. During the renewal of the bidding of the centralized procurement of the Group's cardio-cerebrovascular drug, Tuoping®Valsartan capsules, in Jiangsu Province of the PRC, due to the adoption of the strategy of lower pricing by competing bidders, the sales volume of Tuoping for the Year was affected. The Group's revenue declined significantly for the Year, resulting in a remarkable increase in losses. Overall revenue for the Year amounted to HK\$329.9 million (year ended 31 December 2023 (the "Previous Financial Year"): HK\$532.1 million). Loss attributable to shareholders of the Company increased from HK\$24.2 million in the Previous Financial Year to HK\$61.4 million in the Year.

The pharmaceuticals and medical technologies business remaining stable, and the CDMO/CMO business growing rapidly

The pharmaceuticals and medical technologies business reported a weaker-than-expected revenue of HK\$283.9 million for the Year (Previous Financial Year: HK\$470.7 million), due to the impact of the fading of aftershocks of the pandemic, shrinking demand and overcapacity in the industry as well as the policies on centralized procurement. The Group is deeply engaged in the fields of cardiovascular, cerebrovascular and pediatric diseases with two leading products being launched: Tuoping®Valsartan capsules for cardio-cerebrovascular disease and pediatric drugs Tuoen®Ibuprofen series. In 2024, the incidence of respiratory diseases, including influenza, was lower than that in previous years, and there were overcapacity and pipeline backlogs in the industry for pandemic-related Four Types of Medicines, leading to a prolonged destocking cycle. As a result, the pediatric drug Tuoen®Ibuprofen recorded a sales revenue of HK\$52.7 million for the Year (Previous Financial Year: HK\$170.4 million), however, it remained the second position in market share in

業務回顧

2024年，本集團通過鞏固核心產品、豐富產品管線、拓展銷售管道，及深化中醫藥產業鏈佈局等系列措施，不斷提升藥物和醫療科技、中醫藥、醫療和保健服務三大業務板塊的經營管理。

受累後疫情餘波消失，用藥需求回歸正常，人們對於「四類藥」（退熱、止咳、抗生素、抗病毒藥）的需求急劇下降，本集團兒科用藥托恩®布洛芬的需求大幅度下滑。惟市場份額仍位列中國內地第二。本集團心腦血管用藥托平®缬沙坦膠囊在中國江蘇省的集採續標中，由於競品採取了更低的價格策略，影響了「托平」本年度的銷售量。本集團於本年度收入明顯下降，致虧損顯著擴大。本年度錄得整體收入3億2,990萬港元（截至2023年12月31日止年度（「上財政年度」）：5億3,210萬港元）。本公司股東應佔虧損由上財政年度的2,420萬港元增加至本年度的6,140萬港元。

藥物和醫療科技業務穩中求勝 CDMO/CMO業務快速增長

受到後疫情餘波消失、需求萎縮迭加行業產能過剩，以及集採政策因素影響，藥物和醫療科技業務本年度不及預期，錄得收入2億8,390萬港元（上財政年度：4億7,070萬港元）。本集團深耕心腦血管及兒科等疾病領域，打造了兩個拳頭產品：心腦血管用藥托平®缬沙坦膠囊及兒科用藥托恩®布洛芬系列。2024年包括流感疫情在內的呼吸道疾病發病率比往年偏低，與疫情相關的四類藥出現行業產能過剩、管道積壓的狀況，面臨較長的去庫存週期，受此影響，兒科用藥托恩®布洛芬於本年度錄得5,270萬港元銷售收入（上財政年度：1億7,040萬港元），但市場份額仍位列中國內地第二。心腦血管用藥托平®缬沙坦膠囊進入省級集採續標階段，銷量比往年有所下

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Mainland China. As the cardio-cerebrovascular drug Tuoping®Valsartan capsules was in the process of the renewal of the bidding for the provincial centralized procurement, the sales volume decreased as compared to previous years. However, it has maintained its position as the best-selling product of the similar variety in the Mainland China market in the Year, recording a sales revenue of HK\$140.0 million for the Year (Previous Financial Year: HK\$186.8 million).

Since three fully automated production lines in the new liquid-finished dosages workshop of Zhuhai Jinwan R&D and production base were put into operation in 2024, the production capacity of chemical pharmaceutical liquid preparations has been increased by three times, with a reduction of packaging personnel by two-thirds, and a significant improvement in production efficiency, thus effectively mitigating quality issues caused by human errors, which has totally resolved the problem on capacity shortage of the Group's chemical pharmaceutical liquid products, and has greatly shortened the trial production period for new liquid preparations R&D. In the meantime, we are also negotiating to utilize our surplus production capacity to undertake the production of some CDMO/CMO products.

The Group's CDMO/CMO business also recorded a rapid growth, with the revenue more than doubling as compared to that in the Previous Financial Year. By the end of 2024, the number of the Group's CDMO projects for pharmaceuticals and health products on hand was 23 (as at the end of 2023: 15).

Further development of the Chinese medicine segment with cooperation among industries, universities, research institutes and medical practitioners

For the Chinese medicine business, leveraging its comprehensive industrial chain for traditional Chinese medicine, the Group has focused on the development of domestic and foreign trading of Chinese medicinal materials, Chinese medicinal decoction pieces and innovative Chinese medicines R&D, continuing to integrate special resources in the industry's upstream and downstream segments with a focus on variety management. During the Year, as business partners in the Chinese medicine segment were under the pressure in the business environment, the Group adopted a more stringent and prudent credit policy in the trading business. Revenue of this segment decreased during the Year, amounting to HK\$27.1 million (Previous Financial Year: HK\$48.4 million).

滑，本年度仍維持在中國內地市場同類產品中銷量第一，於本年度內錄得1億4,000萬港元銷售收入（上財政年度：1億8,680萬港元）。

本集團自從2024年實施珠海金灣研發及生產基地新液體車間3條全自動生產線全部投產，化學藥液體製劑產能提升3倍，外包裝人員減少三分之二，生產效率有明顯增加，人為差錯品質問題得到有效控制，全面解決了本集團化學藥液體產品原產能不足問題，極大縮短研發液體製劑新產品試產進度，同時也在洽談利用盈餘產能承接一些CDMO/CMO產品。

本集團CDMO/CMO業務快速增長，收入較上財政年度增長逾1倍。截至2024年底，本集團在手藥品及健康產品CDMO專案數量23個（截至2023年底：15個）。

深化中醫藥板塊佈局推進產學研醫交流合作

中醫藥業務方面，本集團依託已形成的中醫藥全產業鏈佈局，重點發展中藥材國內外貿易、中藥飲片及創新中藥研發等業務，以品種經營為中心，不斷整合產業上下游特色資源。本年度，中醫藥板塊業務的商業夥伴面對營商環境壓力，因此本集團在貿易業務上採取了更嚴格、謹慎的信貸政策，該板塊於本年度的收入有所下降，錄得2,710萬港元（上財政年度：4,840萬港元）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

The Group has focused on the build-up of varieties management business of Chinese medicinal materials. With the official operation of Tianda Chinese Medicine (Bozhou) Ltd., we have actively promoted the varieties management business of Chinese medicinal materials using this company as a platform.

During the Year, the Group comprehensively promoted in-depth exchanges and collaborations among industries, universities, research institutes and medical practitioners, and systematically progressed the innovation of Chinese medicines, the secondary development of existing proprietary Chinese medicines and the introduction of phased results and new products, enriching the product R&D pipeline, to enhance the core competitiveness of the Group. The Group is gradually forming a strategy for the R&D of TCM with a view of “stronger R&D, larger markets and enhanced efficacy”, harnessing the unique strengths and multifaceted value of TCM. Through technological advancement, resource growth, and outcomes accumulation, the Group aims to realize the leapfrog development of the Chinese medicine business.

TDMall growing with innovative business model to promote TCM culture

The Group created the new type Chinese medicine clinic brand “TDMall”, with the core positioning of “specialist treatments and specialized services, effectiveness and efficacy, combination of recovery and health-preservation, and harmony between nature and mankind”. TDMall continuously improved its medical system, operation system, marketing and sales system, and product system, creating a comprehensive model integrating medical services, operations, marketing, and products. The Group's sixth TDMall in the world and fifth TDMall in the Guangdong-Hong Kong-Macao Greater Bay Area – Jordan TDMall was opened in Hong Kong in October 2024, with the introduction of a renowned medical expert as shareholder. The Group is planning to establish it as the Group's oncology treatment center to promote the growth of its medical and healthcare services business, with the aim to build up an operating model of a chain of conglomerate Chinese medicine clinics.

本集團著力佈局中藥材品種經營業務，隨著天大中醫藥（亳州）有限公司正式啟動，我們以該公司為平台，積極推動中藥材品種經營業務。

本年度，本集團全面推進產學研醫深度交流與合作，積極有序推進創新中藥佈局、已上市中成藥提質二次開發、階段性成果與新品引進，豐富產品研發管線，構建企業發展核心競爭力，逐步形成「大研發、大市場、大效能」中醫藥研發戰略，充分發揮中醫藥特色優勢和多元價值，通過技術深化、資源成長、成果積累，推動中醫藥業務更好實現跨越式發展。

天大館創新業務增長模式 推動中醫藥文化傳承

本集團打造新型中醫館品牌「天大館」，以「專病專科、特色特效、康養結合、天人合一」為核心定位。天大館在醫務體系、運營體系、市場銷售體系、產品體系上不斷完善，打造「醫務+運營+市場銷售+產品」的發展模式。2024年10月，本集團投資的全球第六家、粵港澳大灣區第五家天大館-佐敦天大館，引入名醫專家作為股東，於香港開業，籌畫建立成為本集團腫瘤治療中心，促進醫療和保健服務業務增長，持續打造連鎖中醫館集團化經營模式。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Adhering to the principles of promoting the inheritance of TCM culture and giving back to the community, TDMall organized dozens of "Little Chinese physician" parent-child activities in the Greater Bay Area. TDMall also reached out to communities and conducted over 40 charity clinic sessions during the Year. Furthermore, TDMall regularly hosted TCM-themed lectures and activities for various institutions, chambers of commerce, schools, and other organizations to popularize TCM-related knowledge.

Expanding sales channels to strengthen its penetration in lower-tier markets

The Group will always adhere to its market-oriented approach, focusing on customers and patients, and will continue to enhance and upgrade its marketing system. The Group will fully leverage the advantages of centralized procurement varieties and advantages in terms of product concentration in chronic disease, expanding its reach to achieve economies of scale and drive profitability.

The Group has established a three-tier comprehensive marketing network nationwide, covering all regions, all channels, and all terminals. It continuously strengthens its first terminal marketing team centered on urban public medical institutions and grassroots public medical institutions, rapidly establishes the second terminal OTC elite team focused on the top 100 nationwide chain drugstores, and continues expanding its third terminal promotion team aimed at small chain drugstores, individual drugstores and private hospitals and clinics. The Group is committed to developing a highly agile and resilient marketing team in line with the nation's push for the construction of county-level medical community systems and the supportive policies for chronic disease management, so to accelerate the development process of the third terminal and strengthen the penetration into lower-tier markets, diversified marketing and promotion modes, enhanced customer management and standardized the market order, to advance the systematic and efficient growth of county-level markets thereby expanding its market coverage.

Tianda will bolster its e-commerce operations, expanding internally the Group's online product sales and diagnostic service platform, and externally building an international marketing network for pharmaceutical and health products, continuously enhancing the promotion of cross-border e-commerce channels.

秉持推動中醫藥文化傳承和回饋社區的理念，天大館在大灣區開展了數十場「小小中醫師」親子活動，並走進社區，年內開展了逾40場義診活動。同時，天大館亦為各大機構、商會、學校等組織持續舉辦中醫藥主題課程及活動，以普及中醫藥知識。

拓展銷售管道 加強下沉市場滲透

本集團將始終堅持以市場為導向，以客戶和患者和為中心，持續加大行銷體系建設及升級，把提升行銷能力作為重中之重的工作來抓，充分發揮集採品種及慢病品種集群優勢，向覆蓋要規模，向規模要利潤。

本集團已在全國建立全區域、全管道、全終端覆蓋的三層立體行銷網路：不斷強化以城市公立醫療機構及基層公立醫療機構為主的第一終端行銷戰隊，快速建立了以全國性百強連鎖藥店為主攻方向的第二終端OTC精兵團隊，不斷壯大以小型連鎖、單體藥店和私立醫院及診所為主要目標的第三終端推廣團隊。本集團將持續打造更具戰鬥力的行銷狼性團隊，順應國家加大縣域醫共體建設要求及慢病管理扶持政策導向，加快第三終端開發進程，加強下沉市場滲透，拓展多元化行銷及推廣模式，強化客戶管理，規範市場秩序，推動縣域市場的有序高效開發，以獲取更多的市場覆蓋。

天大將加強電商業務的發展力度，對內拓展本集團的線上產品銷售及診療服務平台，對外打造醫藥及健康產品的國際化行銷網路，不斷增強跨境電商的管道推廣。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

R&D entering harvest period with intensive new product launches

Driven by a three-pronged strategy of independent R&D, cooperation with external R&D institutions, and the introduction of new projects, Tianda has continuously strengthened its innovative drug R&D system. The Group's R&D capabilities have been significantly enhanced, forming a rich R&D pipeline. At present, R&D projects include one TCM innovative drug of Class 1, three TCM new drugs of Class 3 originated from ancient TCM prescriptions, twelve chemical generic drugs, and several health products. After years of R&D investment with accumulated know-how, several R&D projects have entered the registration stage during the Year. As at the date of this announcement, 4 new varieties have obtained drug registration approvals in 2024, and there are a total of 4 new varieties that have entered the registration stage, which will bring new growth momentum to the Group.

In the next two years, the Group will have an impressive lineup of new varieties set to be launched. Among the four new products approved to be launched in 2024, the pediatric drugs include Ibuprofen suspension, Ibuprofen drops (deemed to have passed the consistency assessment, and to prepare for further expansion into the hospital market and future centralized procurement of Ibuprofen); the cardiocerebrovascular drug includes Nicorandil for injection. Other new variety is Metformin Hydrochloride Empagliflozin tablets for diabetes treatment. Furthermore, there are also three new varieties that have entered the registration stage, i.e. Ambroxol Hydrochloride and Clenbuterol Hydrochloride oral solution for pediatric expectorant, Montelukast sodium granules for pediatric asthma and Bisoprolol Amlodipine tablets for hypertension in the cardiovascular category, which are expected to be launched in 2025.

During the Year, the Group has accelerated the progress of the Phase II clinical trials of the Class 1 TCM innovative drug, which is a clinical unmet cardiovascular drug used for the treatment of chronic heart failure. In terms of the R&D on TCM, the Group will continue to advance the R&D of TCM innovative medicine candidates, classic ancient prescriptions and improved new drugs with several new drug varieties in reserve, as well as the R&D of multi-category functional health products. The ongoing secondary technology upgrading and development of existing proprietary Chinese medicines and major variety incubation projects will foster the adoption and advancement of cutting-edge pharmaceutical technologies in the Group.

研發進入收穫期 新產品將密集上市

在自主研發、外部聯合研發以及專案引進三輪驅動下不斷強健天大新藥研發體系，本集團研發實力顯著增強，已經形成了豐富的研發管線佈局。目前，研發項目包括一個第1類中藥創新藥、三個經典名方第3類中藥新藥、十二個化藥仿製藥和若干健康產品。經過數年的研發投入和積累，多個研發項目已於本年度內進入註冊階段。截至本公告日，4個新品種已於2024年取得藥品註冊證書，進入註冊階段的新品種共有4個，將為本集團帶來新的增長動力。

未來兩年本集團新品種將以亮眼陣容密集上市。於2024年獲批上市的4個新品種中，兒科用藥包括布洛芬混懸液、布洛芬混懸滴劑（視同通過一致性評價，將為進一步開拓院內市場及未來布洛芬進入集採做好準備），心腦血管用藥為注射用尼可地爾，其它類別新品種為糖尿病用藥二甲雙胍恩格列淨片；此外，進入註冊階段的還有三個新品種，為兒科類祛痰藥氨溴特羅口服溶液、兒科類哮喘用藥孟魯司特鈉顆粒及心腦血管類高血壓用藥比索洛爾氨氯地平片，預計於2025年上市。

本年度，第1類中藥創新藥二期臨床加速推進，該藥品為臨床尚未滿足的心腦血管用藥，用於治療慢性心力衰竭。中藥研發方面將持續推進在研中藥創新藥、經典名方複方製劑、改良型新藥及多個備選新藥品種儲備與多品類的功能性健康產品研發，已開展的上市中成藥二次技術提升開發與大品種孵化計畫，將穩步促進本集團製藥新技術的應用與技術進步。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

The Group will continue to be market oriented and adhere to the dual focus of generic and innovative drug development, aligning efforts in innovative drug promotion, generic drug development, and secondary advancements. The Group will focus on advantageous areas such as cardiovascular and pediatric fields while actively expanding into other sectors, to keep enriching its R&D pipeline.

OUTLOOK

The Group will continue to focus on solidifying the core market positions of “Tuoen” and “Tuoping” in the treatment of cardiovascular and cerebrovascular diseases, pediatrics and respiratory system, and accelerate the capture of the consumer healthcare market share with health product series such as “Tuokang”. Meanwhile, it will increase the R&D and introduction of specialized varieties, focusing on expanding multi-terminal markets, especially the out-of-hospital markets. It will also leverage TCM-related policy advantages to accelerate the high-quality development of the Chinese medicine business, and promote a collaborative development model of “drugs + medical services”. The Group will optimize the operation and management system of TDMalls and improve their operations and services, to establish a group-oriented operating model for TCM chain clinics. The Group will also monitor investment and merger opportunities, constantly boost its domestic businesses, and expand its presence in international markets leveraging its geographical advantages.

FINANCIAL REVIEW

During the Year, the Group recorded a revenue of HK\$329.9 million (Previous Financial Year: HK\$532.1 million).

For the Pharmaceuticals and medical technologies business, revenue for the Year was HK\$283.9 million, a decrease of 39.7% from HK\$470.7 million in the Previous Financial Year. During the COVID-19 pandemic, end-users stockpiled large quantities of Tuoen®Ibuprofen, a pediatric drug. Demand for the product decreased as a result of destocking in the market during the Year. Sales volume of Tuoping®Valsartan capsules, another major cardiocerebrovascular drug, was also affected due to the adoption of the strategy of lower pricing by a new competing bidder during the bidding for the centralized procurement in Jiangsu Province in 2024.

本集團將繼續以市場需求為導向，堅持仿創結合，統籌推進創新藥、仿製藥及二次開發；聚焦心腦血管及兒科等優勢領域，同時積極佈局其它板塊，不斷豐富研發管線。

展望

本集團將繼續致力打造「托恩」、「托平」等產品在心腦血管、兒科、呼吸系統等治療領域的核心地位，加快「托康」等健康產品系列搶佔消費醫療市場，同時將加大特色專科品種的研發和引進，注重多終端，尤其院外市場佈局。亦將把握中醫藥政策紅利，加快中醫藥業務高品質發展，推動「藥物 + 醫療服務」協同發展模式。本集團將優化天大館運營及管理系統，改進運營和服務，打造連鎖中醫館集團化的經營模式。本集團也將關注投資並購機會，不斷提振國內業務，並利用區位優勢拓展國際市場。

財務回顧

在本年度，本集團錄得收入3億2,990萬港元（上財政年度：5億3,210萬港元）。

藥物和醫療科技業務方面，本年度收入為2億8,390萬港元，對比上財政年度的4億7,070萬港元下跌39.7%。新冠疫情期間，終端用戶對兒科用藥托恩®布洛芬大量囤貨，及至本年度市場在消化庫存，對產品需求減少；另一主要產品心腦血管用藥托平®巰沙坦膠囊也因為2024年有新競品在江蘇省的集採中以低價策略競標，影響了托平®的銷量。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

For the Chinese medicine business, due to intense competition in the market, the Group adopted a more conservative strategy by selecting promising and potential varieties for operation and consolidated its sales team, resulting in a decrease in revenue for the Year, recording HK\$27.1 million (Previous Financial Year: HK\$48.4 million). Given the continuous loss-making position of the Chinese medicine business, an impairment provision of HK\$1.3 million was made on the goodwill of Tianda Chinese Medicine (China) during the Year. For the Medical and healthcare services, the business grew steadily and, with the opening of the Jordan TDMall in Hong Kong in October 2024, the revenue amounted to HK\$19.0 million for the Year (Previous Financial Year: HK\$13.0 million).

Gross profit was HK\$152.0 million (Previous Financial Year: HK\$255.5 million), and the gross profit margin decreased from 48.0% in the Previous Financial Year to 46.1% in the Year, mainly due to the fact that fixed costs such as depreciation of fixed assets did not decrease in line with the decrease in production volume, which led to the increase in average production costs. However, the Group has strengthened its stringent control over its costs, and the selling and distribution expenses decreased from HK\$186.5 million in the Previous Financial Year to HK\$107.9 million in the Year, representing a decrease of approximately 2.4 percentage points in the selling and distribution expense to revenue ratio, which partially offset the impact of the decrease in gross profit margin.

Administrative expenses and R&D expenses were HK\$85.0 million and HK\$13.3 million (Previous Financial Year: HK\$85.0 million and HK\$13.1 million) respectively, which were maintained at a similar level as the Previous Financial Year. For the latest progress of major R&D projects, please refer to the business review section above. Other income and net income for the Year amounted to HK\$4.7 million (Previous Financial Year: HK\$8.3 million), mainly due to the decrease in bank deposit interest rates, resulting in the decrease in interest income from bank deposits and an impairment of goodwill was made in the Year.

In summary, the loss attributable to shareholders of the Company increased from HK\$24.2 million in the Previous Financial Year to HK\$61.4 million in the Year. The change in profitability was mainly attributable to the Group's business performance analyzed above.

中醫藥業務方面，由於市場競爭劇烈，本集團採取更保守策略，篩選有可為及潛力的品種經營，並整合銷售團隊，使本年度的收入有所下降，錄得2,710萬港元（上財政年度：4,840萬港元），而由於中醫藥業務持續虧損，於本年度就天大中醫藥（中國）之商譽作減值130萬港元。醫療和保健服務方面穩定增長，2024年10月佐敦天大館於香港開業，本年度的收入為1,900萬港元（上財政年度：1,300萬港元）。

毛利為1億5,200萬港元（上財政年度：2億5,550萬港元），毛利率由上財政年度的48.0%下跌至本年度的46.1%，主要因為固定資產折舊等固定成本未有隨產量下降而減少，令平均生產成本上漲，惟本集團已加強嚴格控制成本，銷售及分銷費由上財政年度1億8,650萬港元減少至本年度1億790萬港元，銷售及分銷費用對收入比率減少約2.4個百分點，部份抵銷了毛利率下跌的影響。

行政費用及研發費用分別為8,500萬港元及1,330萬港元（上財政年度：8,500萬港元及1,310萬港元），維持和上財政年度相若水平。主要研發項目最新進展見上述業務回顧章節。本年度其它收入及淨收益為470萬港元（上財政年度：830萬港元），下跌主要原因是銀行存款息率下跌，令銀行存款利息收入減少，以及商譽減值所致。

綜上而述，本公司股東應佔虧損由上財政年度2,420萬港元擴大至本年度6,140萬港元。盈利能力的轉變主要源自上文分析的本集團業務表現。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

LIQUIDITY AND FINANCIAL RESOURCES

As at 31 December 2024, the Group had cash and cash equivalents of HK\$85.7 million (31 December 2023: HK\$162.4 million), of which approximately 83.3% were denominated in Renminbi ("RMB") with the remaining in Hong Kong dollar, Australian dollar, Euro, Macau pataca and United States dollar. As at 31 December 2024, the bank borrowings maturing in one year amounted to HK\$122.1 million, which were denominated in RMB and bear interest at the rate ranging from China LPR + 0% to China LPR + 1%.

As at 31 December 2024, the Group recorded net current liabilities of HK\$35.1 million. At the beginning of 2025, the Group has been granted new banking facilities of RMB50.0 million by a bank. In addition, the Group has been discussing with certain banks on new long-term financing arrangements to improve its liquidity position, but the financing options have yet to be finalized. The Group's financial position remains healthy.

FOREIGN EXCHANGE EXPOSURE

The Group's assets, liabilities and transactions are substantially denominated in Hong Kong dollar, RMB, United States dollar and Australian dollar. The Group has sales and investments in foreign operations which use currencies other than its functional currency RMB. As such, the Group has some exposures to foreign currency risks. The management from time to time determines suitable measures, such as entering into forward currency contracts, to lessen exposure to exchange rate fluctuations in material transactions denominated in currencies other than RMB. The Group did not enter into any forward currency contracts to hedge its foreign currency risks as at 31 December 2024.

CHARGES ON ASSETS

As at 31 December 2024, the Group pledged certain right-of-use assets and property, plant and equipment with carrying value HK\$259.6 million (31 December 2023: HK\$254.0 million) in aggregate to secure a bank loan facility granted to the Group.

流動資金及財務資源

於2024年12月31日，本集團有現金及現金等值項目共8,570萬港元（2023年12月31日：1億6,240萬港元），其中約83.3%以人民幣計值，餘額則以港元、澳元、歐元、澳門元及美元計值，於2024年12月31日，一年內到期的銀行借款為1億2,210萬港元，均以人民幣計值，並按中國貸款市場報價利率加0%至中國貸款市場報價利率加1%計息。

於2024年12月31日，本集團錄得淨流動負債3,510萬港元。本集團於2025年初，已獲得一間銀行新批融資額度人民幣5,000萬元，另外亦跟若干銀行商討新長期融資安排，藉以改善流動性狀況，惟有關融資方案尚待落實。本集團財務狀況依然穩健。

匯率風險

本集團資產、負債及交易大部份以港元、人民幣、美元及澳元計值。本集團設有海外銷售及投資業務，乃以本集團之功能貨幣人民幣以外之貨幣計算。因此，本集團面對若干外匯風險。管理層不時釐定適當措施，例如訂立外幣遠期合約，以減低以人民幣以外貨幣計值之重大交易所面臨之匯率波動風險。於2024年12月31日，本集團概無訂有任何外幣遠期合約以對沖其外幣風險。

資產抵押

於2024年12月31日，本集團已就本集團獲授之一項銀行貸款融資抵押若干使用權資產以及物業、廠房及設備，賬面金額合共2億5,960萬港元（2023年12月31日：2億5,400萬港元）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

EMPLOYMENT AND REMUNERATION POLICY

As at 31 December 2024, the Group employed approximately 701 employees in Hong Kong, the PRC and Australia. The Group remunerates its employees based on market terms the qualifications and experience of the employees concerned.

MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARIES

There were no material acquisition and disposal of subsidiaries and associated companies during the year ended 31 December 2024.

僱員及薪酬政策

於2024年12月31日，本集團於香港、中國及澳大利亞聘有約701名僱員。本集團根據市場條款以及有關僱員之資歷及經驗向僱員釐定薪酬。

附屬公司的重大收購及出售事項

於截至2024年12月31日止年度內，概無重大收購及出售附屬公司及關聯公司。

CORPORATE GOVERNANCE REPORT

企業管治報告

The Company is firmly committed to maintaining statutory and regulatory standards and adhering to the principles of corporate governance, emphasizing transparency and accountability to the shareholders.

The Company has complied with the code provisions of the Corporate Governance Code (the “CG Code”) in Appendix C1 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the “Listing Rules”) during the year ended 31 December 2024 (the “Year”) except as mentioned below.

Mr. Fang Wen Quan is the Chairman of the Board and the Managing Director of the Company. Pursuant to code provision of C.2.1 of the CG Code, the roles of the chairman and chief executive officer of an issuer should be separated and should not be performed by the same individual. The division of responsibilities between the chairman and chief executive officer should be clearly established and set out in writing. Having considered the current business operation and the size of the Group, the Board is of the view that Mr. Fang Wen Quan has been the key leader of the Group, who has been primarily involved in formulation of business strategies and determination of the overall direction of the Group. He has also been chiefly responsible for the Group's operations as he directly supervises the management team of the Group. Taking into account the continuation of the implementation of the Group's business plans, the Directors (including the Independent Non-executive Directors) consider that Mr. Fang Wen Quan acting as both the Chairman of the Board and the Managing Director of the Company is acceptable and in the best interest of the Group. The Board has reviewed this situation periodically.

Value, Mission and Vision

The Group adheres to the philosophy of “Tianda for health!” as core value, which shows the Company's continuous commitment to the passion and pursuit of health and care. The Group fully realizes our social responsibilities and insists on the corporate mission - to adopt market-driven and innovative approach; follow international standards and assure quality & safety control; strengthen good management practice; value talents; enhance research and development; offer quality products. Focus on cost efficiency and create better returns for shareholders; improve service to make our business partners more satisfied; boost up the incentive mechanism to make our employees more devoted to work. Our vision is committed to becoming a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.

本公司堅決致力維持法定及監管標準，並緊守企業管治之原則，強調透明度及向股東問責。

於截至2024年12月31日止年度（「本年度」），本公司已遵守在香港聯交所證券上市規則（「上市規則」）附錄C1所載企業管治守則之守則條文，惟下文所述之情況除外。

方文權先生為本公司董事長兼董事總經理。根據企業管治守則之守則條文第C.2.1條，發行人董事長及行政總裁之職務應分開及不應由同一人士擔任，並應以書面明確界定董事長與行政總裁各自之職責。經考慮本集團目前業務運作及規模，董事會認為由方文權先生一直為本集團之主要領導人，主要負責制訂本集團之業務策略及釐定本集團之整體方針。由於彼直接監督本集團管理層，故彼亦一直為本集團之最高營運負責人。考慮到實施本集團業務計劃之連續性，董事（包括獨立非執行董事）認為，方文權先生同時出任本公司之董事長及董事總經理屬可接受情況，且符合本集團最佳利益。董事會已定期檢討有關情況。

價值觀、使命及願景

本集團秉承「您的健康是天大的事！」的核心價值觀，表達了天大藥業源源不斷奉獻健康與關愛的願望與追求。本集團時刻牢記企業所應承擔的各項社會責任，並堅持企業使命—以市場為導向，以創新為推力；遵循國際標準，嚴控質量安全；加強規範管理，高度重視人才；提高研發水平，提供優質產品。注重效益，為投資者創造更好回報；提升服務，使合作夥伴更滿意；完善激勵機制，令員工更愉快投入工作。我們的願景為致力成為立足中國，輻射全球的領先醫藥企業。

CORPORATE GOVERNANCE REPORT

企業管治報告

BOARD OF DIRECTORS

The Board is responsible for the leadership and control of the Company and oversees the businesses, strategic development, financial performance and corporate governance of the Group. The management is delegated with the powers and authorities for overseeing the day-to-day operation of the Group.

The Board consists of 6 male Directors and 1 female Director, comprising 2 Executive Directors, 2 Non-executive Directors and 3 Independent Non-executive Directors (INEDs) namely:

Executive Directors:

Mr. Fang Wen Quan (*Chairman and Managing Director*)
Mr. Lui Man Sang

Non-executive Directors:

Mr. Zhong Tao
Mr. Feng Quanming

INEDs:

Mr. Lam Yat Fai
Mr. Chiu Sung Hong
Dr. Xian Yanfang

There was no change of board composition and functions during the Year. The Board, not being a single gender Board, believes that the balance between Executive Directors and Non-executive Directors is reasonable and adequate to provide sufficient balances that protect the interest of the shareholders and the Group.

INEDs and Non-executive Directors are appointed for a term of 2 years and are subject to retirement in accordance with the Company's articles of association.

At least one of the INEDs, namely Mr. Lam Yat Fai, has appropriate professional qualification in accounting or related financial management expertise. Save as disclosed in the biographical details of each Director, there is no other relationship (including financial, business, family, or other material/relevant relationship) among members of the Board.

The articles of association of the Company provide that one-third of all the directors for the time being (or, if their number is not a multiple of three, the number nearest to but not less than one-third) shall retire from office by rotation at each annual general meeting (AGM), and all directors are subject to this provision.

董事會

董事會負責領導及控制本公司，並監察本集團之業務、策略發展、財務表現及企業管治。管理層則獲授予權力與授權以監察本集團之日常運作。

董事會現由六名男董事及一名女董事組成，包括兩名執行董事、兩名非執行董事及三名獨立非執行董事，即：

執行董事：

方文權先生 (*董事長兼董事總經理*)
呂文生先生

非執行董事：

鍾濤先生
馮全明先生

獨立非執行董事：

林日輝先生
趙崇康先生
冼彥芳博士

本年度董事會之組成及職能並無變動。董事會並非單一性別之董事會，認為執行董事及非執行董事之間之平衡為合理，且足以提供充分平衡，以保障股東及本集團之利益。

獨立非執行董事及非執行董事之任期為2年，並須根據本公司之章程細則告退。

至少一名獨立非執行董事（即林日輝先生）擁有適當之會計專業資格或相關財務管理專長。除於各董事簡歷內所披露者外，各董事會成員之間並無其它關係（包括財務、業務、家屬或其它重大／相關關係）。

本公司之章程細則規定，當時所有董事之三分之一（倘董事人數並非三之倍數，則為最接近之數目但不少於三分之一）須於每屆股東週年大會上輪值退任，全體董事均受此條文規限。

CORPORATE GOVERNANCE REPORT

企業管治報告

The Company has received annual confirmation of independence from the three INEDs in accordance with Rule 3.13 of the Listing Rules.

The Board has established a formal schedule of matters specifically reserves to the Board for its decision. The Board reviews this schedule on a periodic basis to ensure that it remains appropriate to the needs of the Board.

The Board has adopted effective mechanisms to ensure independent view and input are available to the Board and established procedures to enable directors, upon reasonable request, to seek independent professional advice in appropriate circumstances to enable them to discharge their duties at the Company's expenses. The articles of association of the Company contain description of responsibility and operation procedures of the Board. The Board meets regularly to review the financial and operating performance of the Group.

Board Independence Evaluation Mechanism

The Board has adopted the board independence evaluation mechanism (the "Mechanism") which sets out the principles and guidelines for the Company to ensure independent view and input to be available to the Board.

Continuing improvement and development of the Board of the Company and its committee processes and procedures through Board independence evaluation provides a powerful and valuable feedback mechanism for improving Board effectiveness, maximising strengths, and identifying the areas that need improvement or further development. The evaluation process also clarifies what actions of the Company need to be taken to maintain and improve the Board performance.

The Mechanism enhances INEDs contribution with independent views to the Board as below:

- Invite INEDs to serve as the audit, remuneration, nomination and if any, other Board committees;
- Encourage INEDs to raise questions and voice their concerns during the meetings;
- Take the lead by INEDs where potential conflicts of interest arise; and

本公司已收到三名獨立非執行董事根據上市規則第3.13條所規定之有關獨立性之年度確認。

董事會已建立正式之預定計劃表，列載特別要董事會作決定之事項。董事會定期檢討該表以確保其仍適當滿足董事會之要求。

董事會已採納有效機制，以確保向董事會提供獨立的觀點及意見，並建立一套程序，讓董事按合理要求，可在適當之情況下尋求獨立專業意見以使彼等能履行其責任，費用由本公司支付。本公司之章程細則包含董事會責任及運作程序之描述。董事會定期召開會議以審閱本集團之財務及經營表現。

董事會獨立性評估機制

董事會已採納董事會的獨立性評估機制（「該機制」），當中載列本公司的原則及指引，以確保董事會獲得獨立的觀點及意見。

通過董事會的獨立性評估，本公司董事會及其委員會的流程和程序得以持續改進和發展，為提高董事會效率、發揮其最大優勢、識別需要改進或進一步發展的領域提供了有力且有益的反饋機制。評估程序亦釐清本公司須採取何種行動以維持及改善董事會表現。

該機制提高獨立非執行董事對董事會貢獻的獨立意見的措施如下：

- 邀請獨立非執行董事擔任審核、薪酬、提名以及其它董事會委員會（如有）；
- 鼓勵獨立非執行董事在會議期間提出問題並表達他們的關切；
- 在出現潛在利益衝突時由獨立非執行董事牽頭處理；及

CORPORATE GOVERNANCE REPORT

企業管治報告

- Keep INEDs up-to-date with the affairs of the Company and its subsidiaries so that INEDs may scrutinise the Company's performance in achieving agreed corporate goals and objectives, and monitor performance reporting when (1) annually reviewing the structure, size, composition and diversity of the Board and assessing the independence of INEDs; (2) recommending INED to be re-elected at the AGM of the Company; and/or (3) recommending any individual as new INED, the nomination committee of the Company shall take into account the contribution by each INED/individual.

The Board reviews the effectiveness of such Mechanism on an annual basis.

Corporate Governance Functions

The Board is responsible for performing the corporate governance duties including the following matters attended by the Board during the Year:

- developed and reviewed the Company's policies, including the Board Diversity Policy, mechanism to ensure independent view of the Board and the Shareholders Communication Policy, and practices on corporate governance and make recommendations;
- reviewed and monitored the training and continuous professional development of directors and senior management;
- reviewed and monitored the Company's policies and practices on compliance with legal and regulatory requirements;
- developed, reviewed and monitored the code of conduct and compliance manual (if any) applicable to employees and directors; and
- reviewed the Company's compliance with the CG Code and disclosure in the Corporate Governance Report under Appendix C1 to the Listing Rules.

Directors' training and professional development

Directors of the Company are continually updated with legal and regulatory developments, and the business environment to facilitate the discharge of their responsibilities.

- 讓獨立非執行董事了解本公司及其附屬公司的最新情況，以便獨立非執行董事可以審查本公司在實現商定的本公司目標和目的方面的表現及監控績效報告，並在(1)每年審查董事會的結構、規模、組成和多元化，以及評估獨立非執行董事的獨立性；(2)在本公司股東週年大會上推薦獨立非執行董事連任；及／或(3)推薦任何個人為新的獨立非執行董事，本公司提名委員會應考慮每名獨立非執行董事／個人的貢獻。

董事會每年檢討該機制之有效性。

企業管治職能

董事會負責履行企業管治職責，包括於本年度所處理之下列事宜：

- 制定及檢討本公司之政策（包括確保董事會提出獨立意見機制的董事會多元化政策及股東溝通政策），以及企業管治政策及常規，並作出推薦意見；
- 檢討及監察董事及高級管理人員之培訓及持續專業發展；
- 檢討及監察本公司在遵守法律及監管規定方面之政策及常規；
- 制定、檢討及監察適用於僱員及董事之操守準則及合規手冊（如有）；及
- 檢討本公司遵守企業管治守則之情況及根據上市規則附錄C1在企業管治報告內之披露。

董事培訓及專業發展

本公司董事持續獲提供有關法律及監管發展以及業務環境之最新資料，以協助彼等履行職責。

CORPORATE GOVERNANCE REPORT

企業管治報告

All Directors are also provided with monthly updates on the Company's performance, position and prospects to enable the Board as a whole and each Director to discharge their duties.

All Directors are encouraged to participate in continuous professional development to develop and refresh their knowledge and skills. Newly appointed Directors are provided with the necessary induction and information to ensure that they have a proper understanding of the Company's operations and businesses as well as their responsibilities under the relevant statutes, laws, rules and regulations.

Based on the training records provided to the Company by the Directors, all the Directors have participated in the trainings by reading newspapers, journals and updates and/or attending seminars relating to corporate governance, regulatory updates, economy, general business or director's duties and responsibilities, etc. during the Year.

Directors' meetings

During the Year, the Board held 4 full board meetings. The attendances of the Directors at the meetings are as follows:

Directors	董事	Number of Meetings Attended/Held 出席／舉行會議次數
Executive Directors:	執行董事：	
Mr. Fang Wen Quan (Chairman and Managing Director)	方文權先生 (董事長兼董事總經理)	4/4
Mr. Lui Man Sang	呂文生先生	4/4
Non-executive Directors:	非執行董事：	
Mr. Zhong Tao	鍾濤先生	2/4
Mr. Feng Quanming	馮全明先生	3/4
INEDs:	獨立非執行董事：	
Mr. Lam Yat Fai	林日輝先生	4/4
Mr. Chiu Sung Hong	趙崇康先生	4/4
Dr. Xian Yanfang	冼彥芳博士	4/4

The Board has also established the audit committee, nomination committee, remuneration committee and risk management committee which comprises a majority of INEDs. Each of these committees has its own terms of reference to set out its specific duties and authorities and reports to the Board. For the terms of reference of each committee, please visit the website of our Company www.tiandapharma.com.

所有董事每月獲提供有關本公司表現、狀況及前景之最新資料，以便董事會整體及各董事履行其職責。

本公司鼓勵所有董事參與持續專業發展，以發展彼等之知識及技能並且溫故知新。新委任董事獲提供必需之指引及資料，以確保彼等充分了解本公司之營運及業務，以及彼等根據相關法令、法例、規則及法規之責任。

根據各董事向本公司提供之培訓記錄，全體董事於本年度內透過閱覽報章、期刊及最新資訊及／或出席講座參與培訓，內容有關企業管治、最新監管規例、經濟、一般商業或董事職責等。

董事會會議

於本年度內，董事會舉行四次董事會會議。董事出席會議之情況如下：

董事會亦成立了審核委員會、提名委員會、薪酬委員會及風險管理委員會，成員包括大部分獨立非執行董事。該等委員會各自訂有本身之職權範圍，當中載列其指定職責及授權以及須向董事會匯報。有關各委員會之職權範圍，請參閱本公司網站 www.tiandapharma.com。

CORPORATE GOVERNANCE REPORT

企業管治報告

Emoluments of Directors and Senior Management

Particulars regarding Directors' emoluments and five highest paid employees are set out in notes 9 and 10 to the consolidated financial statements. Also, the Group's business are under the direct responsibility of the two Executive Directors, who are the senior management of the Company.

REMUNERATION COMMITTEE

The remuneration committee of the Company was established with specific written terms of reference. It comprises three INEDs of the Company, Mr. Chiu Sung Hong, Mr. Lam Yat Fai and Dr. Xian Yanfang and one Executive Director of the Company, Mr. Fang Wen Quan. Mr. Chiu Sung Hong is the Chairman of the remuneration committee during the Year.

The remuneration committee is responsible for making recommendations to the Board on, among other things, the Company's policy and structure for the remuneration to all Directors and senior management of the Company and is delegated by the Board the responsibility to determine on behalf of the Board the specific remuneration packages for all Executive Directors and senior management of the Company.

The remuneration committee held 1 meeting during the Year to review and make recommendations to the Board on the remuneration packages of Individual Executive Directors, the Non-executive Directors, the INEDs and senior management; and to review the bonus to senior management.

Details of individual attendance of its members during the Year are as follows:

董事及高級管理人員之薪酬

有關董事薪酬及五名最高薪酬僱員的詳情載於綜合財務報表的附註9及10。此外，本集團的業務由兩名執行董事直接負責，彼等均為本公司的高級管理人員。

薪酬委員會

本公司之薪酬委員會已告成立，訂有具體書面職權範圍書。成員包括本公司之三名獨立非執行董事趙崇康先生、林日輝先生及冼彥芳博士，以及本公司之一名執行董事方文權先生。趙崇康先生於本年度內為薪酬委員會之主席。

薪酬委員會負責（其中包括）就本公司所有董事及高級管理人員之薪酬政策及架構向董事會提出建議，並獲董事會授予職責以代表董事會釐定本公司之全體執行董事及高級管理人員之特定薪酬組合。

於本年度，薪酬委員會舉行一次會議，以審閱個別執行董事、非執行董事及獨立非執行董事以及高級管理人員之薪酬待遇並就此作出推薦意見；及檢討高級管理人員之花紅。

於本年度內個別成員之出席詳情如下：

		Number of Meetings Attended/Held 出席／舉行會議次數
Mr. Chiu Sung Hong (<i>Chairman</i>)	趙崇康先生 (<i>主席</i>)	1/1
Mr. Fang Wen Quan	方文權先生	1/1
Mr. Lam Yat Fai	林日輝先生	1/1
Dr. Xian Yanfang	冼彥芳博士	1/1

CORPORATE GOVERNANCE REPORT

企業管治報告

The work performed by the remuneration committee during the Year includes the followings:

- reviewed the Directors' fees and made recommendation to the Board for approval;
- reviewed the current remuneration structure/package of the Executive Directors and senior management and recommended the Board to approve their specific packages; and
- reviewed the revised remuneration policy and term of reference of the remuneration committee.

NOMINATION COMMITTEE

The Company has established nomination committee comprising two INEDs, Mr. Lam Yat Fai and Mr. Chiu Sung Hong and one Executive Director of the Company, Mr. Fang Wen Quan (who is the chairman of the nomination committee).

The duties of the nomination committee are reviewing and supervising the structure, size and composition of the Board, identifying qualified individuals to become members of the Board, assessing the independence of the INEDs and making recommendations to the Board on the appointment or re-appointment of Directors.

During the Year, the nomination committee held 1 meeting. Details of individual attendance of its members are as follows:

於本年度內，薪酬委員會履行之工作包括以下各項：

- 檢討董事袍金並向董事會提供推薦意見以供批准；
- 檢討執行董事及高級管理層之現時薪酬架構／待遇水平，並就批准彼等之具體薪酬待遇向董事會提供建議；及
- 檢討經修訂薪酬委員會之薪酬政策及職權範圍。

提名委員會

本公司已成立提名委員會，成員包括兩名獨立非執行董事林日輝先生及趙崇康先生，以及本公司之一名執行董事方文權先生（為提名委員會主席）。

提名委員會之職責為檢討及監察董事會之架構、規模及組合，物色具備合適資格可擔任董事會成員之人士，評核獨立非執行董事之獨立性，以及就董事之委任或重新委任向董事會提出建議。

於本年度內，提名委員會舉行一次會議。個別成員之出席詳情如下：

		Number of Meetings Attended/Held 出席／舉行會議次數
Mr. Fang Wen Quan (<i>Chairman</i>)	方文權先生 (主席)	1/1
Mr. Lam Yat Fai	林日輝先生	1/1
Mr. Chiu Sung Hong	趙崇康先生	1/1

CORPORATE GOVERNANCE REPORT

企業管治報告

The work performed by the nomination committee during the Year includes the follows:

- reviewed the structure, size, composition and diversity of the Board;
- reviewed the revised board diversity policy, nomination policy and terms of reference of the nomination committee;
- reviewed the independence of the INEDs;
- reviewed the confirmation from the Directors on time commitment in performing their duties as Directors; and
- made recommendation to the Board on the re-election of Directors at the 2024 AGM.

There was no change on the composition of the Board during the Year.

Board Diversity Policy

The Board recognises the importance of having a diverse board in enhancing the Board effectiveness and corporate governance. The Company has a board diversity policy aiming at setting out the approach on diversity of the Board of the Company.

The nomination committee is responsible for reviewing the structure, size and composition (including the skills, knowledge and experience) of the Board and make recommendations to the Board regarding any proposed changes, identifying individuals suitably qualified to become Board members and select or make recommendations to the Board on the selection of, individuals nominated for directorships with regards to their qualifications, skills, experience and knowledge, assess the independence of INEDs, and make recommendations to the Board on relevant matters relating to the appointment of Directors and succession planning for Directors in particular the chairman and the chief executive officer.

The nomination committee is also responsible for reviewing and reporting on the board diversity on an annual basis.

於本年度內，提名委員會履行之工作包括以下各項：

- 檢討董事會之架構、人數、構成及多元化；
- 檢討經修訂董事會多元化政策、提名委員會之提名政策及職權範圍；
- 檢討獨立非執行董事之獨立性；
- 檢討董事就履行擔任董事之職責所投入時間之確認；及
- 就於2024股東週年大會上膺選連任之董事向董事會提供推薦意見。

董事會的組成於本年度內沒有發生變化。

董事會成員多元化政策

董事會知悉董事會成員多元化對提升董事會效能及企業管治之重要性。本公司已制訂一項董事會成員多元化政策，以載列本公司多元化董事會成員之措施。

提名委員會負責審閱董事會架構、規模及組成（包括技能、知識及經驗），並就任何擬進行之變動向董事會提出建議、物色合資格成為董事會成員之適當人選，並根據資歷、技能、經驗及知識甄選提名董事人選或就此向董事會提供建議，評估獨立非執行董事之獨立性，及就董事委任及董事續聘計劃（尤其是主席及行政總裁）之有關事宜向董事會提出建議。

提名委員會亦負責每年檢討董事會成員多元化，並向董事會匯報。

CORPORATE GOVERNANCE REPORT

企業管治報告

Measurable Objectives

Appointments of directors will not only be based on merit and candidates will be considered against objective criteria, having due regard for the benefits of diversity on the Board, but also will be based on a range of diversity perspectives, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service. The ultimate decision will be based on merit and contribution that the selected candidates will bring to the Board.

The Board currently comprises of six male and one female Directors. The female representation is about 48% at workforce level.

Review of this Policy

The Board has reviewed this policy on an annual basis to ensure its continued effectiveness.

For compliance with the Listing Rules and the board diversity policy, the following measurable objectives were reviewed and implemented:

- at least one-third of the members of the Board shall be Independent Non-executive Directors;
- at least one of the members of the Board shall have obtained accounting or other professional qualifications;
- at least 70% of the members of the Board shall have more than seven years of experience in the industry he/she is specialised in;
- at least two of the members of the Board shall have China-related work experience; and
- no single gender Board.

可計量目標

董事會以用人唯才之原則委任董事，除了根據客觀標準，經適當考慮董事會成員多元化之裨益後，對候選人加以考慮外，還將按一系列多元化範疇為基準，包括但不限於性別、年齡、文化及教育背景、種族、專業經驗、技能、知識及服務任期。最終將按人選的長處及可為董事會作出的貢獻而作決定。

董事會目前由6名男性董事及1名女性董事組成。僱員層面中女性佔約48%。

檢討本政策

董事會會每年檢討本政策，以確保本政策行之有效。

為遵守上市規則及董事會成員多元化政策，已審閱及採納以下可計量目標：

- 至少三分之一董事會成員須為獨立非執行董事；
- 至少一名董事會成員須獲得會計或其它專業資格；
- 至少70%董事會成員須於其專攻行業內擁有7年以上經驗；
- 至少兩名董事會成員須擁有中國相關工作經驗；及
- 不會有單一性別的董事會。

CORPORATE GOVERNANCE REPORT

企業管治報告

Nomination Policy

The Board has also adopted a nomination policy. The nomination committee reviews the structure, size and composition of the Board periodically and make recommendation on any proposed changes to the Board to complement the Company's corporate strategy. When it is necessary to fill a casual vacancy or appoint an additional director, the nomination committee identifies or selects candidates as recommended to the committee pursuant to the criteria set out in the nomination policy. Based upon the recommendation of the nomination committee, the Board deliberates and decides on the appointment. In addition, pursuant to the articles of association of the Company, every director shall be subject to retirement at least once every three years and shall be eligible for re-election. The nomination committee shall review the overall contribution and service to the Company, expertise and professional qualifications of the retiring directors, who offered himself/herself for re-election at the AGM, to determine whether such director continues to meet the criteria as set out in the nomination policy. The nomination committee reviews and assesses the independence of all INEDs on an annual basis.

The nomination policy which sets out the procedures and criteria for the selection, appointment and reappointment of Directors. The selection criteria that nomination committee has to consider in evaluating and selecting a candidate for directorship include the following:

- character and integrity;
- qualifications including professional qualifications, skills, knowledge and experience and diversity aspects under the board diversity policy that are relevant to the Company's business and corporate strategy;
- any measurable objectives adopted for achieving diversity on the Board;
- requirement for the Board to have independent non-executive directors in accordance with the Listing Rules and whether the candidate would be considered independent with reference to the independence guidelines set out in the Listing Rules;

提名政策

董事會亦已採納一項提名政策。提名委員會定期檢討董事會架構、人數及組成，並就任何為配合本公司的發展策略而擬對董事會架構作出的變動提出建議。當有必要填補空缺或增加額外董事時，提名委員根據提名政策所載的準則物色人選或甄選向委員會推薦的人選。根據提名委員會的推薦建議，董事會審議並決定任命。此外，根據本公司的章程細則，每名董事須至少每三年退任一次，並合資格膺選連任。提名委員會須審視願意在股東週年大會上膺選連任之退任董事為本公司作出的整體貢獻及服務、專業知識及專業資格，以釐定有關董事是否繼續符合提名政策所載列的準則。提名委員會每年均檢討及評審全部獨立非執行董事的獨立性。

提名政策，當中列載甄選、委任及重新委任董事的程序及準則。提名委員會在評審和甄選董事候選人時必須考慮下列甄選準則：

- 性格及誠信；
- 包括專業資格、技能、知識及經驗在內的資格，以及根據董事會多元化政策與本公司業務及公司策略有關的多元化範疇；
- 為達致董事會多元化採納的任何可計量目標；
- 根據上市規則董事會成員須包括獨立非執行董事的規定，以及參照上市規則所載的獨立性指引，候選人是否被視為獨立；

CORPORATE GOVERNANCE REPORT

企業管治報告

- any potential contributions the candidate can bring to the Board in terms of qualifications, skills, experience, independence and gender diversity;
- willingness and ability to devote adequate time to discharge duties as a member of the Board and/or Board committee(s) of the Company; and
- such other perspectives that are appropriate to the Company's business and succession plan and where applicable, may be adopted and/or amended by the Board and/or the nomination committee from time to time for nomination of directors and succession planning.
- 候選人在資格、技能、經驗、獨立性及性別多元化方面可對董事會作出的任何潛在貢獻；
- 投放充份時間履行董事會及／或本公司董事委員會成員的職務的意向及能力；及
- 就本公司的業務及繼任計劃而言屬適當的其它觀點；以及（如適用）董事會及／或提名委員會不時就董事提名及繼任計劃可能採納及／或修訂的其它觀點。

NOMINATION PROCESS

Appointment of New Director

1. The nomination committee and/or the Board may select candidates for directorship from various channels, including but not limited to internal promotion, re-designation, referral by other member of the management and external recruitment agents.
2. The nomination committee and/or the Board should, upon receipt of the proposal on appointment of new director and the biographical information (or relevant details) of the candidate, evaluate such candidate based on the criteria as set out above to determine whether such candidate is qualified for directorship.
3. If the process yields one or more desirable candidates, the nomination committee and/or the Board should rank them by order of preference based on the needs of the Company and reference check of each candidate (where applicable).
4. The nomination committee should then recommend to the Board to appoint the appropriate candidate for directorship, as applicable.
5. For any person that is nominated by a shareholder for election as a director at the general meeting of the Company, the nomination committee and/or the Board should evaluate such candidate based on the criteria as set out above to determine whether such candidate is qualified for directorship.

Where appropriate, the nomination committee and/or the Board should make recommendation to shareholders in respect of the proposed election of director at the general meeting.

There was no change in directors during the Year.

提名程序

委任新董事

1. 提名委員會及／或董事會可從不同渠道物色董事人選，包括但不限於內部提升、調任、其它管理層成員引介及外界招聘代理等。
2. 提名委員會及／或董事會應在收到委任新董事的建議及候選人的個人資料（或相關詳情）後，依據上述準則評估該候選人，以判斷該候選人是否合資格擔任董事。
3. 如過程涉及一個或多個合意的候選人，提名委員會及／或董事會應根據本公司的需要及每位候選人的證明審查（如適用）排列他們的優先次序。
4. 提名委員會隨後應就委任合適人選擔任董事一事向董事會提出建議（如適用）。
5. 就任何經由股東提名於本公司股東大會上選舉為董事的人士，提名委員會及／或董事會應依據上述準則評估該候選人，以判斷該候選人是否合資格擔任董事。

在適用情況下，提名委員會及／或董事會可就於股東大會上選舉董事的提案向股東提出建議。

本年度董事並無變動。

CORPORATE GOVERNANCE REPORT

企業管治報告

Re-election of Director at General Meeting

1. The nomination committee and/or the Board should review the overall contribution and service to the Company of the retiring director and the level of participation and performance on the Board.
2. The nomination committee and/or the Board should also review and determine whether the retiring director continues to meet the criteria as set out above.
3. The nomination committee and/or the Board should then make recommendation to shareholders in respect of the proposed re-election of director at the general meeting.

Where the Board proposes a resolution to elect or re-elect a candidate as director at the general meeting, the relevant information of the candidate will be disclosed in the circular to shareholders and/or explanatory statement accompanying the notice of the relevant general meeting in accordance with the Listing Rules and/ or applicable laws and regulations.

Re-election of INED at General Meeting

Where the Board proposes a resolution to elect an individual as an INED at the general meeting, it should set out in the circular to shareholders and/or explanatory statement accompanying the notice of the relevant general meeting:

1. the process used for identifying the individual and why the Board believes the individual should be elected and the reasons why it considers the individual to be independent;
2. if the proposed INED will be holding their seventh (or more) listed company directorship, why the Board believes the individual would still be able to devote sufficient time to the Board;
3. the perspectives, skills and experience that the individual can bring to the Board; and
4. how the individual contributes to diversity (including gender diversity) of the Board.

於股東大會上重選董事

1. 提名委員會及／或董事會應檢討退任董事對本公司的整體貢獻及服務，以及在董事會的參與程度及表現。
2. 提名委員會及／或董事會亦應檢討及確定重選的退任董事是否仍然符合上述準則。
3. 提名委員會及／或董事會應就於股東大會上重選退任董事的提案向股東提出建議。

若董事會擬於股東大會上提呈決議案選舉或重選某位人士為董事，有關股東大會通告所隨附的致股東通函及／或說明函件中，將會按上市規則及／或相關適用法律及規則要求載列候選人的有關資料。

於股東大會上重選獨立非執行董事

倘董事會於股東大會上提呈決議案選任某人士為獨立非執行董事，則須於隨附相關股東大會通告的致股東通函及／或說明函件內載明：

1. 用以物色該名人士的流程及董事會認為應選任該名人士的理由以及認為該名人士屬獨立人士的原因；
2. 如建議獨立非執行董事將出任第七家（或以上）上市公司的董事，董事會認為該名人士仍可投入足夠時間於董事會的原因；
3. 該名人士可為董事會帶來的觀點、技能及經驗；及
4. 該名人士如何促進董事會成員多元化（包括性別多元化）。

CORPORATE GOVERNANCE REPORT

企業管治報告

The nomination committee has conducted annual review on the structure, size and composition of the Board and this Policy and where appropriate, make recommendations on changes to the Board to complement the Company's corporate strategy and business needs, to comply with all applicable laws and regulations from time to time and maintain good corporate governance practice.

AUDIT COMMITTEE

The audit committee comprises three INEDs of the Company, being, Mr. Lam Yat Fai, Mr. Chiu Sung Hong and Dr. Xian Yanfang and one Non-executive Director, Mr. Zhong Tao. Mr. Lam Yat Fai with professional accounting qualification and experience is the chairman of the audit committee.

The role and function of the audit committee include the followings:

- review of and monitor the external auditor's independence and objectivity and the effectiveness of the audit process in accordance with applicable standard;
- review of the annual and interim financial statements prior to their approval by the Board, and recommend application of accounting policies and changes to the financial reporting requirements; and
- review of the Company's financial controls, internal controls and risk management systems to ensure that management has discharged its duty to have an effective internal control system.

During the Year, the audit committee held 2 meetings. Details of individual attendance of its members are as follows:

提名委員會為董事會的架構、規模及組成以及本政策舉行年度檢討，並在有需要時向董事會提出修訂建議，以完善本公司的企業策略及切合本公司的業務需要，以不時遵守所有適用的法律及法規以及維持良好企業管治常規。

審核委員會

審核委員會成員包括本公司之三名獨立非執行董事，即林日輝先生、趙崇康先生、冼彥芳博士及一名非執行董事鍾濤先生。擁有專業會計資格及經驗的林日輝先生為審核委員會主席。

審核委員會之職責及功能包括以下各項：

- 按適用標準檢討及監察外聘核數師是否獨立客觀及核數程序是否有效；
- 於提呈董事會批准前審閱年度及中期財務報表，以及建議應用會計政策及財務匯報要求之變動；及
- 審閱本公司之財務監控、內部監控及風險管理制度，以確保管理層已履行職責建立有效之內部監控系統。

於本年度內，審核委員會舉行兩次會議。個別成員之出席詳情如下：

		Number of Meetings Attended/Held 出席／舉行會議次數
Mr. Lam Yat Fai (<i>Chairman</i>)	林日輝先生 (主席)	2/2
Mr. Chiu Sung Hong	趙崇康先生	2/2
Dr. Xian Yanfang	冼彥芳博士	2/2
Mr. Zhong Tao	鍾濤先生	1/2

CORPORATE GOVERNANCE REPORT

企業管治報告

The work performed by the audit committee during the Year includes the followings:

- reviewed the financial statements for the year ended 31 December 2023 and for the six months ended 30 June 2024;
- considered and approved of the remuneration and terms of engagement of the external auditor;
- considered and reviewed the scope of internal audit, findings and recommendation;
- reviewed the revised audit policy and term of reference of audit committee;
- reviewed the internal control and financial reporting matters of the Company; and
- reviewed arrangement (including investigation and following action) to raise concerns about possible improprieties in financial reporting, internal control or other matters through the whistle-blowing policy adopted by the Company.

於本年度內，審核委員會履行之工作包括以下各項：

- 審閱截至2023年12月31日止年度及截至2024年6月30日止六個月之財務報表；
- 考慮及批准外聘核數師之酬金及聘用條款；
- 考慮及審閱內部審計、結論及建議推薦；
- 檢討經修訂審核委員會之審核政策及職權範圍；
- 審閱本公司之內部監控及財務匯報事宜；及
- 透過審閱安排（包括調查及後續行動），對本公司採納的舉報政策就財務報告、內部監控或其它事項中可能存在的不當行為引起關注。

RISK MANAGEMENT COMMITTEE

The risk management committee, which was established by the Board, comprises two INEDs, Mr. Chiu Sung Hong (chairman of risk management committee) and Mr. Lam Yat Fai and one Executive Director, Mr. Fang Wen Quan.

The role and function of the risk management committee include the followings:

- enhance and strengthen the system of risk management of the Group and provide comments and recommendations thereon to the Board;
- identify the risks of the Group and provide recommendations to the Board; and
- other matters authorised by the Board.

風險管理委員會

董事會已成立風險管理委員會，成員包括兩名獨立非執行董事趙崇康先生（其為風險管理委員會之主席）及林日輝先生，及一名執行董事方文權先生。

風險管理委員會之職責及功能包括以下各項：

- 完善及提高本集團之風險管理機制，並對風險管理狀況向董事會提出意見和建議；
- 識別本集團之風險並向董事會提供建議；及
- 其它由董事會授權之事宜。

CORPORATE GOVERNANCE REPORT

企業管治報告

During the Year, the risk management committee held 1 meeting. Details of individual attendance of its members are as follows:

於本年度內，風險管理委員會舉行一次會議。個別成員之出席詳情如下：

		Number of Meetings Attended/Held 出席／舉行會議次數
Mr. Chiu Sung Hong (<i>Chairman</i>)	趙崇康先生 (主席)	1/1
Mr. Fang Wen Quan	方文權先生	1/1
Mr. Lam Yat Fai	林日輝先生	1/1

The work performed by the risk management committee during the Year includes the followings:

於本年度內，風險管理委員會履行之工作包括以下各項：

- Assisted the Board to perform its responsibilities of risk management and internal control;
- Oversaw and reviewed the Group's risk management and internal control systems on an ongoing basis; and
- Reviewed the revised risk management policy and term of reference of risk management committee.
- 協助董事會執行其風險管理及內部監控的職責；
- 持續監督及檢討本集團的風險管理及內部監控系統；及
- 檢討經修訂風險管理委員會之風險管理政策及職權範圍。

DIVIDEND POLICY

The Board has adopted a dividend policy (the "Dividend Policy") which does not provide any pre-determined dividend payout ratio. In considering dividend payment, the Board will take into account factors, such as results of operations, working capital, financial position, future prospects and capital requirements, as well as any other factors which the directors of the Company may consider relevant from time to time. The Board will review the Dividend Policy from time to time and the Dividend Policy does not constitute any commitment or obligation of the Company to declare dividends.

股息政策

董事會已採納股息政策（「股息政策」），股息政策沒有設定任何預定的派息率。在考慮審議股息時，董事會將考慮下列因素如經營業績、營運資金、財務狀況、未來前景及資本要求，以及本公司董事可能不時考慮相關的任何其它因素。董事會將不時檢討股息政策，股息政策並不構成本公司任何宣派股息的承諾或義務。

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code for Securities Transactions by Directors (the "Model Code") of Listed Issuers as set out in Appendix C3 of the Listing Rules as the code of conduct regarding Directors' securities transactions. Having made specific enquiry of all the Directors of the Company, they all confirm that they have complied with the Model Code throughout the Year.

董事進行證券交易的標準守則

本公司已採納上市規則附錄C3所載上市發行人董事進行證券交易的標準守則（「標準守則」），作為董事進行證券交易之操守準則。經向本公司之全體董事作出具體查詢後，彼等確認其於本年度內均已遵守標準守則。

CORPORATE GOVERNANCE REPORT

企業管治報告

AUDITOR'S REMUNERATION

The fees in relation to the audit services and non-audit services, including reviewing interim results and taxation services for the year provided by Messrs. Ernst & Young, Certified Public Accountants, the external auditor of the Company, amounted to HK\$1,390,000 and HK\$340,000 respectively.

DIRECTORS' RESPONSIBILITY FOR PREPARING THE CONSOLIDATED FINANCIAL STATEMENTS

The Directors of the Company acknowledge that it is their responsibilities for preparing the financial statements. The Directors of the Company consider that the Group's financial statements have been properly prepared in accordance with relevant regulations and applicable accounting principles. The Directors of the Company are not aware of any material uncertainties relating to events or conditions which may cast significant doubt upon the Company's ability to continue as a going concern. The statement of the auditor about its reporting responsibilities on the financial statements is set out in the Independent Auditor's Report on pages 57 to 63.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board is responsible for maintaining a sound and effective risk management and internal control systems so as to ensure the shareholders' investment and the Company's assets are properly safeguarded. The systems of risk management and internal control are designed to manage the risk of failure to achieve corporate objectives and can only provide reasonable but not absolute assurance against material misstatement, loss or fraud.

The Company established an internal audit department to assess its risk management and internal control systems, formulating an impartial opinion on the systems, and reporting its findings to the audit committee, the Chairman of the Board and the senior management concerned on a regular basis as well as following up on all reports to ensure that all issues have been satisfactorily resolved.

The Board has reviewed the risk management and internal control systems at least annually to ensure its continued effectiveness and adequacy.

Risk Management Framework

- Each business unit is responsible for identifying, assessing and managing risks (including environmental, social and governance ("ESG") risks) within its business, ensuring that appropriate internal controls for effective risk management are implemented — principal risks are identified and assessed in the yearly business planning process with action plans to manage those risks.

核數師酬金

本公司之外聘核數師安永會計師事務所(執業會計師)於年內所提供核數服務及非核數服務(包括審閱中期業績及稅務服務)之費用分別為1,390,000港元及340,000港元。

董事就編製綜合財務報表之責任

本公司董事認定編製財務報表為彼等之責任。本公司董事認為，本集團之財務報表已根據有關規例及適用會計原則妥為編製。本公司董事並不知悉有任何重要不明朗事件或情況可能令本公司持續經營之能力受到重大質疑。有關核數師就財務報表之報告責任之陳述載於第57至63頁之獨立核數師報告內。

風險管理及內部監控

董事會負責維持穩健及有效之風險管理及內部監控制度，以確保股東之投資及本公司資產得到妥善保障。風險管理及內部監控制度旨在管理未能達成企業目標之風險，並只可就重大錯誤陳述、損失或欺詐行為作出合理而非絕對之保證。

本公司已成立內部審核部門，以評估其內部監控制度，就有關制度達致中立意見，並定期向審核委員會、董事會董事長及高級管理人員匯報結論，以及跟進所有報告，以確保有關問題已獲妥善解決。

董事會至少每年檢討風險管理及內部監控，以確保風險管理及內部監控行之有效及充足性。

風險管理框架

- 各業務單位負責識別、評估及管理其業務內之風險，確保已為有效風險管理(包括環境、社會及管治風險)實施適當內部監控—於年度業務規劃過程中識別及評估主要風險，並制訂行動計劃管理該等風險。

CORPORATE GOVERNANCE REPORT

企業管治報告

2. The management is responsible for overseeing the risk management (including ESG risks) and internal control activities of the Group — regular meetings with each business unit to ensure principals risk are properly managed, and new or changing risks are identified.
3. The Board is responsible for reviewing and approving the effectiveness and adequacy of the Group's risk management (including ESG risks) and internal controls — review of the annual internal audit report and consideration of the audit committee's recommendation.

The risk management framework, coupled with our internal controls, ensures that the risks associated with our different business units are effectively controlled in line with the Group's risk appetite.

The risk management system of the Group is designed to facilitate effective and efficient operations, to ensure the maintenance of proper accounting records, to ensure compliance with applicable laws and regulations, to identify and manage potential risks and to safeguard assets of the Group. The management is responsible for the design, implementation and maintenance of internal controls, while the audit committee and the Board review the effectiveness of the Group's systems of risk management and internal controls through the assistance of the internal audit function.

During the Year, the Board has reviewed the effectiveness of the risk management and internal control systems through the audit committee and the internal audit department of the Company. The Board has also reviewed the adequacy of resources, qualifications and experience of staff of the Company's accounting and financial reporting function as well as those relating to the Company's ESG performance and reporting, and their training programmes and budget.

The Board formed its own view on the effectiveness of the systems based on the review of the internal audit report and the recommendation of the audit committee.

In respect of the Year, the Board considered the risk management and internal control systems of the Group effective and adequate. No significant areas of concern that may affect the financial, operational, compliance controls, and risk management of the Group have been identified. The Board also considered the resources, qualification and experience, training programs and budget of the Group's accounting, internal audit and financial reporting functions adequate. Nevertheless, the Group would take further steps to continually improve its risk management and internal control systems.

2. 管理層負責監察本集團之風險管理(包括環境、社會及管治風險)及內部監控活動—與各業務單位進行定期會議，確保已妥善管理主要風險及已識別新發現或正在變化之風險。
3. 董事會負責檢討及核准本集團風險管理(包括環境、社會及管治風險)及內部監控之有效及充足程度—審閱年度內部審核報告及考慮審核委員會之推薦意見。

風險管理框架(連同內部監控)確保不同業務單位之相關風險在本集團之風險偏向內得到有效控制。

本集團之風險管理制度設計為促進有效及高效營運、確保保存妥善會計記錄、確保遵守適用法例及法規、識別及管理潛在風險及保障本集團資產。管理層負責設計、執行及維持內部監控，而審核委員會及董事會則在內部審核職能之協助下檢討本集團的風險管理及內部監控制度之有效性。

於本年度，董事會亦透過審核委員會及本公司內部審核部門審閱內部監控制度之成效。董事會亦已檢討本公司在會計及財務匯報職能方面及與本公司環境、社會及管治表現和匯報相關之資源、員工資歷及經驗，以及員工所接受之培訓課程及有關預算是否足夠。

董事會根據內部審核報告之審核及審核委員會之推薦意見達致對制度有效程度之意見。

就本年度而言，董事會認為本集團之風險管理及內部監控制度有效及充足。概無所關注之重大範疇識別到可能影響本集團之財務、經營、合規監控及風險管理之問題。董事會亦認為在本集團在會計、內部審核及財務報告職能方面之資源、資歷及經驗、培訓計劃及預算充足。此外本集團將採取進一步行動持續改善風險管理及內部監控制度。

CORPORATE GOVERNANCE REPORT

企業管治報告

DISSEMINATION OF INSIDE INFORMATION

The Company is committed to a consistent practice of timely, accurate and sufficiently detailed disclosure of material information about the Group. The Company has adopted a policy on Disclosure of Inside Information which sets out the obligations, guidelines and procedures for handling and dissemination of inside information. With these guidelines and procedures, the Group has management controls in place to ensure that potential inside information can be promptly identified, assessed and escalated for the attention of the Board to decide about the need for disclosure.

COMPANY SECRETARY

The Company has engaged and appointed Mr. Lo Tai On, a representative from an external secretarial services provider, as the company secretary of the Company. The primary contact person with the company secretary of the Company is the Financial Controller of the Company. Mr. Lo has confirmed that he has taken no less than 15 hours of relevant training.

CONSTITUTIONAL DOCUMENTS

In order to (i) reflect and align with the latest regulatory requirement in relation to the expanded paperless listing regime and the electronic dissemination of corporate communications by listed issuers and the relevant amendments made to the Listing Rules which took effect from 31 December 2023; and (ii) align with other relevant requirements of the Listing Rules and company law of the Cayman Islands and incorporate certain corresponding housekeeping amendments, a special resolution was passed at the annual general meeting of the Company held on 7 June 2024 to amend the articles of association of the Company. The updated memorandum of association and articles of association of the Company was published on the websites of the Hong Kong Stock Exchange and the Company.

發佈內幕消息

本公司致力貫徹執行及時、準確及充足地詳細披露本集團之重大消息。本公司已採納內幕消息披露政策，當中載有處理及發佈內幕消息之責任、指引及程序。在該等指引及程序之基礎下，本集團已設有管理監控，確保可即時識別、評估及提交潛在內幕消息以供董事會決定是否需要作出披露。

公司秘書

本公司已委聘羅泰安先生（一名外聘秘書服務供應商之代表）為本公司之公司秘書。與本公司公司秘書之主要聯絡者為本公司之財務總監。羅先生確認，彼已接受不少於十五小時之相關培訓。

憲章文件

為(i)反映及符合有關擴大無紙化上市機制及上市發行人以電子方式發布公司通訊的最新監管規定，以及自2023年12月31日起生效的上市規則相關修訂；及(ii)符合上市規則及開曼群島公司法的其它相關規定，並納入若干相應的輕微修訂，本公司於2024年6月7日召開股東週年大會通過一項修改本公司章程的特別決議案。本公司經修訂的組織章程大綱及章程細則已於香港聯交所及本公司網站刊載。

CORPORATE GOVERNANCE REPORT

企業管治報告

COMMUNICATION WITH SHAREHOLDERS

The Board recognizes the importance of good communications with shareholders and investors, so the shareholders communication policy is reviewed on an annual basis to ensure its continued effectiveness. The objective of shareholder communication is to provide our shareholders with detailed information about the Company so that they can exercise their rights as shareholders in an informed manner. The Company establishes various communication channels with its shareholders and investors and employs a range of communication tools to ensure its shareholders are kept well informed of key business imperatives. These include general meetings, interim and annual reports, announcements and circulars. The Company believes that the AGM is one of the principal channels for shareholders to exchange views with the Board. The Board welcomes shareholders to attend and express their opinions at the AGM. Directors and external auditor attend the AGM to address shareholders' queries. Separate resolutions are proposed at general meetings on each substantially separate issue, including the re-election of individual Directors. The notice of the meeting, the annual report and the circular containing information on the proposed resolutions are sent to shareholders before the meeting in accordance to the listing rules and the articles of association of the Company. Procedure for voting by poll had been read out at the general meetings. All votes of the shareholders were taken by poll. The Company announced results of the poll in the manner prescribed under the Listing Rules.

The 2024 AGM of the Company was held on 7 June 2024. A notice convening the AGM contained in the circular dated 26 April 2024 was dispatched to the shareholders together with the annual report for the year ended 31 December 2023. A separate resolution was proposed by the chairman of the meeting in respect of each separate issue, including re-election of Directors.

Mr. Fang Wen Quan, the Chairman, Mr. Lui Man Sang, the Executive Director, Mr. Feng Quanming, the Non-executive Director and two INEDs, namely Mr. Lam Yat Fai and Dr. Xian Yanfang, attended the AGM in person or by electronic means to answer questions from shareholders. Mr. Zhong Tao, the Non-executive Director and Mr. Chiu Sung Hong, the INED were unable to attend the AGM due to his other business commitment.

與股東溝通

董事會明瞭與股東及投資者有良好溝通之重要性，所以每年均檢討股東溝通政策，以確保本政策行之有效。股東通訊之目的為向本公司股東提供有關本公司之詳細資料，以使彼等在知情情況下行使作為股東之權利。本公司為股東及投資者建立不同的溝通渠道，並運用一系列通訊工具以確保股東獲知重要業務動向，其中包括股東大會、中期及年度報告、公告及通函。本公司認為，股東週年大會為股東提供與董事會有效交流意見之主要渠道之一。董事會歡迎各股東出席股東週年大會並於會上發表彼等意見。董事及外聘核數師皆出席股東週年大會，以回應股東提問。股東大會上就各項重要獨立之事宜提呈獨立決議案，包括重選個別董事。大會通告、年報及載有擬提呈決議案有關資料之通函皆根據上市規則及本公司的組織章程細則向股東分發。投票表決程序已於股東大會上宣讀。股東之所有表決已按投票表決方式進行。本公司已按上市規則規定之方式公佈投票表決結果。

本公司於2024年6月7日舉行2024年股東週年大會，召開股東週年大會之通告（載於日期為2024年4月26日之通函內）已連同截至2023年12月31日止年度年報寄發予股東。大會主席就每個單獨議題（包括重選董事）提呈個別之決議案。

董事長方文權先生、執行董事呂文生先生，一名非執行董事馮全明先生及兩名獨立非執行董事林日輝先生及冼彥芳博士均親身或以電子方式出席股東週年大會解答股東提問。非執行董事鍾濤先生及獨立非執行董事趙崇康先生因其它事務而未能出席股東週年大會。

CORPORATE GOVERNANCE REPORT

企業管治報告

Shareholders' Communication Policy

The Company is committed to ensuring the shareholders as well as the investment community, are provided with ready, equal and timely access to current and relevant information about the Company (including its financial and operational performance, business plan and strategy, material developments, corporate governance and structures etc), in order to enable the shareholders to have better understanding of the Company as well as to exercise their rights in an informed manner, and to let shareholders and the investment community to enhance communication with the Company. Information shall be communicated to shareholders and the investors through:

- continuous disclosure of all material information of the Company;
- periodic disclosure through financial reports (interim and annual reports) of the Company;
- investor presentations;
- AGMs and other shareholders' meetings of the Company; and
- the Company's website at www.tiandapharma.com and the website of the Hong Kong Exchange and Clearing Limited.

The Board reviews the implementation and effectiveness of the shareholders' communication policy on an annual basis and considered that such policy remains effective in enhancing timely, transparent and open communication between the Company and the shareholders.

WHISTLEBLOWING POLICY

The Company is committed to achieving and maintaining a high standard of probity, openness, and accountability. A whistleblowing policy is in place to create a mechanism for the employees and other stakeholders of the Company to raise concerns, in confidence, about possible improprieties. A designated email account and a dedicated hotline have been set up for this purpose. The identity of each whistleblower and all information provided in connection with a whistleblowing report will be treated with the strictest confidence.

Anti-corruption and money laundering

The Group has established policies and procedures to deal with money laundering in its operations. In addition, the Group also has established prevention system by setting up communication channels for faults and anti-corruption reporting. The whistleblowing system can handle any breach of laws and regulations.

股東通訊政策

本公司致力確保股東及投資者，均可適時取得全面、相同及當前本公司的資料（包括其財務及運營表現、業務計劃及策略、重大發展、企業管治及公司架構等），使股東對公司更瞭解，以及讓股東在知情的情況下行使其權利，並讓股東及投資者與本公司加強溝通。可以通過下列途徑向股東及投資者提供資訊：

- 持續披露本公司所有重大的資訊；
- 定期披露本公司的財務報告（中期及年度報告）；
- 投資者簡報；
- 本公司股東週年大會及其它股東大會；及
- 本公司網站www.tiandapharma.com及香港交易及結算所有限公司網站。

董事會每年審閱股東通訊政策的執行情況及有效性，並認為該政策仍然有效加強本公司與股東之間及時、透明及公開的通訊。

舉報政策

本公司致力達致和保持高標準的廉潔、開放和有責任性。本公司制定了舉報政策旨在設立一個保密機制為員工及其它持份者對懷疑不當的行為提出舉報。就此，指定舉報電子郵件賬戶和舉報專用熱線亦已設立。每位舉報人的身份與舉報報告內有關的一切資料將嚴格保密。

反貪污及洗黑錢

本集團已制訂政策及程序以應對業務的洗黑錢活動。此外，本集團透過訂立申報及反貪污的溝通渠道，成立防範機制，舉報機制可應對任何違法及違規行為。

CORPORATE GOVERNANCE REPORT

企業管治報告

FAIR DISCLOSURE

The Company uses its best endeavors to distribute material information about the Group to all interested parties as timely as possible. Information about the Group can be found on the Company's website including descriptions of each business and the interim and annual reports of the Company.

INVESTOR RELATIONS

The Group fully recognises the importance of employing a professional, truthful and proactive attitude in promoting investor relations. This underscores the Group's persistence in maintaining optimum allround communications with investors, allowing it to collect information and valuable feedbacks from investors and announce its business strategy and direction in due course. These efforts are critical for the Group to improve its corporate governance and strengthen investor confidence.

Ensuring high corporate transparency is a key emphasis in the Group's investor relations activities. During the Year, the Group promoted investor relations through different channels. Regular meetings were held between the management and investors. Latest information regarding the Group and its business is proactively disclosed to investors so that the best investment decisions can be made. Whenever announcements on annual results, interim results and material transactions are made, the Group will capitalise such opportunities to enhance communications with investors, explaining to them the Group's latest operational situations and direction of development.

The Company also maintains a website at www.tiandapharma.com, where updates on the Company's business developments and operations, financial information and news can always be found.

Shareholders and investors may at any time send their enquiries and concerns to the Board in writing through Investor Relations Department whose contact details are as follows:

Address: Suites 2405–2410, 24th Floor, CITIC Tower,
No. 1 Tim Mei Avenue, Central, Hong Kong
Fax: (852) 2541 6558
Email: ir@tianda.com

公平披露

本公司致力向所有希望獲得本集團資料之人士適時地發放有關重要資料。有關本集團的資料(包括本公司每項業務的內容、中期報告及年報)均可於本公司網站尋獲。

投資者關係

本集團深明以專業、坦誠並適時主動之態度，乃推動投資者關係之重要因素。因此，本集團致力與投資者保持充分及良好之溝通，以便收集更多訊息及寶貴意見，並在適當時候公佈集團之業務策略及發展方向，期望在企業管治上力臻完善，增強投資者信心。

在投資者關係活動中，確保企業高透明度乃本集團相當重視之一環。於本年度，本集團透過不同渠道推動投資者關係。管理層定期與投資者會面，積極向投資者披露有關本集團最新資訊及業務消息，讓投資者作出最佳投資決定。每當作出全年業績、中期業績及重大交易公告時，本集團均會抓緊良機，加強與投資者之溝通，解釋本集團最新業務情況及發展方向。

本公司亦設有網站，網址為 www.tiandapharma.com，網站上會不斷更新本公司之業務發展及營運、財務資料及新聞。

股東和投資者可隨時以書面形式將其查詢及關注透過投資者關係部遞交董事會。聯絡詳情如下：

地址：香港中環添美道1號
中信大廈24樓2405–2410室
傳真：(852) 2541 6558
電郵： ir@tianda.com

CORPORATE GOVERNANCE REPORT

企業管治報告

SHAREHOLDERS' RIGHTS

The general meetings of the Company provide an opportunity for communication between the shareholders and the Board. The AGM of the Company shall be held in each year at such place as may be determined by the Board. All general meetings other than AGM shall be called an EGM. Set out below are procedures by which shareholders may (1) convene the EGM; (2) put forward enquires to the Board; and (3) put forward proposals at general meetings. The procedures are subject to the Company's articles of association and applicable legislation and regulations.

(1) Procedures for shareholders to convene the EGM

Any shareholder or shareholders holding at the date of the deposit of the requisition in aggregate not less than 10 per cent of such of the paid up capital of the Company as at the date of the deposit carries the right of voting at general meetings of the Company.

Such requisition must state the objects of the meeting and must be signed by the requisitionists and deposited at the Company's office.

If the Directors do not within 21 days from the date of the deposit of such requisition proceed duly to convene the EGM, the requisitionists themselves may convene a physical EGM at only one location which will be the Principal Meeting Place, and all reasonable expenses incurred by the requisitionists as a result of the failure of the Directors to convene such a meeting shall be reimbursed to them by the Company.

The notice period to be given to all the registered shareholders for consideration of the proposal raised by the requisitionist(s) concerned at the EGM varies according to the nature of the proposal as set out in the Company's articles of association and the CG Code.

(2) Procedures to put forward enquiries to the Board

Shareholders may, at any time, direct enquiries to the Board. All enquiries shall be in writing with the detail contact information of the requisitionists through the Company's principal place of business of Hong Kong at Suites 2405-2410, 24th Floor, CITIC Tower, No. 1 Tim Mei Avenue, Central, Hong Kong or email to ir@tianda.com for the attention of the Board.

(3) Procedures to put forward proposals at general meetings

Shareholders may follow the procedures set out above to convene the EGM for any business specified in such written requisition.

The procedures for shareholder of the Company to propose a person for election as director is posted on the Company website at www.tiandapharma.com.

股東權利

本公司股東大會提供股東與董事會溝通之機會。本公司股東週年大會應每年舉行，開會地點由董事會決定。股東週年大會以外之所有股東大會均稱為股東特別大會。下文載列股東(1)召開股東特別大會；(2)向董事會提出查詢；及(3)在股東大會上提呈議案之程序。該等程序須受本公司章程細則及適用法例法規之規限。

(1) 股東召開股東特別大會之程序

股東特別大會亦可應任何一名或以上股東之書面要求召開，惟該等股東於送交要求之日須合共持有不少於本公司於送交要求之日附帶本公司股東大會投票權之10%繳足股本。

有關請求必須列明會議之目標以及須經由請求人簽署，並送交本公司之辦事處。

倘董事並未於送交要求之日起計21日內正式召開股東特別大會，則請求人本人可自發於一個地點(即主要會議地點)召開現場股東特別大會，而所有因董事未有召開有關大會致使請求人產生之合理開支，須由本公司向彼等償付。

股東特別大會供全體登記股東考慮有關請求人所提出議案之通知期因議案性質而異，詳情載於本公司章程細則及企業管治守則。

(2) 向董事會提出查詢之程序

股東可隨時向董事會直接提出查詢。所有查詢須以書面作出，並連同請求人之詳細聯絡資料，一併郵寄往本公司之香港主要營業地點，地址為香港中環添美道1號中信大廈24樓 2405-2410室，或以電郵發送至 ir@tianda.com，註明收件人為董事會。

(3) 在股東大會上提呈議案之程序

股東可遵循以上所載之程序召開股東特別大會，以處理有關請求書所指定之任何事務。

本公司股東提名候選董事之程序登載於本公司網站 www.tiandapharma.com。

REPORT OF THE DIRECTORS

董事會報告

The Directors present their annual report and the audited consolidated financial statements for the year ended 31 December 2024 (the "Year").

PRINCIPAL ACTIVITIES

The Company and its subsidiaries are principally engaged in R&D, manufacture and sales of pharmaceutical, biotechnology and healthcare products, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services.

BUSINESS REVIEW

The business review of the Group for the Year containing a fair review of the business during the Year and discussion of future business development of the Group and the principal risks and uncertainties facing the Group is set out in the sections headed "Report of the Chairman" and "Management Discussion and Analysis" from pages 11 to 12 and pages 13 to 21 respectively of this Annual Report.

The financial risk management objectives and policies of the Group are shown in note 36 to the consolidated financial statements.

RELATIONSHIP WITH EMPLOYEES, CUSTOMERS AND SUPPLIERS

The Group understands the importance of maintaining a good relationship with its employees, customers and suppliers to meet its immediate and long-term business goals. During the Year under review, there were no material and significant dispute between the Group and its employees, customers and suppliers.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is committed to the sustainable development of the environment and our society. The Group has endeavoured to comply with laws and regulations regarding environmental protection and adopted effective environmental practices to ensure our business meet the required standards and ethics in respect of environmental protection. Further discussions on the Group's environmental policies and the relationships with various stakeholders are covered in a separate "Environmental, Social and Governance Report" published by the Company.

董事呈列截至2024年12月31日止年度(「本年度」)之年報及經審核綜合財務報表。

主要業務

本公司及其附屬公司主要從事醫藥、生物及保健產品之研發、生產和銷售，中藥材、中藥飲片及中藥的銷售，及提供中醫服務。

業務回顧

本集團本年度的業務回顧載有對本年度本集團業務之公正回顧及未來業務發展之討論以及本集團所面臨之主要風險及不確定性因素，分別載於本年報第11至12頁之「董事長報告」及第13至21頁之「管理層討論與分析」。

本集團的財務風險管理目標及政策載於綜合財務報表附註36。

與僱員、客戶及供應商的關係

本集團明白與其僱員、客戶及供應商維持良好關係，對達致即時及長遠業務目標極為重要。於本年度，本集團與其僱員、客戶及供應商概無重大及嚴重糾紛。

環境政策及表現

本集團致力於環境及社會之可持續發展。本集團盡力遵守有關環保之法律及法規，並採取有效環保措施確保我們的業務符合環保所需標準及操守。有關本集團的環境政策及與多個持份者的關係於本公司單獨發布的「環境、社會及管治報告」中進一步討論。

REPORT OF THE DIRECTORS

董事會報告

COMPLIANCE WITH RELEVANT LAWS AND REGULATIONS

During the Year, as far as the Board and management are aware, there was no material breach of or non-compliance with the applicable laws and regulations by the Group that has a significant impact on the businesses and operations of the Group.

SEGMENTAL INFORMATION

An analysis of the Group's revenue and contribution to results by segment for the Year is set out in note 4 to the consolidated financial statements.

MAJOR CUSTOMERS AND SUPPLIERS

For the Year, the five largest customers of the Group accounted for approximately 22.7% of the Group's total revenue while the largest customer of the Group accounted for approximately 6.8% of the Group's total revenue. In addition, for the Year, the five largest suppliers of the Group accounted for approximately 45.5% of the Group's total purchases while the largest supplier of the Group accounted for approximately 22.4% of the Group's total purchases.

During the Year, to the knowledge of the Directors, Shanghai Pharmaceuticals Holding Co., Ltd., together with its subsidiaries is one of the five major customers of the Group; and Tianda Group and Hongta Tobacco (Group) Limited indirectly hold the respective of 60% and 40% equity interest in Zhuhai S.E.Z. Cheng Cheng Printing Company Limited which is one of the five major suppliers of the Group.

RESULTS

The results of the Group for the Year are set out in the consolidated statement of profit or loss and other comprehensive income on pages 64 to 65.

DIVIDEND

The Board does not recommended the payment of any dividend for the year ended 31 December 2024 (2023: final dividend of HK0.26 cent per share).

遵守相關法律及法規

就董事會及管理層所知悉，本年度本集團概無嚴重違反或不遵守適用法律及法規，以致對本集團之業務及營運造成重大影響。

分部資料

本集團本年度之收入及分部對業績貢獻之分析載於綜合財務報表附註4。

主要客戶及供應商

於本年度，本集團之五大客戶及最大客戶分別佔本集團之總收入約22.7%及約6.8%。此外，於本年度，本集團之五大供應商及最大供應商分別佔本集團之採購總額約45.5%及約22.4%。

於本年度，就董事所知，上海醫藥集團股份有限公司及其附屬公司為本集團五大客戶之一；而天大集團及紅塔煙草（集團）有限責任公司分別間接持有本集團五大供應商之一珠海經濟特區誠成印務有限公司之60%及40%股權。

業績

本集團本年度之業績載於第64至65頁之綜合損益及其它全面收益表。

股息

董事會不建議就截至2024年12月31日止年度派付任何股息（2023年：末期股息每股0.26港仙）。

REPORT OF THE DIRECTORS

董事會報告

SUMMARY FINANCIAL INFORMATION

A summary of the results and of the assets and liabilities of the Group for the last five financial years/period is set out on page 176 of this annual report.

PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Group during the Year are set out in note 14 to the consolidated financial statements.

SHARE CAPITAL

Details of the Company's share capital are set out in note 29 to the consolidated financial statements.

RESERVES

Details of movements in the reserves of the Group and the Company during the Year are set out in the consolidated statement of changes in equity set out on page 68 and note 38 to the consolidated financial statements of this annual report.

DISTRIBUTABLE RESERVES

As at 31 December 2024, the Company's reserves available for distribution as computed in accordance with the Companies Act (as revised) of the Cayman Islands of amounted to HK\$290.7 million.

DONATIONS

No donation was made by the Group for charitable purposes during the Year.

財務資料概要

本集團於過往五個財政年度／期間之業績以及資產及負債之概要載於本年報第176頁。

物業、廠房及設備

本集團之物業、廠房及設備於本年度之變動詳情載於綜合財務報表附註14。

股本

本集團之物業、廠房及設備於本年度之變動詳情載於綜合財務報表附註29。

儲備

本集團及本公司於本年度之儲備變動詳情載於本年報第68頁之綜合權益變動表及綜合財務報表附註38。

可供分派儲備

於2024年12月31日，本公司根據開曼群島公司法（經修訂）計算之可供分派儲備為2億9,070萬港元。

捐款

本集團於本年度並無作出慈善目的之捐款。

REPORT OF THE DIRECTORS

董事會報告

DIRECTORS

The Directors of the Company during the Year and up to the date of this report were:

Executive Directors:

Mr. Fang Wen Quan (*Chairman and Managing Director*)
Mr. Lui Man Sang

Non-executive Directors:

Mr. Feng Quanming
Mr. Zhong Tao

Independent non-executive Directors (INEDs):

Mr. Lam Yat Fai
Mr. Chiu Sung Hong
Dr. Xian Yanfang

In accordance with Articles 99 of the Company's articles of association, Mr. Lui Man Sang, Mr. Lam Yat Fai and Dr. Xian Yanfang shall retire from their office by rotation at the forthcoming AGM and being eligible, they will offer themselves for re-election.

INEDs and Non-executive Directors are appointed for a term of 2 years and are subject to retirement in accordance with the Company's articles of association.

DIRECTORS' SERVICE CONTRACTS

None of the Directors has entered into any service agreement with the Company which is not determinable by the Company within 1 year without payment of compensation, other than statutory compensation.

董事

於本年度內及截至本報告日期之本公司董事為：

執行董事：

方文權先生 (*董事長兼董事總經理*)
呂文生先生

非執行董事：

馮全明先生
鍾濤先生

獨立非執行董事：

林日輝先生
趙崇康先生
冼彥芳博士

根據本公司之章程細則第99條，呂文生先生、林日輝先生及冼彥芳博士將於應屆股東週年大會上輪值告退，且合資格並願意膺選連任。

獨立非執行董事及非執行董事之任期為2年，並須根據本公司之章程細則告退。

董事服務合約

概無董事與本公司訂立本公司不作出賠償 (除法定賠償外) 而不可於一年內予以終止之任何服務協議。

REPORT OF THE DIRECTORS

董事會報告

DIRECTORS' INTERESTS IN SHARES AND UNDERLYING SHARES

At 31 December 2024, the interests of the Company's Directors, chief executives and their associates in the shares and underlying shares of the Company and its associated corporations as recorded in the register maintained by the Company pursuant to Section 352 of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) (SFO), were as follows:

Shares of the Company

Name of Director 董事姓名	Capacity 身份	Number of Shares held 所持股份數目	% 百分比
Mr. Fang Wen Quan	Held by controlled corporation	1,219,579,370	56.72
方文權先生	受控法團持有	(Note) (附註)	

Note: All the above shares are beneficially owned by Tianda Group. Mr. Fang Wen Quan has 100% equity interests in Tianda Group and, accordingly, is deemed to have a corporate interest in the above shares owned by Tianda Group and all the interests stated above represent long positions.

SHARE OPTION SCHEME

At an annual general meeting held on 28 August 2020, the Company approved the adoption of a new share option scheme (the "Scheme") and the terms of the Scheme are as follows.

The purpose of the Scheme is to enable the Company to recognise the future and/or past contributions of the participants (as defined in the Scheme) to the Company, and to attract and retain such important participants and/or to maintain a continuing relationship, with participants who have contributed to the result, growth, success and benefit of the Group, and in relation to administrative staff, to recruit and retain experienced and talented individuals and/or to reward their past contributions.

The Scheme is for a period of 10 years from the date of adoption on 28 August 2020. The Directors may, at their discretion, make an offer to any participant to take up options. An option is deemed to have been granted and accepted by the grantee upon his or her signing the duplicate letter comprising acceptance of the option and paying HK\$1 by way of consideration for the grant thereof.

董事於股份及相關股份之權益

於2024年12月31日，根據證券及期貨條例（香港法例第571章）（證券及期貨條例）第352條本公司所存置登記冊之記錄，本公司之董事、最高行政人員及彼等之聯繫人於本公司及其相聯法團之股份及相關股份中擁有之權益如下：

本公司股份

附註：上述所有股份乃由天大集團實益擁有。方文權先生於天大集團擁有全部股權，因此，彼被視為於天大集團所擁有之上述股份中擁有公司權益。上述所有權益皆為好倉。

購股權計劃

本公司於2020年8月28日舉行之股東週年大會上批准採納新購股權計劃（「該計劃」），該計劃之條款如下。

該計劃之目的為讓本公司確認參與者（定義見該計劃）於未來及／或過往對本公司之貢獻，以及吸引及挽留有關重要參與者及／或與已對本集團之業績、成長、成功及利益作出貢獻之參與者維持持續關係，並就行政人員而言，招募及挽留經驗豐富之人才及／或對彼等過往之貢獻作出獎勵。

該計劃自2020年8月28日採納當日起為期十年。董事可酌情邀請任何參與者接納購股權。承授人於簽署有關接納購股權之複印函件，並支付獲授購股權之代價1港元後，有關購股權即被視為已授出及獲接納。

REPORT OF THE DIRECTORS

董事會報告

The subscription price for shares of the Company under the Scheme shall be no less than the higher of (i) the closing price of the shares of the Company as stated in the Hong Kong Stock Exchange's daily quotations sheet on the offer date (which date must be a business day); (ii) a price being the average of the closing prices of the shares of the Company as stated in the Hong Kong Stock Exchange's daily quotations sheets for the 5 business days immediately preceding the offer date; and (iii) the nominal value of a share of the Company on the offer date.

The total number of shares of the Company which may be issued upon exercise of all options to be granted under the Scheme and any other share option schemes of the Company shall not in aggregate exceed 10 per cent of the total number of shares of the Company in issue as at the date of approval of the Scheme. An option may be exercised during a period to be determined by the Directors in its absolute discretion and in any event such period shall not be longer than 10 years from the date upon which the option is granted.

The total number of shares issued and to be issued upon exercise of the options granted to each participant under the Scheme in any 12-month period shall not exceed 1 per cent of the total number of shares in issue of the Company. Any further grant of options in excess of the 1 per cent limit shall be subject to shareholders' approval in a general meeting with such participant and his or her associates abstaining from voting.

No share option has been granted since the adoption of the Scheme on 28 August 2020. The Company can grant options under the Scheme for subscription of up to a total of 215,004,188 shares, representing 10% of the shares of the Company in issue as at the date of adoption, 1 January 2024, 31 December 2024 and the date of this report.

根據該計劃認購本公司股份之認購價將不低於下列三者中較高者：(i)本公司股份於授出日期（該日必須為營業日）在香港聯交所每日報價表所報之收市價；(ii)本公司股份於緊接授出日期前五個營業日在香港聯交所每日報價表所報之平均收市價；及(iii)本公司股份於授出日期之面值。

因行使根據該計劃及本公司任何其它購股權計劃授出之所有購股權而可能發行之本公司股份總數，合共不得超過批准該計劃當日本公司已發行股份總數之10%。購股權可於董事全權酌情釐定之期間內行使，並於任何情況下，該期間由購股權獲授出之日起計不得長於十年。

於任何十二個月期間內，每名參與者根據該計劃行使所獲授之購股權而獲發行及將獲發行之股份總數，不得超過本公司已發行股份總數之1%。進一步授出超過1%上限之購股權，須得到股東於股東大會上批准，而該名參與者及其聯繫人須就此放棄其投票權。

自於2020年8月28日採納該計劃以來，並無授出任何購股權。本公司可根據該計劃授出最多認購合共215,004,188股股份的購股權，相當於本公司於採納日期、2024年1月1日、2024年12月31日及本報告日期已發行股份的10%。

REPORT OF THE DIRECTORS

董事會報告

DIRECTORS' INTERESTS IN TRANSACTIONS, AGREEMENTS OR CONTRACTS OF SIGNIFICANCE

Save as disclosed in note 33 to the consolidated financial statements, no transaction, agreement or contract of significance to which the Company, its holding company or any of its subsidiaries was a party and in which a Director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the Year or at any time during the Year.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save for the Scheme of the Company disclosed above, at no time during the Year was the Company, its holding company or any of its subsidiaries a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate and none of the Directors nor any of their spouses or children under the age of 18 had any rights to subscribe for the securities of the Company, or had exercised any such rights during the Year.

PERMITTED INDEMNITY PROVISION

The articles of association of the Company provides that every Director shall be indemnified out of the funds of the Company against all liability incurred by him or her as such director in defending any proceedings, whether civil or criminal, in which judgment is given in his or her favour, or in which he or she is acquitted.

The Company has taken out insurance against the liabilities and costs associated with defending any proceedings which may be brought against the Directors of the Company and its subsidiaries.

董事於重大交易、協議或合約之權益

除於綜合財務報表附註33所披露者外，本公司、其控股公司或其任何附屬公司概無於本年度末存續或本年度任何時間訂立任何本公司董事於其中擁有重大權益（不論直接或間接）之重大交易、協議或合約。

董事收購股份或債券之權利

除上文所披露之本公司該計劃外，本公司、其控股公司或其任何附屬公司概無於本年度內訂立任何安排，以令董事可藉收購本公司或任何其它法人團體之股份或債券而從中獲益。此外，董事或彼等之配偶或年齡為十八歲以下之子女於本年度內概無任何可認購本公司證券之權利或已行使有關權利。

獲准許之彌償條文

本公司章程細則規定，各董事以董事身分，在其獲判得直或無罪的任何民事或刑事訴訟中應訊所產生的一切責任，可獲本公司撥資賠償。

本公司已就本公司及其附屬公司之董事可能面對任何訴訟時產生的責任和相關費用投購保險。

REPORT OF THE DIRECTORS

董事會報告

SUBSTANTIAL SHAREHOLDERS

At 31 December 2024, the register of substantial shareholders maintained by the Company pursuant to Section 336 of the SFO shows that the following shareholders had notified the Company of the relevant interests in 5% or more of the issued share capital of the Company:

主要股東

2024年12月31日，根據證券及期貨條例第336條本公司所存置之主要股東登記冊所示，下列股東已知會本公司其已持有本公司5%或以上已發行股本之相關權益：

Name of Shareholder 股東名稱	Capacity 身份	Number of Shares held 所持股份數目	% 百分比
Tianda Group 天大集團	Beneficial owner 實益擁有人	1,219,579,370 (Note 1) (附註1)	56.72
Mr. Fang Wen Quan 方文權先生	Held by controlled corporation 受控法團持有	1,219,579,370 (Note 1) (附註1)	56.72
SIIC Medical Science and Technology (Group) Limited ("SMST") 上海實業醫藥科技(集團)有限公司 (「上實醫藥」)	Beneficial owner 實益擁有人	280,517,724 (Note 2) (附註2)	13.05
Shanghai Pharmaceuticals Holding Co., Ltd. (「SPHL」) 上海醫藥集團股份有限公司(「上海醫藥」)	Held by controlled corporation 受控法團持有	280,517,724 (Note 2) (附註2)	13.05
Shanghai Industrial Investment (Holdings) Co., Ltd. ("SIIC") 上海實業(集團)有限公司(「上實集團」)	Held by controlled corporation 受控法團持有	280,517,724 (Note 2) (附註2)	13.05
Hongta Tobacco (Group) Limited 紅塔煙草(集團)有限責任公司	Beneficial owner 實益擁有人	207,616,264	9.66

Notes:

- (1) These 1,219,579,370 shares are beneficially owned by Tianda Group. Mr. Fang Wen Quan has 100% equity interests in Tianda Group and, accordingly, is deemed to have a corporate interest in the said 1,219,579,370 shares owned by Tianda Group.
- (2) These 280,517,724 shares are beneficially owned by SMST. SMST is beneficially owned as to 100% by SPHL and SIIC is the controlling shareholder of SPHL. Accordingly, SIIC and SPHL are deemed to be interested in the said 280,517,724 shares owned by SMST.

附註：

- (1) 該等1,219,579,370股股份由天大集團實益擁有。方文權先生於天大集團擁有全部股權，因此，彼被視為於天大集團所擁有之上述1,219,579,370股股份中擁有公司權益。
- (2) 該等280,517,724股股份由上實醫藥實益擁有。上海醫藥實益擁有上實醫藥全部權益，而上實集團為上海醫藥的控股股東。因此，上實集團及上海醫藥被視為於上實醫藥所擁有之上述280,517,724股股份中擁有權益。

REPORT OF THE DIRECTORS

董事會報告

All the interests stated above represent long positions. As at 31 December 2024, no short position was recorded in the register kept by the Company under section 336 of the SFO.

Save as disclosed above, the Company has not been notified of any other interest representing 5% or more in the Company's issued share capital as at 31 December 2024.

PURCHASE, SALE AND REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Year, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

ANNUAL CONFIRMATION OF INDEPENDENCE

The Company has received, from each of the INEDs, an annual confirmation of his or her independence pursuant to Rule 3.13 of the Listing Rules. The Company considers all of the INEDs are independent.

CONTINUING CONNECTED TRANSACTIONS

During the Year, the Group conducted certain transactions with connected persons which constituted "continuing connected transactions" under the Listing Rules. Details of these continuing connected transactions which are subject to the reporting requirements under Rule 14A.71 of the Listing Rules are summarised as follows:

PURCHASES OF THE INSTRUCTION LEAFLETS, PACKAGING BOXES AND RELATED PRODUCTS AND SERVICES

On 1 April 2022, a framework agreement was entered into between the Company and Tianda Culture Holdings (China) Limited* ("TCH (China)") for governing the transactions of purchasing printed instruction leaflets, packaging boxes and related products and designing services from TCH (China) and its subsidiaries by the Group for a term of three years commencing from 1 April 2022 to 31 March 2025. Details of the transactions are set out in the Company's announcement dated 1 April 2022.

* For identification purpose only

上述全部權益皆為好倉。於2024年12月31日，本公司根據證券及期貨條例第336條所存置之登記冊並無任何淡倉記錄。

除上文披露者外，本公司並無獲知會任何人士於2024年12月31日持有本公司5%或以上已發行股本之任何其它權益。

購買、出售及贖回本公司之上市證券

本公司或其任何附屬公司於本年度內概無購買、出售或贖回本公司任何上市證券。

年度獨立性確認

根據上市規則第3.13條，本公司已收到各獨立非執行董事就其獨立性所發出之年度確認。本公司認為所有獨立非執行董事均為獨立人士。

持續關連交易

於本年度內，本集團與關連人士進行若干交易，該等交易根據上市規則構成「持續關連交易」。該等持續關連交易須遵守上市規則第14A.71條項下之申報規定，其詳情概述如下：

採購說明書、包裝盒及相關產品及服務

於2022年4月1日，本公司與天大文化控股(中國)有限公司(「天大文控(中國)」)訂立框架協議，以監管本集團向天大文控(中國)及其附屬公司採購印刷說明書、包裝盒及相關產品及設計服務之該等交易，年期由2022年4月1日至2025年3月31日為期三年。有關交易詳情載於本公司日期為2022年4月1日之公告。

* 僅供參考

REPORT OF THE DIRECTORS

董事會報告

The Company had changed its financial year end date from 31 March to 31 December on 25 November 2022. In order to align with the Company's new financial year end date, the Company revised on 29 December 2022 the relevant period of the existing annual caps of the continuing connected transactions so that the revised annual caps cover the period/year ending on 31 December. Details of the revisions are set out in the Company's announcement dated 29 December 2022.

TCH (China) is a subsidiary of Tianda Group, the controlling shareholder of the Company, so it is a connected person of the Company under the Listing Rules. Accordingly, the framework agreement and the transactions contemplated under these framework agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

The annual cap and the actual amount of the above continuing connected transactions for the Year are as follows:

Business type 業務種類		The annual cap 年度上限 HK\$'000 千港元	The actual transaction amount 實際交易金額 HK\$'000 千港元
Purchasing printed instruction leaflets, packaging boxes and related products and services	採購印刷說明書、包裝盒及相關產品及服務	24,000	7,214

On 18 December 2024, a framework agreement was entered into between the Company and TCH (China) (the "2024 Framework Agreement") from 1 January 2025 to 31 December 2027, pursuant to which the Group purchase printed instruction leaflets, packaging boxes and related products and designing services from TCH (China) and its subsidiaries. Details of the 2024 Framework Agreement are set out in the Company's announcement dated 18 December 2024.

本公司於2022年11月25日把其財政年度的結算日期由3月31日更改為12月31日。為與本公司之新財政年度結算日保持一致，本公司於2022年12月29日，修訂現有持續關連交易之年度上限之有關期限，以使經修訂年度上限涵蓋於截至12月31日止之期間／年度。有關修訂詳情載於本公司日期為2022年12月29日之公告。

天大文控（中國）為本公司控股股東天大集團之附屬公司，故根據上市規則屬本公司之關連人士。據此，根據上市規則第14A章，框架協議及據該等框架協議擬進行之交易構成本公司之持續關連交易。

上述持續關連交易於本年度之年度上限及實際金額列示如下：

於2024年12月18日，本公司與天大文控（中國）訂立框架協議（「2024框架協議」），年期由2025年1月1日開始至2027年12月31日，據此本集團向天大文控（中國）及其附屬公司採購印刷說明書、包裝盒及相關產品及設計服務之該等交易。有關2024框架協議詳情載於本公司日期為2024年12月18日之公告。

REPORT OF THE DIRECTORS

董事會報告

PROVIDING PRODUCTS AND LOGISTICS SERVICES

On 20 September 2023, the Company entered into a 3-year term framework agreement with Shanghai Pharmaceuticals Holding Co., Ltd.* ("SPHL"). (the "2023 Framework Agreement") for a term of three years from 1 January 2024 to 31 December 2026, pursuant to which the Group from time to time enters into transactions by providing products (including pharmaceuticals products, Chinese medicines and healthcare products) and logistics services to each other during the ordinary and usual course of business. Details of the 2023 Framework Agreement are set out in the Company's announcement dated 18 October 2023.

A resolution regarding the 2023 Framework Agreement has been passed at the extraordinary meeting of the Company held on 9 November 2023.

As SPHL is a substantial shareholder of the Company, which indirectly holds 13.05% interest in the issued share capital of the Company. SPHL is therefore a connected person of the Company under Chapter 14A of the Listing Rules. Accordingly, the framework agreement and the transactions contemplated under the framework agreement constitute continuing connected transactions of the Company.

The annual cap and the actual amount of the above continuing connected transactions for the Year are as follows:

Business type 業務種類		The annual cap 年度上限 HK\$'000 千港元	The actual transaction amount 實際交易金額 HK\$'000 千港元
Sale of pharmaceutical products, Chinese medicine and healthcare products	銷售藥品、中藥及保健產品	38,000	28,334

* For identification purpose only

提供產品及物流配送服務

於2023年9月20日，本公司與上海醫藥集團股份有限公司（「上海醫藥」）訂立一份三年期的框架協議（「2023框架協議」），年期由2024年1月1日開始至2026年12月31日為期三年，據此本集團在一般及日常業務過程中，會不時向對方提供產品（包括成藥、中藥及保健產品）及物流配送服務。有關2023框架協議詳情載於本公司日期為2023年10月18日之公告。

一項有關2023框架協議的決議案已於本公司於2023年11月9日舉行之股東特別大會上獲得通過。

上海醫藥為本公司的主要股東，間接持有本公司已發行股本的13.05%之權益，根據上市規則第14A章，上海醫藥因此為本公司的關連人士。因此，框架協議及其項下所擬進行的該等交易構成本公司在上市規則下的持續關連交易。

上述持續關連交易於本年度之年度上限及實際金額列示如下：

* 僅供參考

REPORT OF THE DIRECTORS

董事會報告

Pursuant to Rule 14A.55 of the Listing Rules, INEDs have reviewed the above continuing connected transactions and confirmed that:

1. these transactions were in the Group's ordinary and usual course of business;
2. these transactions were entered into on normal commercial terms; and
3. these transactions were carried out in accordance with respective agreement terms which were fair and reasonable, and in the interests of the Company and the shareholders as a whole.

Ernst & Young, the Company's auditor, was engaged to report on the Group's continuing connected transactions in accordance with Hong Kong Standard on Assurance Engagements 3000 (Revised) *Assurance Engagements Other than Audits or Reviews of Historical Financial Information* and with reference to Practice Note 740 (Revised) *Auditor's Letter on Continuing Connected Transactions under the Hong Kong Listing Rules* issued by the Hong Kong Institute of Certified Public Accountants. Ernst & Young have issued their unmodified letter containing the findings and conclusions in respect of the continuing connected transactions disclosed above by the Group in accordance with Rule 14A.56 of the Listing Rules.

RELATED PARTY TRANSACTIONS

Details of the material related party transactions undertaken by the Group in its normal course of business are set out in note 33 to the consolidated financial statements. Those related party transactions which constituted continuing connected transactions/connected transactions under the Listing Rules which are set out in the section headed "Continuing Connected Transactions" above and complied with Chapter 14A of the Listing Rules.

EMOLUMENT POLICY

The emolument policy regarding the employees of the Group is based on their merit, qualifications and competence. The emoluments of the Directors are reviewed by the remuneration committee, having regard to the Company's operating results, individual performance and comparable market statistics. No Director or any of his or her associates and executive is involved in dealing his or her own remuneration.

根據上市規則第14A.55條，獨立非執行董事已審閱上述持續關連交易，並確認：

1. 該等交易為於本集團之一般及日常業務過程中進行；
2. 該等交易按一般商業條款訂立；及
3. 該等交易根據相關協議條款進行，而該等條款屬公平合理，並符合本公司及股東之整體利益。

本公司核數師安永會計師事務所已獲委聘就本集團之持續關連交易作出匯報，有關匯報乃根據《香港核證聘用準則》第3000號（經修訂）*歷史財務資料審計或審閱以外的核證聘用*，並參考香港會計師公會發出之《實務說明》第740號（經修訂）*關於香港《上市規則》所述持續關連交易的核數師函件進行*。安永會計師事務所已根據聯交所上市規則第14A.56條之規定，就本集團於上文所披露之持續關連交易發出無保留意見函件，當中載列其發現及結論。

關連人士交易

本集團於日常業務過程中進行之重大關連人士交易之詳情載列於綜合財務報表附註33。構成上市規則項下之持續關連交易／關連交易之關連人士交易已載於上述「持續關連交易」章節，並已遵守上市規則第14A章之規定。

薪酬政策

本集團就僱員之薪酬政策乃按其表現、資格及能力而定。董事之薪酬乃由薪酬委員會審閱，並參考本公司之經營業績、個人表現及可資比較之市場統計。概無董事或彼之任何聯繫人，以及行政人員參與處理其本身之薪酬。

REPORT OF THE DIRECTORS 董事會報告

PRE-EMPTIVE RIGHTS

There are no provisions for pre-emptive rights under the Company's articles of association or the laws of the Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to existing shareholders.

SUFFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of its Directors, the Company has maintained the prescribed public float under the Listing Rules throughout the Year.

AUDITOR

The financial statements of the Company and its subsidiaries for year ended 31 December 2024 have been audited by Ernst & Young, who retire and, being eligible, offer themselves for re-appointment. A resolution will be submitted to the forthcoming AGM to re-appoint Ernst & Young as auditor of the Company.

On behalf of the Board
Tianda Pharmaceuticals Limited

Fang Wen Quan
Chairman

Hong Kong, 28 March 2025

優先購買權

本公司之章程細則或開曼群島法例概無任何規定本公司有責任按比例提呈新股予現有股東之優先購買權規定。

足夠之公眾持股量

就本公司可獲之公開資料及其董事所知，於本年度內，本公司一直維持上市規則所指定之公眾持股量。

核數師

本公司及其附屬公司於截至2024年12月31日止年度之財務報表已經由安永會計師事務所審核，安永會計師事務所將任滿告退，並合資格及願意重選連任。於應屆股東週年大會上將提呈一項決議案以續聘安永會計師事務所為本公司之核數師。

代表董事會
天大藥業有限公司

方文權
董事長

香港，2025年3月28日

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌英皇道979號
太古坊一座27樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

To the shareholders of Tianda Pharmaceuticals Limited
(Incorporated in the Cayman Islands with limited liability)

致：天大藥業有限公司股東
(於開曼群島註冊成立之有限公司)

OPINION

We have audited the consolidated financial statements of Tianda Pharmaceuticals Limited (the "Company") and its subsidiaries (the "Group") set out on pages 64 to 175, which comprise the consolidated statement of financial position as at 31 December 2024, and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year ended 31 December 2024, and notes to the consolidated financial statements, including material accounting policy information.

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2024, and of its consolidated financial performance and its consolidated cash flows for the year ended 31 December 2024 in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants (the "HKICPA") and have been properly prepared in compliance with the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the consolidated financial statements section of our report. We are independent of the Group in accordance with the HKICPA's *Code of Ethics for Professional Accountants* (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

意見

我們已審核載於第64頁至175頁天大藥業有限公司（「貴公司」）及其附屬公司（「貴集團」）之綜合財務報表，包括於2024年12月31日之綜合財務狀況表與截至2024年12月31日止年度之綜合損益及其它全面收益表、綜合權益變動表及綜合現金流量表，以及綜合財務報表附註，包括重大會計政策資料。

我們認為，綜合財務報表已根據香港會計師公會頒佈的香港財務報告準則真實公平地反映 貴集團於2024年12月31日之綜合財務狀況及 貴集團截至2024年12月31日止年度之綜合財務表現及綜合現金流量，並已按照香港公司條例妥為編製。

意見的基礎

我們已根據香港會計師公會頒佈之《香港審計準則》進行審計。我們在該等準則下承擔的責任已於本報告「核數師就審計綜合財務報表承擔之責任」一節作進一步闡述。根據香港會計師公會頒佈之《專業會計師道德守則》（「守則」），我們獨立於 貴集團，並已履行守則中的其它道德責任。我們相信，我們所獲得之審計憑證能充足及適當地為我們之意見提供基礎。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

We have fulfilled the responsibilities described in the *Auditor's responsibilities for the audit of the consolidated financial statements* section of our report, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the consolidated financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying consolidated financial statements.

Key audit matter 關鍵審計事項

Impairment assessment of non-current non-financial assets 非流動非金融資產減值評估

The carrying amounts of property, plant and equipment, right-of-use assets, goodwill and other intangible assets of the Group (collectively, the "Non-current Non-financial Assets") as at 31 December 2024 amounted to approximately HK\$537 million in aggregate, which represented 70% of the Group's total assets.

於2024年12月31日，貴集團之物業、廠房及設備、使用權資產、商譽及其它無形資產（統稱「非流動非金融資產」）之賬面值合共約為5.37億港元，佔貴集團總資產之70%。

關鍵審計事項

關鍵審計事項是根據我們的專業判斷，認為對本期綜合財務報表的審計最為重要的事項。這些事項是在我們審計整體綜合財務報表及出具意見時進行處理的。我們不會對這些事項提供單獨的意見。就下文各事項而言，我們於文內提供我們的審計如何處理關鍵審計事項的詳情。

我們已履行本報告「核數師就審計綜合財務報表承擔的責任」章節所述的責任，包括有關該等事項的責任。因此，我們的審計包括執行為應對綜合財務報表重大錯報風險的評估而設的程序。審計程序的結果包括處理以下事項的程序，為我們就隨附的綜合財務報表的審計意見提供基礎。

How our audit addressed the key audit matter 我們的審計如何處理關鍵審計事項

We evaluated the assumptions and data used by the Group in the impairment assessment of the Non-current Non-financial Assets, and involved our internal valuation specialists to assist us in evaluating the methodologies adopted by the Company and the terminal growth rate and discount rate applied. In addition, we assessed the adequacy of the disclosure of impairment assessment in the consolidated financial statements.

我們評估了貴集團在評估非流動非金融資產減值時所採用的假設和數據，並邀請我們的內部估值專家協助我們評估貴公司所採用的方法以及所採用的終期增長率和折現率。此外，吾等亦評估綜合財務報表中有關減值評估的披露是否足夠。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



Key audit matter 關鍵審計事項

How our audit addressed the key audit matter 我們的審計如何處理關鍵審計事項

Impairment assessment of non-current non-financial assets (continued) 非流動非金融資產減值評估(續)

In light of the operating performance of the three operating segments in the current year, management considered that the Non-current Non-financial Assets of the Group may be impaired. Accordingly, management performed an impairment assessment on these assets in accordance with Hong Kong Accounting Standard ("HKAS") 36 *Impairment of Assets* issued by the HKICPA. In this regard, the Group estimated the recoverable amounts of the relevant cash-generating units of each operating segment on the value in use basis or the fair value less costs of disposal basis. The value-in-use calculation is based on management expectations, assumptions and estimates of future results of the relevant cash-generating units whereas the fair value less costs of disposal requires estimation of the prices at which an orderly transaction to sell the relevant assets would take place.

鑑於本年度三個經營分部的經營表現，管理層認為 貴集團的非流動非金融資產可能已出現減值。因此，管理層根據香港會計師公會頒佈的香港會計準則（「香港會計準則」）第 36 號 *資產減值* 對該等資產進行減值評估。就此而言， 貴集團按使用價值基準或公允價值減處置成本基準估計各經營分部相關現金產生單位的可收回金額。使用價值的計算是基於管理層對相關現金產生單位未來業績的預期、假設及估計，而公允價值減處置成本則需要估計有序交易出售相關資產的價格。

Given the material balance of the Non-current Non-financial Assets and the judgemental nature of the impairment assessment, we considered this a key audit matter.

鑒於非流動非金融資產的重大結餘及減值評估的判斷性質，我們認為這是一個關鍵的審計事項。

The accounting policies, significant accounting judgement and estimate and disclosures about the Non-current Non-financial Assets are included in notes 14, 15(a), 16 and 17 to the consolidated financial statements.

有關非流動非金融資產的會計政策、重大會計判斷及估計以及披露已載於綜合財務報表附註14、15(a)、16及17。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



OTHER INFORMATION INCLUDED IN THE ANNUAL REPORT

The directors of the Company are responsible for the other information. The other information comprises the information included in the Annual Report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF THE DIRECTORS FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors of the Company are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors of the Company either intend to liquidate the Group or to cease operations or have no realistic alternative but to do so.

The directors of the Company are assisted by the Audit Committee in discharging their responsibilities for overseeing the Group's financial reporting process.

年報所載的其它信息

貴公司董事需對其它信息負責。其它信息包括刊載於年報內的信息（綜合財務報表及我們的核數師報告除外）。

我們對綜合財務報表的意見並不涵蓋其它信息，我們亦不對該等其它信息發表任何形式的鑒證結論。

結合我們對綜合財務報表的審計，我們的責任是閱讀其它信息，在此過程中，考慮其它信息是否與綜合財務報表或我們在審計過程中所了解的情況存在重大抵觸或者似乎存在重大錯誤陳述的情況。基於我們已執行的工作，如果我們認為其它信息存在重大錯誤陳述，我們需要報告該事實。在這方面，我們就此並無任何報告。

董事就綜合財務報表須承擔的責任

貴公司董事須負責根據香港會計師公會頒佈的《香港財務報告準則》及《香港公司條例》的披露規定擬備真實而中肯的綜合財務報表，並對其認為為使綜合財務報表的擬備不存在因欺詐或錯誤而導致的重大錯誤陳述所需的內部控制負責。

在擬備綜合財務報表時，貴公司董事負責評估貴集團持續經營的能力，並在適用情況披露與持續經營有關的事項，以及使用持續經營為會計基礎，除非貴公司董事有意將貴集團清盤或停止經營，或別無其它實際的替代方案。

審核委員會協助貴公司董事履行監督貴集團的財務報告程序的責任。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Our report is made solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

核數師就審計綜合財務報表承擔的責任

我們的目標，是對綜合財務報表整體是否不存在因欺詐或錯誤而導致的重大錯誤陳述取得合理保證，並出具包括我們意見的核數師報告。我們僅向閣下（作為整體）作出報告，除此以外，我們的報告不可用作其它用途。我們並不就本報告之內容對任何其它人士承擔任何責任或接受任何義務。

合理保證是高水準的保證，但不能保證按照《香港審計準則》進行的審計，在某一重大錯誤陳述存在時總能發現。錯誤陳述可以由欺詐或錯誤引起，如果合理預期他們單獨或匯總起來可能影響使用者依賴綜合財務報表所作出的經濟決定，則有關的錯誤陳述可被視為重大。

在根據《香港審計準則》進行審計的過程中，我們運用了專業判斷，保持了專業懷疑態度。我們亦：

- 識別和評估由於欺詐或錯誤而導致綜合財務報表存在重大錯誤陳述的風險，設計及執行審計程序以應對這些風險，以及獲取充足和適當的審計憑證，作為我們意見的基礎。由於欺詐可能涉及串謀、偽造、蓄意遺漏、虛假陳述、或凌駕於內部控制之上，因此未能發現因欺詐而導致的重大錯誤陳述的風險高於未能發現因錯誤而導致的重大錯誤陳述的風險。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis of forming an opinion on the consolidated financial statements. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.
- 瞭解與審計相關的內部控制，以設計適當的審計程序，但目的並非對 貴集團內部控制的有效性發表意見。
- 評價董事所採用會計政策的恰當性及作出會計估計和相關披露的合理性。
- 對董事採用持續經營會計基礎的恰當性作出結論。根據所獲取的審計憑證，確定是否存在與事項或情況有關的重大不確定性，從而可能導致對 貴集團的持續經營能力產生重大疑慮。如果我們認為存在重大不確定性，則有必要在核數師報告中提請使用者注意綜合財務報表中的相關披露。假若有關的披露不足，則我們應當發表非無保留意見。我們的結論是基於核數師報告日止所取得的審計憑證。然而，未來事項或情況可能導致 貴集團不能持續經營。
- 評價綜合財務報表的整體列報方式、結構和內容，包括披露，以及綜合財務報表是否中肯反映交易和事項。
- 計劃及執行集團審計，就 貴集團內實體或業務單位的財務信息獲取充足、適當的審計憑證，作為對綜合財務報表發表意見的依據。我們負責集團審計的方向、監督和對審計工作進行檢討。我們為審計意見承擔全部責任。

INDEPENDENT AUDITOR'S REPORT

獨立核數師報告



We communicate with the Audit Committee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Audit Committee, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is CHENG Man.

除其它事項外，我們與審核委員會溝通了計劃的審計範圍、時間安排、重大審計發現等，包括我們在審計中識別出內部控制的任何重大缺陷。

我們還向審核委員會提交聲明，說明我們已符合有關獨立性的相關專業道德要求，並與他們溝通有可能合理地被認為會影響我們獨立性的所有關係和其它事項，以及在適用的情況，為消除對獨立性的威脅所採取的行動或防範措施。

從與審核委員會溝通的事項中，我們確定哪些事項對本期綜合財務報表的審計最為重要，因而構成關鍵審計事項。我們在核數師報告中描述這些事項，除非法律法規不允許公開披露這些事項，或在極端罕見的情況，如果合理預期在我們報告中溝通某事項造成的負面後果超過產生的公眾利益，我們決定不應在報告中溝通該事項。

出具本獨立核數師報告的審計項目合夥人是鄭敏。

Ernst & Young
Certified Public Accountants
Hong Kong
28 March 2025

安永會計師事務所
執業會計師
香港
2025年3月28日

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其它全面收益表

Year ended 31 December 2024 截至2024年12月31日止年度

		Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
REVENUE	收入	5	329,937	532,089
Cost of sales	銷售成本		(177,913)	(276,557)
Gross profit	毛利		152,024	255,532
Other income, gains and losses, net	其它收入、收益及虧損淨額	6	4,663	8,275
Selling and distribution expenses	銷售及分銷支出		(107,851)	(186,458)
Administrative expenses	行政支出		(85,039)	(84,992)
Research and development expenses	研發支出		(13,283)	(13,105)
Finance costs	融資成本	8	(4,854)	(4,946)
LOSS BEFORE TAX	除稅前虧損	7	(54,340)	(25,694)
Income tax	所得稅	11	(7,074)	689
LOSS FOR THE YEAR	本年度虧損		(61,414)	(25,005)
OTHER COMPREHENSIVE LOSS	其它全面虧損			
<i>Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:</i>	<i>於往後期間將不會重新分類為損益之其它全面虧損：</i>			
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其它全面收益之股本投資之公允價值變動		(216)	(525)
Exchange differences on translation of the Company's financial statements	換算本公司財務報表所產生之匯兌差額		(1,932)	(1,477)
			(2,148)	(2,002)
<i>Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:</i>	<i>於往後期間或會重新分類為損益之其它全面虧損：</i>			
Exchange differences on translation of subsidiaries' financial statements	換算附屬公司財務報表所產生之匯兌差額		(17,124)	(4,476)
OTHER COMPREHENSIVE LOSS FOR THE YEAR	本年度其它全面虧損		(19,272)	(6,478)
TOTAL COMPREHENSIVE LOSS FOR THE YEAR	本年度全面虧損總額		(80,686)	(31,483)

continued / ...
續 / ...

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

綜合損益及其它全面收益表

Year ended 31 December 2024 截至2024年12月31日止年度

		Note	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
		附註		
Loss for the year attributable to:	應佔本年度虧損：			
Shareholders of the Company	本公司股東		(61,371)	(24,155)
Non-controlling interests	非控股權益		(43)	(850)
			(61,414)	(25,005)
Total comprehensive loss for the year attributable to:	應佔本年度全面虧損總額：			
Shareholders of the Company	本公司股東		(80,643)	(29,834)
Non-controlling interests	非控股權益		(43)	(1,649)
			(80,686)	(31,483)
LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	本公司股東 應佔每股虧損		HK cents 港仙	HK cents 港仙
Basic and diluted	基本及攤薄	13	(2.85)	(1.12)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

綜合財務狀況表

31 December 2024 於2024年12月31日

		Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	14	349,759	371,346
Right-of-use assets	使用權資產	15(a)	36,328	41,392
Goodwill	商譽	16	90,391	95,230
Other intangible assets	其它無形資產	17	60,530	20,677
Deposits paid for acquisition of property, plant and equipment and other intangible assets	就購買物業、廠房及設備以及其它無形資產支付的按金	22	12,138	35,222
Financial asset at fair value through profit or loss	按公允價值計入損益之金融資產	18	–	9,000
Equity investment designated at fair value through other comprehensive income	指定為按公允價值計入其它全面收益之股本投資	19	–	216
Total non-current assets	非流動資產總值		549,146	573,083
CURRENT ASSETS	流動資產			
Inventories	存貨	20	40,209	65,148
Trade and bills receivables	應收賬款及應收票據	21	77,423	104,801
Prepayments, deposits and other receivables	預付款項、按金及其它應收款	22	11,894	11,505
Due from a fellow subsidiary	應收一間同系附屬公司款項	23(a)	87	312
Income tax recoverable	可收回所得稅		575	–
Cash and bank balances	現金及銀行結餘	24	85,688	162,442
Total current assets	流動資產總值		215,876	344,208
CURRENT LIABILITIES	流動負債			
Trade payables	應付賬款	25	67,438	106,018
Other payables and accruals	其它應付款及應計費用	26	46,885	88,923
Due to fellow subsidiaries	應付同系附屬公司款項	23(b)	11,659	12,458
Income tax payables	應付所得稅		750	3,743
Bank borrowings	銀行借款	27	122,074	96,492
Lease liabilities	租賃負債	15(b)	2,192	5,678
Total current liabilities	流動負債總額		250,998	313,312
NET CURRENT ASSETS/(LIABILITIES)	流動資產／(負債) 淨值		(35,122)	30,896
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債		514,024	603,979

continued / ...
續／ ...

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

綜合財務狀況表

31 December 2024 於2024年12月31日

			2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
	Notes 附註			
NON-CURRENT LIABILITIES		非流動負債		
Bank borrowings	27	銀行借款	–	8,358
Lease liabilities	15(b)	租賃負債	3,179	3,069
Deferred tax liabilities	28	遞延稅項負債	5,180	611
Total non-current liabilities		非流動負債總額	8,359	12,038
NET ASSETS		資產淨值	505,665	591,941
EQUITY		權益		
Equity attributable to shareholders of the Company		本公司股東應佔權益		
Issued capital	29	已發行股本	215,004	215,004
Reserves	30	儲備	290,834	377,067
			505,838	592,071
Non-controlling interests		非控股權益	(173)	(130)
TOTAL EQUITY		權益總額	505,665	591,941

Fang Wen Quan
方文權
Chairman
董事長

Lui Man Sang
呂文生
Executive Director
執行董事

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

綜合權益變動表

Year ended 31 December 2024 截至2024年12月31日止年度

		Attributable to shareholders of the Company 本公司股東應佔										Non-controlling interests 非控股權益		Total equity 權益總額
		Share capital 股本 HK\$'000 千港元	Share premium 股份溢價 HK\$'000 千港元	Capital redemption reserve 資本贖回儲備 HK\$'000 千港元	Capital contribution reserve 資本供款儲備 HK\$'000 千港元	Capital reserve 資本儲備 HK\$'000 千港元	Special reserve 特別儲備 HK\$'000 千港元	Statutory reserve 法定儲備 HK\$'000 千港元	Investment revaluation reserve 投資重估儲備 HK\$'000 千港元	Exchange fluctuation reserve 匯兌波動儲備 HK\$'000 千港元	Retained profits 保留溢利 HK\$'000 千港元	Total 總額 HK\$'000 千港元	Non-controlling interests 非控股權益 HK\$'000 千港元	Total equity 權益總額 HK\$'000 千港元
At 1 January 2023	於2023年1月1日	215,004	355,703	67	8,959	-	3,460	30,883	(10,983)	(72,544)	97,282	627,831	26,411	654,242
Loss for the year	本年度虧損	-	-	-	-	-	-	-	-	-	(24,155)	(24,155)	(850)	(25,005)
Other comprehensive loss for the year:	本年度其它全面虧損：													
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其它全面收益之股本投資之公允價值變動	-	-	-	-	-	-	-	(525)	-	-	(525)	-	(525)
Exchange differences on translation of financial statements	換算財務報表所產生之匯兌差額	-	-	-	-	-	-	-	-	(5,154)	-	(5,154)	(799)	(5,953)
Total comprehensive loss for the year	本年度全面虧損總額	-	-	-	-	-	-	-	(525)	(5,154)	(24,155)	(29,834)	(1,649)	(31,483)
Acquisition of non-controlling interests (note 33(b)(ii))	收購非控股權益 (附註33(b)(ii))	-	-	-	-	(336)	-	-	-	-	-	(336)	(24,892)	(25,228)
Release of reserves	釋放儲備	-	-	-	-	-	-	(3,382)	-	-	3,382	-	-	-
Final dividends for the nine months ended 31 December 2022 declared	已宣派截至2022年12月31日止九個月之末期股息	-	-	-	-	-	-	-	-	-	(5,590)	(5,590)	-	(5,590)
At 31 December 2023 and 1 January 2024	於2023年12月31日及2024年1月1日	215,004	355,703*	67*	8,959*	(336)*	3,460*	27,501*	(11,508)*	(77,698)*	70,919*	592,071	(130)	591,941
Loss for the year	本年度虧損	-	-	-	-	-	-	-	-	-	(61,371)	(61,371)	(43)	(61,414)
Other comprehensive loss for the year:	本年度其它全面虧損：													
Changes in fair value of equity investments designated at fair value through other comprehensive income	指定為按公允價值計入其它全面收益之股本投資之公允價值變動	-	-	-	-	-	-	-	(216)	-	-	(216)	-	(216)
Exchange differences on translation of financial statements	換算財務報表所產生之匯兌差額	-	-	-	-	-	-	-	-	(19,056)	-	(19,056)	-	(19,056)
Total comprehensive loss for the year	本年度全面虧損總額	-	-	-	-	-	-	-	(216)	(19,056)	(61,371)	(80,643)	(43)	(80,686)
Final dividends for the year ended 31 December 2023 declared	已宣派截至2023年12月31日止年度之末期股息	-	(5,590)	-	-	-	-	-	-	-	-	(5,590)	-	(5,590)
At 31 December 2024	於2024年12月31日	215,004	350,113*	67*	8,959*	(336)*	3,460*	27,501*	(11,724)*	(96,754)*	9,548*	505,838	(173)	(505,665)

* These reserve accounts comprise the consolidated reserves of HK\$290,834,000 (2023: HK\$377,067,000) in the consolidated statement of financial position as at 31 December 2024.

* 此等儲備賬包含於2024年12月31日的綜合財務狀況表內的綜合儲備290,834,000港元(2023年：377,067,000港元)。

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量表

Year ended 31 December 2024 截至2024年12月31日止年度

	Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動所得現金流量		
Loss before tax	除稅前虧損	(54,340)	(25,694)
Adjustments for:	就下列各項作出之調整：		
Finance costs	融資成本	8	4,946
Interest income	利息收入	6	(1,100)
Loss/(gain) on disposal/write-off of property, plant and equipment	出售／撇銷物業、廠房及設備之虧損／(收益)	6	103
Impairment of goodwill	商譽減值	16	1,339
Impairment/(reversal of impairment) of financial assets, net	金融資產之減值／(減值撥回)，淨額	7	(1,596)
Fair value loss/(gains), net:	公允價值虧損／(收益)，淨額：		
Financial assets at fair value through profit or loss	按公允價值計入損益之金融資產	6	(377)
Structured deposits	結構性存款	6	(260)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	7	28,746
Depreciation of right-of-use assets	使用權資產折舊	7	6,599
Amortisation of other intangible assets	其它無形資產攤銷	7	2,887
Reversal of write-down of inventories to net realisable value	撥回撇減存貨至可變現淨值	7	(406)
Recognition of government grants	確認政府補助		(90)
		(13,641)	12,790
Decrease/(increase) in inventories	存貨減少／(增加)	23,503	(18,899)
Decrease in trade and bills receivables	應收賬款及應收票據減少	26,002	33,305
Decrease in prepayments, deposits and other receivables	預付款項、按金及其它應收款減少	288	5,191
Increase in trade payables	應付賬款增加	4,847	35,484
Decrease in other payables and accruals	其它應付款及應計費用減少	(39,706)	(117,082)
Decrease in amount due from a fellow subsidiary	應收一間同系附屬公司款項減少	208	1,134
Increase/(decrease) in amounts due to fellow subsidiaries	應付同系附屬公司款項增加／(減少)	(386)	2,894
Cash generated from/(used in) operations	經營所得／(所用) 現金	1,115	(45,183)
PRC taxes refunded/(paid)	退回／(已付) 中國稅項	(5,959)	372
Interest paid	已付利息	(4,854)	(4,946)
Net cash flows used in operating activities	經營活動所用之現金流量淨額	(9,698)	(49,757)

continued / ...
續／...

CONSOLIDATED STATEMENT OF CASH FLOWS

綜合現金流量表

Year ended 31 December 2024 截至2024年12月31日止年度

	Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金流量		
Interest received	已收利息	1,100	3,032
Capitalised portion of interest paid	已付利息的資本化部分	8	(380)
Deposits paid for purchases of property, plant and equipment and other intangible assets	購買物業、廠房及設備以及其它無形資產所支付的按金	(5,116)	-
Proceeds from disposal of items of property, plant and equipment	出售物業、廠房及設備項目之所得款項	89	283
Purchases of property, plant and equipment	購買物業、廠房及設備	(20,605)	(48,898)
Purchases of other intangible assets	購買其它無形資產	(16,881)	(17,003)
Investments in financial assets at fair value through profit or loss	於按公允價值計入損益之金融資產之投資	(6,000)	(10,000)
Proceeds from disposal of financial assets at fair value through profit or loss	出售按公允價值計入損益之金融資產之所得款項	15,377	-
Proceeds from structured deposits	來自結構性存款之所得款項	86,450	300,279
Investments in structured deposits	於結構性存款之投資	(86,189)	(296,414)
Net cash flows used in investing activities	投資活動所用之現金流量淨額	(31,775)	(69,101)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金流量		
Dividends paid	已付股息	31(b)	(5,588)
Acquisition of non-controlling interests	收購非控股權益	33(b)(ii)	-
New bank loans	新造銀行貸款	75,915	43,455
Repayment of bank loans	償還銀行貸款	(94,916)	(64,407)
Repayment of lease liabilities	償還租賃負債	31(b)	(6,060)
Net cash flows used in financing activities	融資活動所用之現金流量淨額	(30,649)	(57,394)
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等值項目減少淨額	(72,122)	(176,252)
Cash and cash equivalents at beginning of year	於年初之現金及現金等值項目	162,442	340,277
Effect of foreign exchange rate changes, net	外匯匯率變動之影響(淨額)	(4,632)	(1,583)
CASH AND CASH EQUIVALENTS AT END OF YEAR	於年終之現金及現金等值項目	85,688	162,442
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等值項目結餘之分析		
Cash and bank balances as stated in the statement of financial position	於財務狀況表列賬之現金及銀行結餘	24	85,688
			162,442

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

1. CORPORATE AND GROUP INFORMATION

Tianda Pharmaceuticals Limited (the “Company”) is a limited liability company incorporated in the Cayman Islands and the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The registered office address of the Company is located Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands and its principal place of business is Suites 2405-2410, 24th floor, CITIC Tower, No. 1 Tim Mei Avenue, Central, Hong Kong.

During the year, the Company and its subsidiaries (collectively, the “Group”) were involved in the research and development, manufacture and sale of pharmaceuticals, biotechnology and healthcare products, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services.

In the opinion of the directors, the immediate holding company and the ultimate holding company of the Company is Tianda Group Limited, which is a private limited liability company incorporated in Hong Kong.

Information about principal subsidiaries

Particulars of the Company's principal subsidiaries as at 31 December 2024 are as follows:

Company name 公司名稱	Place of incorporation/ registration and business 註冊成立/ 註冊及經營地點	Issued ordinary share capital or paid-up capital/ registered capital 已發行普通股或 實繳股本／註冊資本	Percentage of equity attributable to the Company 本公司應佔 權益百分比		Principal activities 主要業務
			Direct 直接	Indirect 間接	
天大藥業(雲南)有限公司* ("Tianda Pharmaceuticals (Yunnan)") (「天大藥業(雲南)」)	People's Republic of China ("PRC")/ Mainland China 中華人民共和國 (「中國」)／ 中國大陸	RMB36,000,000 人民幣36,000,000元	–	100	Research and development, manufacture and sale of pharmaceutical, biotechnology and healthcare products 醫藥、生物科技及 保健產品之研究、 開發、生產及銷售

1. 公司及集團資料

天大藥業有限公司(「本公司」)為於開曼群島註冊成立之有限公司，其股份於香港聯合交易所有限公司(「聯交所」)上市。本公司之註冊辦事處位於Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands，主要營業地點位於香港中環添美道1號中信大廈24樓2405-2410室。

年內，本公司及其附屬公司(統稱「本集團」)從事醫藥、生物科技及保健產品之研發、生產及銷售，中藥材、中藥飲片及中藥的銷售，及提供中醫服務。

董事認為，本公司的直接控股公司及最終控股公司為天大集團有限公司(於香港註冊成立的私人有限公司)。

有關主要附屬公司之資料

本公司於2024年12月31日之主要附屬公司之資料如下：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

1. CORPORATE AND GROUP INFORMATION (continued)

1. 公司及集團資料 (續)

Information about principal subsidiaries (continued)

有關主要附屬公司之資料 (續)

Company name 公司名稱	Place of incorporation/ registration and business 註冊成立/ 註冊及經營地點	Issued ordinary share capital or paid-up capital/ registered capital 已發行普通股或 實繳股本／註冊資本	Percentage of equity attributable to the Company 本公司應佔 權益百分比		Principal activities 主要業務
			Direct 直接	Indirect 間接	
天大藥業(珠海)有限公司* (“Tianda Pharmaceuticals (Zhuhai)”) (「天大藥業(珠海)」)	PRC/ Mainland China 中國／中國大陸	RMB113,000,000/ RMB126,000,000 人民幣113,000,000元／ 人民幣126,000,000元	–	100	Research and development, manufacture and sale of pharmaceutical and biotechnology products 醫藥及生物科技產品之研究、開發、生產及銷售
天大中醫藥(中國)有限公司** (“TCM (China)”) (「天大中醫藥(中國)」)	PRC/ Mainland China 中國／中國大陸	RMB30,000,000/ RMB50,000,000 人民幣30,000,000元／ 人民幣50,000,000元	–	100	Wholesale of pharmaceutical products, Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicines 醫藥產品、中藥材、中藥飲片及中藥的批發
珠海天大中藥飲片有限公司*** (“Zhuhai TPCHM”) (「珠海天大中藥飲片」)	PRC/ Mainland China 中國／中國大陸	RMB12,580,000/ RMB50,000,000 人民幣12,580,000元／ 人民幣50,000,000元	–	100	Production and sale of traditional Chinese medicine decoction pieces and trading of agricultural by-products 中藥飲片生產及銷售以及農副產品的買賣
珠海天大館有限公司^@	PRC/ Mainland China 中國／中國大陸	RMB14,340,000/ RMB100,000,000 人民幣14,340,000元／ 人民幣100,000,000元	–	100	Provision of traditional Chinese medicine clinical services and sale of Chinese medicine products 提供中醫服務及銷售中藥產品

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

1. CORPORATE AND GROUP INFORMATION (continued)

1. 公司及集團資料 (續)

Information about principal subsidiaries (continued)

有關主要附屬公司之資料 (續)

Company name 公司名稱	Place of incorporation/ registration and business 註冊成立/ 註冊及經營地點	Issued ordinary share capital or paid-up capital/ registered capital 已發行普通股或 實繳股本/註冊資本	Percentage of equity attributable to the Company 本公司應佔 權益百分比		Principal activities 主要業務
			Direct 直接	Indirect 間接	
天大館(中國)有限公司*@@	PRC/ Mainland China 中國/中國大陸	RMB30,630,000/ RMB100,000,000 人民幣30,630,000元/ 人民幣100,000,000元	–	100	Investment holding and sale of healthcare products 投資控股及 保健產品之銷售
TDMall (Tsim Sha Tsui) Limited 天大館(尖沙咀)有限公司	Hong Kong 香港	HK\$1,900,000 1,900,000港元	–	90	Provision of traditional Chinese medicine clinical services and sale of Chinese medicine products 提供中醫服務及 銷售中藥產品
TDMall (Hong Kong) Limited 天大館(香港)有限公司	Hong Kong 香港	HK\$10,000 10,000港元	–	100	Provision of traditional Chinese medicine clinical services and sale of Chinese medicine products 提供中醫服務 及銷售中藥產品
TDMall (Jordan) Limited [%] 天大館(佐敦)有限公司 [%]	Hong Kong 香港	–	–	90	Provision of traditional Chinese medicine clinical services and sale of Chinese medicine products 提供中醫服務 及銷售中藥產品
TDMall (Australia) Pty. Ltd.	Australia 澳大利亞	AUD10,000 10,000澳元	–	100	Provision of traditional Chinese medicine clinical services and sale of Chinese medicine products 提供中醫服務 及銷售中藥產品

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

1. CORPORATE AND GROUP INFORMATION (continued)

Information about principal subsidiaries (continued)

- * Registered as wholly-foreign-owned enterprises under PRC law
- ^ Registered as a limited liability company under PRC law
- & At 31 December 2024, the Group has injected RMB113,000,000 to Tianda Pharmaceuticals (Zhuhai). The outstanding capital contribution of RMB13,000,000 to the subsidiary is due to be paid on or before 5 August 2029 in accordance with the subsidiary's articles of association.
- # At 31 December 2024, the Group has injected RMB30,000,000 to TCM (China). The outstanding capital contribution of RMB20,000,000 to the subsidiary is due to be paid on or before 31 December 2025 in accordance with the subsidiary's articles of association.
- ## At 31 December 2024, the Group has injected RMB12,580,000 to Zhuhai TPCHM. The outstanding capital contribution of RMB37,420,000 to the subsidiary is due to be paid on or before 6 December 2029 in accordance with the subsidiary's revised articles of association.
- @ At 31 December 2024, the Group has injected RMB14,340,000 to 珠海天大館有限公司. The outstanding capital contribution of RMB85,660,000 to the subsidiary is due to be paid on or before 31 December 2030 in accordance with the subsidiary's articles of association.
- @@ At 31 December 2024, the Group has injected RMB30,630,000 to 天大館(中國)有限公司. The outstanding capital contribution of RMB69,370,000 to the subsidiary is due to be paid on or before 22 December 2047 in accordance with the subsidiary's articles of association.
- % According to the articles of association of TDMall (Jordan) Limited, the total amount of share capital to be paid up amounted to HK\$1,500,000. As at 31 December 2024, the Group and the non-controlling shareholder have not yet injected capital into TDMall (Jordan) Limited. The outstanding capital contribution of HK\$1,500,000 is due to be paid.

The above table lists the subsidiaries of the Company which, in the opinion of the directors, principally affected the results for the year or formed a substantial portion of the net assets of the Group. To give details of other subsidiaries would, in the opinion of the directors, result in particulars of excessive length.

1. 公司及集團資料(續)

有關主要附屬公司之資料(續)

- * 根據中國法律註冊之外商獨資企業
- ^ 根據中國法律註冊之有限公司
- & 於2024年12月31日，本集團已向天大藥業(珠海)注資人民幣113,000,000元。根據該附屬公司的組織章程細則，應付該附屬公司的未繳出資款人民幣13,000,000元應於2029年8月5日或之前支付。
- # 於2024年12月31日，本集團已向天大中醫藥(中國)注資人民幣30,000,000元。根據該附屬公司的組織章程細則，應付該附屬公司的未繳出資款人民幣20,000,000元應於2025年12月31日或之前支付。
- ## 於2024年12月31日，本集團已向珠海天大中藥飲片注資人民幣12,580,000元。根據該附屬公司的經修訂組織章程細則，應付該附屬公司的未繳出資款人民幣37,420,000元應於2029年12月6日或之前支付。
- @ 於2024年12月31日，本集團已向珠海天大館有限公司注資人民幣14,340,000元。根據該附屬公司的組織章程細則，應付該附屬公司的未繳出資款人民幣85,660,000元應於2030年12月31日或之前支付。
- @@ 於2024年12月31日，本集團已向天大館(中國)有限公司注資人民幣30,630,000元。根據該附屬公司的組織章程細則，應付該附屬公司的未繳出資款人民幣69,370,000元應於2047年12月22日或之前支付。
- % 根據天大館(佐敦)有限公司的組織章程細則，應繳股本總額為1,500,000港元。於2024年12月31日，本集團及非控股股東尚未向天大館(佐敦)有限公司注資。應付未繳出資款為1,500,000港元。

上表列出董事認為對本年度本集團業績有主要影響或構成本集團資產淨值主要部份的本公司附屬公司。董事認為將其它附屬公司之資料列出會令篇幅過於冗長。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES

2.1 BASIS OF PRESENTATION AND PREPARATION

Basis of presentation

The consolidated financial statements for the year ended 31 December 2024 have been prepared on the going concern basis notwithstanding that the Group had net current liabilities of approximately HK\$35.1 million as at 31 December 2024 and reported a net loss and operating cash outflow of approximately HK\$61.4 million and approximately HK\$9.7 million, respectively for the year then ended, as the directors of the Company consider that the Group will have adequate funds available to enable it to operate as a going concern for the twelve months from the end of the reporting period, based on the Group's cash flow projection which, took into account, inter alia, the following:

- (a) as at the end of the reporting period, the Group had unutilised credit facilities of HK\$13,663,000 from banks. The total facility amount is HK\$135,737,000, of which an amount of HK\$122,074,000 was drawn down during the year and outstanding as at the end of the reporting period; and
- (b) the Group has good track records and relationship with banks which would enhance the Group's ability on restructuring its borrowing facilities. The Group is confident that sufficient financing can be arranged from the refinancing or renewal of bank borrowings upon or before the maturity date.

Basis of preparation

These financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards ("HKASs") and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and the disclosure requirements of the Hong Kong Companies Ordinance. They have been prepared under the historical cost convention, except for equity investments designated at fair value through other comprehensive income and financial assets at fair value through profit or loss which have been measured at fair value. These financial statements are presented in Hong Kong dollar ("HK\$") and all values are rounded to the nearest thousand except when otherwise indicated.

2. 會計政策

2.1 呈報及編製基準

呈報基準

儘管本集團於2024年12月31日之流動負債淨額約為3,510萬港元，及截至該日止年度分別錄得虧損淨額及經營現金流出約6,140萬港元及約970萬港元，截至2024年12月31日止年度之綜合財務報表已按持續經營基準編製，因為本公司董事認為本集團自報告期末起計十二個月將有足夠可用資金使其能夠持續經營。有關結論乃根據本集團之現金流量預測得出，乃經考慮(其中包括)以下各項：

- (a) 於報告期末，本集團之未動用銀行信貸融資為13,663,000港元。融資總額為135,737,000港元，其中122,074,000港元於年內提取，且於報告期末仍未償還；及
- (b) 本集團與銀行的往績記錄及關係良好，可加強本集團重組其借貸融資的能力。本集團相信於到期日或之前可透過銀行借貸再融資或續期籌備充足資金。

編製基準

財務報表乃根據香港會計師公會頒佈之香港財務報告準則(包括全部香港財務報告準則、香港會計準則及詮釋)及香港公司條例的披露規定編製。該等財務報表採用歷史成本法編製，惟指定為按公允價值計入其它全面收益之股本投資及按公允價值計入損益之金融資產按公允價值計量。該等財務報表以港元呈列，而除另有指明外，所有數值均約整至最近的千位數。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.1 BASIS OF PRESENTATION AND PREPARATION (continued)

Basis of preparation (continued)

Basis of consolidation

The consolidated financial statements include the financial statements of the Company and its subsidiaries for the year ended 31 December 2024. A subsidiary is an entity (including a structured entity), directly or indirectly, controlled by the Company. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).

Generally, there is a presumption that a majority of voting rights results in control. When the Company has, directly or indirectly, less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- (a) the contractual arrangement with the other vote holders of the investee;
- (b) rights arising from other contractual arrangements; and
- (c) the Group's voting rights and potential voting rights.

The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. The results of subsidiaries are consolidated from the date on which the Group obtains control, and continue to be consolidated until the date that such control ceases.

Profit or loss and each component of other comprehensive income are attributed to the shareholders of the Company and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

2. 會計政策 (續)

2.1 呈報及編製基準 (續)

編製基準 (續)

綜合基準

綜合財務報表包括本公司及其附屬公司截至2024年12月31日止年度之財務報表。附屬公司為本公司直接或間接控制之實體(包括結構性實體)。當本集團對參與投資對象業務的浮動回報承擔風險或享有權利以及能透過對投資對象之權力(即本集團獲賦予現有能力以主導投資對象相關活動之既存權利)影響該等回報時,即取得控制權。

於一般情況下均存在多數投票權形成控制權之推定。倘本公司直接或間接擁有少於投資對象大多數投票或類似權利的權利,則本集團於評估其是否擁有對投資對象之權力時會考慮一切相關事實及情況,包括:

- (a) 與投資對象其它投票持有人之合約安排;
- (b) 其它合約安排所產生之權利;及
- (c) 本集團之投票權及潛在投票權。

附屬公司的財務報表乃按與本公司相同的報告期間及一致的會計政策編製而成。附屬公司之業績自本集團取得控制權當日起綜合入賬,直至該項控制權終止為止。

損益及其它全面收益之各組成部分歸屬於本公司股東及非控股權益,即使此舉引致非控股權益結餘出現虧絀。所有本集團內公司間之資產及負債、權益、收入、開支以及與本集團成員公司之間交易有關之現金流量均於綜合賬目時悉數對銷。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.1 BASIS OF PRESENTATION AND PREPARATION (continued)

Basis of preparation (continued)

Basis of consolidation (continued)

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control described above. A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

If the Group loses control over a subsidiary, it derecognises the related assets (including goodwill), liabilities, any non-controlling interest and the exchange fluctuation reserve; and recognises the fair value of any investment retained and any resulting surplus or deficit in profit or loss. The Group's share of components previously recognised in other comprehensive income is reclassified to profit or loss or retained profits/accumulated losses, as appropriate, on the same basis as would be required if the Group had directly disposed of the related assets or liabilities.

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The Group has adopted the following revised HKFRSs for the first time for the current year's financial statements:

Amendments to HKFRS 16	<i>Lease Liability in a Sale and Leaseback</i>
Amendments to HKAS 1	<i>Classification of Liabilities as Current or Non-current (the "2020 Amendments")</i>
Amendments to HKAS 1	<i>Non-current Liabilities with Covenants (the "2022 Amendments")</i>
Amendments to HKAS 7 and HKFRS 7	<i>Supplier Finance Arrangements</i>

2. 會計政策 (續)

2.1 編製基準 (續)

編製基準 (續)

綜合基準 (續)

倘事實及情況顯示上文附屬公司會計政策所述的三項控制因素中一項或多項出現變動，本集團會重新評估其是否仍然控制投資對象。倘於附屬公司的擁有權權益變動並無失去控制權，則按權益交易入賬。

倘本集團失去對一間附屬公司之控制權，則終止確認相關資產（包括商譽）、負債、任何非控股權益及匯兌波動儲備，並確認所保留任何投資之公允價值；及損益內任何因此產生之盈餘或虧絀。先前於其它全面收益內確認之本集團應佔部份則按倘本集團直接出售有關資產或負債所規定之相同基準重新分類至損益或保留溢利／累計虧損（如適用）。

2.2 會計政策及披露變更

本集團於本年度之財務報表首次採納下列經修訂香港財務報告準則：

香港財務報告準則第16號之修訂	售後回租的租賃負債
香港會計準則第1號之修訂	負債分類為流動負債或非流動負債（「2020年修訂」）
香港會計準則第1號之修訂	附帶契諾的非流動負債（「2022年修訂」）
香港會計準則第7號及香港財務報告準則第7號之修訂	供應商融資安排

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

The nature and the impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 16 specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains. Since the Group has no sale and leaseback transactions with variable lease payments that do not depend on an index or a rate occurring from the date of initial application of HKFRS 16 Leases, the amendments did not have any impact on the financial position or performance of the Group.
- (b) The 2020 Amendments clarify the requirements for classifying liabilities as current or non-current, including what is meant by a right to defer settlement and that a right to defer must exist at the end of the reporting period. Classification of a liability is unaffected by the likelihood that the entity will exercise its right to defer settlement. The amendments also clarify that a liability can be settled in its own equity instruments, and that only if a conversion option in a convertible liability is itself accounted for as an equity instrument would the terms of a liability not impact its classification. The 2022 Amendments further clarify that, among covenants of a liability arising from a loan arrangement, only those with which an entity must comply on or before the reporting date affect the classification of that liability as current or non-current. Additional disclosures are required for non-current liabilities that are subject to the entity complying with future covenants within 12 months after the reporting period.

2. 會計政策 (續)

2.2 會計政策及披露變更 (續)

經修訂香港財務報告準則的性質及影響詳述如下：

- (a) 香港財務報告準則第16號之修訂訂明賣方一承租人於計量售後租回交易產生的租賃負債時使用的規定，以確保賣方一承租人不會確認與其所保留使用權有關的任何收益或虧損金額。由於本集團自首次應用香港財務報告準則第16號租賃之日起，並無不取決於指數或比率的可變租賃付款額的售後租回交易，因此該等修訂對本集團的財務狀況或表現並無任何影響。
- (b) 2020年修訂澄清將負債分類為流動或非流動的規定，包括遞延結算權利的含義及於報告期末必須存在的遞延權利。負債的分類不受實體將行使其遞延結算權利的可能性所影響。該等修訂亦澄清負債可以其自身權益工具結算，以及僅在可轉換負債的轉換選擇權自身作為權益工具入賬的情況下，負債的條款才不會影響其分類。2022年修訂進一步澄清在貸款安排產生的負債契諾中，僅實體須於報告日期或之前遵守的契諾方會影響該負債分類為流動或非流動。非流動負債（實體須於報告期後12個月內遵守未來契諾）須作出額外披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.2 CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

- (c) Amendments to HKAS 7 and HKFRS 7 clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

As a result of the implementation of the amendments, the Group has provided additional disclosures about its supplier finance arrangements in notes 27 and 31 to the financial statements.

2. 會計政策 (續)

2.2 會計政策及披露變更 (續)

- (c) 香港會計準則第7號及香港財務報告準則第7號之修訂澄清供應商融資安排的特點，並規定額外披露有關安排。該等修訂的披露規定旨在協助財務報表的使用者了解供應商融資安排對實體負債、現金流量及流動性風險的影響。

由於實施該等修訂，本集團已於財務報表附註27及31中提供更多有關其供應商融資安排的披露資料。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS

The Group has not applied the following applicable new and revised HKFRSs, that have been issued but are not yet effective, in these financial statements:

HKFRS 18	<i>Presentation and Disclosure in Financial Statements</i> ³
HKFRS 19	<i>Subsidiaries without Public Accountability: Disclosures</i> ³
Amendments to HKFRS 9 and HKFRS 7	<i>Amendments to the Classification and Measurement of Financial Instruments</i> ²
Amendments to HKFRS 10 and HKAS 28	<i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i> ⁴
Amendments to HKAS 21	<i>Lack of Exchangeability</i> ¹
<i>Annual Improvements to HKFRS Accounting Standards – Volume 11</i>	Amendments to HKFRS 1, HKFRS 7, HKFRS 9, HKFRS 10 and HKAS 7 ²

- ¹ Effective for annual periods beginning on or after 1 January 2025
- ² Effective for annual periods beginning on or after 1 January 2026
- ³ Effective for annual/reporting periods beginning on or after 1 January 2027
- ⁴ No mandatory effective date yet determined but available for adoption

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則

本集團並未於該等財務報表中採納以下已頒佈但尚未生效之適用新訂及經修訂香港財務報告準則。

香港財務報告準則第18號	<i>財務報表的呈列及披露</i> ³
香港財務報告準則第19號	<i>非公共受託責任之附屬公司：披露</i> ³
香港財務報告準則第9號及香港財務報告準則第7號之修訂	<i>金融工具分類及計量 (修訂本)</i> ²
香港財務報告準則第10號及香港會計準則第28號之修訂	<i>投資者與其聯營公司或合資公司之間的資產出售或注資</i> ⁴
香港會計準則第21號之修訂	<i>缺乏可兌換性</i> ¹
香港財務報告準則會計準則的年度改進—第11冊	香港財務報告準則第1號、香港財務報告準則第7號、香港財務報告準則第9號、香港財務報告準則第10號及香港會計準則第7號之修訂 ²

- ¹ 於2025年1月1日或之後開始的年度期間生效
- ² 於2026年1月1日或之後開始的年度期間生效
- ³ 於2027年1月1日或之後開始的年度／報告期間生效
- ⁴ 並無釐定強制生效日期但可供採納

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS (continued)

The Group intends to apply these applicable new and revised HKFRSs, if applicable, when they become effective. Further information about those applicable new and revised HKFRSs that are expected to be applicable to the Group is described below.

- (a) HKFRS 18 replaces HKAS 1 *Presentation of Financial Statements*. While a number of sections have been brought forward from HKAS 1 with limited changes, HKFRS 18 introduces new requirements for presentation within the statement of profit or loss, including specified totals and subtotals. Entities are required to classify all income and expenses within the statement of profit or loss into one of the five categories: operating, investing, financing, income taxes and discontinued operations and to present two new defined subtotals. It also requires disclosures about management-defined performance measures in a single note and introduces enhanced requirements on the grouping (aggregation and disaggregation) and the location of information in both the primary financial statements and the notes. Some requirements previously included in HKAS 1 are moved to HKAS 8 *Accounting Policies, Changes in Accounting Estimates and Errors*, which is renamed as HKAS 8 *Basis of Preparation of Financial Statements*. As a consequence of the issuance of HKFRS 18, limited, but widely applicable, amendments are made to HKAS 7 *Statement of Cash Flows*, HKAS 33 *Earnings per Share* and HKAS 34 *Interim Financial Reporting*. In addition, there are minor consequential amendments to other HKFRSs. HKFRS 18 and the consequential amendments to other HKFRSs are effective for annual periods beginning on or after 1 January 2027 with earlier application permitted. Retrospective application is required. The Group is currently analysing the new requirements and assessing the impact of HKFRS 18 on the presentation and disclosure of the Group's financial statements.

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則 (續)

本集團擬於該等適用新訂及經修訂香港財務報告準則 (如適用) 生效時應用該等準則。預期將適用於本集團之該等適用新訂及經修訂香港財務報告準則之其它資料載列於下文。

- (a) 香港財務報告準則第18號取代香港會計準則第1號財務報表的呈列。儘管香港會計準則第1號的多個部分已被繼承並作出有限變動，但香港財務報告準則第18號對損益表內的呈列方式引入新規定，包括指定總計及小計。實體須將損益表內的所有收入及開支分類為五個類別之一：經營、投資、融資、所得稅及已終止經營業務，並呈列兩個新界定的小計。其亦規定在單一附註中披露管理層界定的績效指標，並對主要財務報表及附註中的組合 (總計及分類) 及資訊位置提出更高的規定。之前包含在香港會計準則第1號的部分規定已移至香港會計準則第8號會計政策、會計估計變動及錯誤，並重新命名為香港會計準則第8號財務報表的編製基準。由於香港財務報告準則第18號的頒佈，香港會計準則第7號現金流量表、香港會計準則第33號每股盈利及香港會計準則第34號中期財務報告已作出有限但廣泛適用的修訂。此外，其它香港財務報告準則亦有輕微相應修訂。香港財務報告準則第18號及其它香港財務報告準則之相應修訂於2027年1月1日或之後開始之年度期間生效，並可提早應用。本集團須追溯應用。本集團現正分析新規定及評估香港財務報告準則第18號對本集團財務報表的呈列及披露的影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS (continued)

(b) HKFRS 19 allows eligible entities to elect to apply reduced disclosure requirements while still applying the recognition, measurement and presentation requirements in other HKFRSs. To be eligible, at the end of the reporting period, an entity must be a subsidiary as defined in HKFRS 10 *Consolidated Financial Statements*, cannot have public accountability and must have a parent (ultimate or intermediate) that prepares consolidated financial statements available for public use which comply with HKFRSs. Earlier application is permitted. As the Company is a listed company, it is not eligible to elect to apply HKFRS 19. Some of the Company's subsidiaries are considering the application of HKFRS 19 in their specified financial statements.

(c) Amendments to HKFRS 9 and HKFRS 7 clarify the date on which a financial asset or financial liability is derecognised and introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. The amendments shall be applied retrospectively with an adjustment to opening balance of retained profits/accumulated losses (or other component of equity) at the initial application date. Prior periods are not required to be restated and can only be restated without the use of hindsight. Earlier application of either all the amendments at the same time or only the amendments related to the classification of financial assets is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則 (續)

(b) 香港財務報告準則第19號允許合資格實體選擇應用精簡披露規定，同時仍應用其它香港財務報告準則中之確認、計量及呈列規定。為符合資格，於報告期末，實體必須為香港財務報告準則第10號綜合財務報表所界定之附屬公司，無公眾問責性且須有一個編製符合香港財務報告準則之綜合財務報表供公眾使用之母公司（最終或中間公司）。允許提早應用。由於本公司為上市公司，其不符合資格選擇應用香港財務報告準則第19號。本公司若干附屬公司正考慮於彼等特定財務報表內應用香港財務報告準則第19號。

(c) 香港財務報告準則第9號及香港財務報告準則第7號（修訂本）闡明終止確認財務資產或財務負債之日期，並引入一項會計政策選擇，即在符合特定條件情況下，終止確認於結算日前透過電子付款系統結算之財務負債。修訂闡明如何評估具有環境、社會及管治以及其它類似或然特徵的財務資產的合約現金流量特徵。此外，修訂闡明具有無追索權特徵的財務資產及合約掛鉤工具的分類要求。修訂亦包括指定按公允價值計入其它全面收益之股本工具投資及具有或然特徵之金融工具之額外披露。修訂應追溯應用，並於首次應用日期對保留溢利期初結餘／累計虧損（或權益的其它組成部分）進行調整。過往期間毋須重列，且僅可在不須預知的情況下重列。允許同時提早應用所有修訂或僅提早應用與財務資產分類相關的修訂。預期該等修訂不會對本集團的財務報表造成任何重大影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS (continued)

(d) Amendments to HKFRS 10 and HKAS 28 address an inconsistency between the requirements in HKFRS 10 and in HKAS 28 *Investments in Associates and Joint Ventures* in dealing with the sale or contribution of assets between an investor and its associate or joint venture. The amendments require a full recognition of a gain or loss resulting from a downstream transaction when the sale or contribution of assets constitutes a business. For a transaction involving assets that do not constitute a business, a gain or loss resulting from the transaction is recognised in the investor's profit or loss only to the extent of the unrelated investor's interest in that associate or joint venture. The amendments are to be applied prospectively. The previous mandatory effective date of amendments to HKFRS 10 and HKAS 28 was removed by the HKICPA. However, the amendments are available for adoption now.

(e) Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. Earlier application is permitted. When applying the amendments, an entity cannot restate comparative information. Any cumulative effect of initially applying the amendments shall be recognised as an adjustment to the opening balance of retained profits/accumulated losses or to the cumulative amount of translation differences accumulated in a separate component of equity, where appropriate, at the date of initial application. The amendments are not expected to have any significant impact on the Group's financial statements.

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則 (續)

(d) 香港財務報告準則第10號及香港會計準則第28號之修訂針對香港財務報告準則第10號及香港會計準則第28號於聯營公司及合資公司之投資之間有關投資者及其聯營公司或合營企業間的資產出售或注資兩者規定的不一致性。該等修訂規定，當資產出售或注資構成一項業務時，須確認來自下遊交易的全數收益或虧損。當交易涉及不構成一項業務的資產時，由該交易產生的收益或虧損於該投資者的損益內確認，惟僅以不相關投資者於該聯營公司或合營企業的權益為限。該等修訂應用於未來期間。香港會計師公會已移除香港財務報告準則第10號及香港會計準則第28號之修訂之過往強制性生效日期。然而，該等修訂可供現時採納。

(e) 香港會計準則第21號之修訂訂明實體應如何評估某種貨幣是否可兌換為另一種貨幣，以及在缺乏可兌換性的情況下，實體應如何估計於計量日期的即期匯率。該等修訂要求披露讓財務報表使用者能夠了解貨幣不可兌換的影響的資料，允許提早應用。於應用該等修訂時，實體不能重列比較資料。初始應用該等修訂的任何累計影響應於初始應用當日確認為對保留溢利期初結餘／累計虧損的調整或對權益單獨組成部分中累積的匯兌差額累計金額的調整(如適用)。預期該等修訂不會對本集團的財務報表產生任何重大影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS (continued)

- (f) *Annual Improvements to HKFRS Accounting Standards – Volume 11* set out amendments to HKFRS 1 *First-time Adoption of Hong Kong Financial Reporting Standards*, HKFRS 7 *Financial Instruments: Disclosures* (and the accompanying Guidance on implementing HKFRS 7), HKFRS 9 *Financial Instruments*, HKFRS 10 and HKAS 7. Details of the amendments that are expected to be applicable to the Group are as follows:

- HKFRS 7: The amendments have updated certain wording in paragraph B38 of HKFRS 7 and paragraphs IG1, IG14 and IG20B of the Guidance on implementing HKFRS 7 for the purpose of simplification or achieving consistency with other paragraphs in the standard and/or with the concepts and terminology used in other standards. In addition, the amendments clarify that the Guidance on implementing HKFRS 7 does not necessarily illustrate all the requirements in the referenced paragraphs of HKFRS 7 nor does it create additional requirements. Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則 (續)

- (f) *香港財務報告準則會計準則的年度改進—第11冊* 載列香港財務報告準則第1號 *首次採納香港財務報告準則*、香港財務報告準則第7號 *金融工具：披露* (及隨附香港財務報告準則第7號實施指引)、香港財務報告準則第9號 *金融工具*、香港財務報告準則第10號及香港會計準則第7號之修訂。預期適用於本集團的修訂詳情如下：

- 香港財務報告準則第7號：該等修訂已更新香港財務報告準則第7號第B38段及香港財務報告準則第7號實施指引第IG1、IG14及IG20B段之若干措辭，以簡化或達致與該準則其它段落及／或其它準則所用概念及詞彙一致。此外，該等修訂闡明香港財務報告準則第7號實施指引未必全面詳盡香港財務報告準則第7號之引用段落之所有規定，亦無產生額外規定。該等修訂允許提早應用。預期該等修訂不會對本集團的財務報表造成任何重大影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.3 ISSUED BUT NOT YET EFFECTIVE HONG KONG FINANCIAL REPORTING STANDARDS (continued)

(f) (continued)

- HKFRS 9: The amendments clarify that when a lessee has determined that a lease liability has been extinguished in accordance with HKFRS 9, the lessee is required to apply paragraph 3.3.3 of HKFRS 9 and recognise any resulting gain or loss in profit or loss. In addition, the amendments have updated certain wording in paragraph 5.1.3 of HKFRS 9 and Appendix A of HKFRS 9 to remove potential confusion. Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.
- HKFRS 10: The amendments clarify that the relationship described in paragraph B74 of HKFRS 10 is just one example of various relationships that might exist between the investor and other parties acting as de facto agents of the investor, which removes the inconsistency with the requirement in paragraph B73 of HKFRS 10. Earlier application is permitted. The amendments are not expected to have any significant impact on the Group's financial statements.
- HKAS 7: The amendments replace the term "cost method" with "at cost" in paragraph 37 of HKAS 7 following the prior deletion of the definition of "cost method". Earlier application is permitted. The amendments are not expected to have any impact on the Group's financial statements.

2. 會計政策 (續)

2.3 已頒佈但尚未生效之香港財務報告準則 (續)

(f) (續)

- 香港財務報告準則第9號：該等修訂闡明，當承租人根據香港財務報告準則第9號釐定租賃負債已終止時，承租人須應用香港財務報告準則第9號第3.3.3段，並在損益中確認所產生之任何收益或虧損。此外，該等修訂已更新香港財務報告準則第9號第5.1.3段及香港財務報告準則第9號附錄A的若干措辭，以消除可能出現的混淆。該等修訂允許提早應用。預期該等修訂不會對本集團的財務報表造成任何重大影響。
- 香港財務報告準則第10號：該等修訂闡明香港財務報告準則第10號第B74段所述的關係僅是投資者與作為投資者實際代理的其它各方之間可能存在的各種關係的一個例子，從而消除與香港財務報告準則第10號第B73段規定的不一致之處。該等修訂允許提早應用。預期該等修訂不會對本集團的財務報表造成任何重大影響。
- 香港會計準則第7號：該等修訂先前刪除香港會計準則第7號第37段「成本法」的定義，並以「按成本」一詞取代「成本法」。該等修訂允許提早應用。預期該等修訂不會對本集團的財務報表造成任何影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES

Goodwill

Goodwill is initially measured at cost, being the excess of the aggregate of the consideration transferred, the amount recognised for non-controlling interests and any fair value of the Group's previously held equity interests in the acquiree over the identifiable net assets acquired and liabilities assumed. If the sum of this consideration and other items is lower than the fair value of the net assets acquired, the difference is, after reassessment, recognised in profit or loss as a gain on bargain purchase.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired. The Group performs its annual impairment test of goodwill as at 31 December. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Group's cash-generating units, or groups of cash-generating units, that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the Group are assigned to those units or groups of units.

Impairment is determined by assessing the recoverable amount of the cash-generating unit (group of cash-generating units) to which the goodwill relates. Where the recoverable amount of the cash-generating unit (group of cash-generating units) is less than the carrying amount, an impairment loss is recognised. An impairment loss recognised for goodwill is not reversed in a subsequent period.

Where goodwill has been allocated to a cash-generating unit (or group of cash-generating units) and part of the operation within that unit is disposed of, the goodwill associated with the operation disposed of is included in the carrying amount of the operation when determining the gain or loss on the disposal. Goodwill disposed of in these circumstances is measured based on the relative value of the operation disposed of and the portion of the cash-generating unit retained.

2. 會計政策 (續)

2.4 重大會計政策

商譽

商譽起初按成本計量，即已轉讓對價、非控股權益的確認金額及本集團先前持有的被收購方股本權益的任何公允價值總額，與所收購可識別淨資產及所承擔負債之間的差額。如對價與其它項目的總額低於所收購淨資產的公允價值，於重新評估後該差額將於損益賬內確認為議價收購收益。

於初始確認後，商譽按成本減任何累計減值虧損計量。商譽須每年作減值測試，若有事件發生或情況改變顯示賬面值有可能減值時，則會更頻密地進行測試。本集團於12月31日進行商譽的年度減值測試。為進行減值測試，因業務合併而購入的商譽自收購日期起被分配至預期可從合併產生的協同效益中獲益的本集團各現金產生單位或現金產生單位組別，而無論本集團其它資產或負債是否已分配至該等單位或單位組別。

減值乃通過評估與商譽有關的現金產生單位（或現金產生單位組別）的可收回金額釐定。當現金產生單位（或現金產生單位組別）的可收回金額低於賬面金額時，減值虧損便予以確認。已就商譽確認的減值虧損不得於隨後期間撥回。

如商譽分配至現金產生單位（或現金產生單位組別）而該單位的部分業務已出售，則在釐定出售損益時，與所出售業務相關的商譽會計入該業務的賬面金額。在該等情況出售的商譽乃根據所出售業務的相對價值及現金產生單位的保留份額進行計量。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Fair value measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Group. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

2. 會計政策 (續)

2.4 重大會計政策 (續)

公允價值計量

公允價值為市場參與者於計量日期在有序交易中出售資產所收取或轉讓負債所支付之價格。公允價值計量乃基於假設出售資產或轉讓負債之交易於資產或負債之主要市場或(在無主要市場情況)資產或負債之最具優勢市場進行。主要或最具優勢市場須為本集團可進入之市場。資產或負債之公允價值乃按市場參與者於資產或負債定價時所使用之假設計量，並假設市場參與者會以最佳經濟利益行事。

非金融資產之公允價值計量須計及市場參與者透過使用該資產之最高及最佳用途或將該資產出售予將使用其最高及最佳用途之另一市場參與者而產生經濟效益之能力。

本集團採納適用於不同情況且具備充分數據以供計量公允價值之估值方法，以盡量使用相關可觀察輸入數據及盡量減少使用不可觀察輸入數據。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Fair value measurement (continued)

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 – based on quoted prices (unadjusted) in active markets for identical assets or liabilities
- Level 2 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is observable, either directly or indirectly
- Level 3 – based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by reassessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

2. 會計政策 (續)

2.4 重大會計政策 (續)

公允價值計量 (續)

於財務報表中計量或披露公允價值之所有資產及負債乃按對公允價值計量整體而言屬重大之最低層輸入數據按以下公允價值等級分類：

- 第1級－ 基於相同資產或負債於活躍市場之報價 (未經調整)
- 第2級－ 基於對公允價值計量而言屬重大之可觀察 (直接或間接) 最低層輸入數據之估值方法
- 第3級－ 基於對公允價值計量而言屬重大之不可觀察最低層輸入數據之估值方法

就按經常性基準於財務報表確認之資產及負債而言，本集團透過於各報告期末重新評估分類 (基於對公允價值計量整體而言屬重大之最低層輸入數據) 釐定是否發生不同等級轉移。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Related parties

A party is considered to be related to the Group if:

- (a) the party is a person or a close member of that person's family and that person
 - (i) has control or joint control over the Group;
 - (ii) has significant influence over the Group; or
 - (iii) is a member of the key management personnel of the Group or of a holding company of the Group;

or

- (b) the party is an entity where any of the following conditions applies:
 - (i) the entity and the Group are members of the same group;
 - (ii) one entity is an associate or joint venture of the other entity (or of a holding company, subsidiary or fellow subsidiary of the other entity);
 - (iii) the entity and the Group are joint ventures of the same third party;
 - (iv) one entity is a joint venture of a third entity and the other entity is an associate of the third entity;
 - (v) the entity is a post-employment benefit plan for the benefit of employees of either the Group or an entity related to the Group;

2. 會計政策 (續)

2.4 重大會計政策 (續)

關連人士

在下列情況，一方將視為與本集團有關連：

- (a) 該方為一名人士或該人士之近親，而該人士
 - (i) 對本集團擁有控制權或共同控制權；
 - (ii) 對本集團具有重大影響力；或
 - (iii) 為本集團或本集團一家控股公司之主要管理層人員；

或

- (b) 該人士為符合下列任何條件之實體：
 - (i) 該實體與本集團屬同一集團的成員公司；
 - (ii) 一實體為另一實體（或另一實體之一家控股公司、附屬公司或同系附屬公司）之聯營公司或合營企業；
 - (iii) 該實體與本集團為同一第三方之合營企業；
 - (iv) 一實體為一名第三方實體之合營企業，而另一實體為該第三方實體之聯營公司；
 - (v) 該實體為本集團或與本集團有關連的實體為僱員福利而設的離職後福利計劃；

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Related parties (continued)

(b) (continued)

- (vi) the entity is controlled or jointly controlled by a person identified in (a);
- (vii) a person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a holding company of the entity); and
- (viii) the entity, or any member of a group of which it is a part, provides key management personnel services to the Group or to a holding company of the Group.

Property, plant and equipment and depreciation

Property, plant and equipment, other than construction in progress, are stated at cost less accumulated depreciation and any impairment losses. The cost of an item of property, plant and equipment comprises its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Expenditure incurred after items of property, plant and equipment have been put into operation, such as repairs and maintenance, is normally charged to profit or loss in the period in which it is incurred. In situations where the recognition criteria are satisfied, the expenditure for a major inspection is capitalised in the carrying amount of the asset as a replacement. Where significant parts of property, plant and equipment are required to be replaced at intervals, the Group recognises such parts as individual assets with specific useful lives and depreciates them accordingly.

2. 會計政策 (續)

2.4 重大會計政策 (續)

關連人士 (續)

(b) (續)

- (vi) 該實體受(a)所述人士控制或共同控制；
- (vii) 於(a)(i)所述人士對該實體具有重大影響力，或為該實體（或該實體之一家控股公司）之主要管理層成員；及
- (viii) 該實體（或其所屬集團之任何成員公司）向本集團或本集團之一家控股公司提供主要管理層人員服務。

物業、廠房及設備與折舊

除在建工程外，物業、廠房及設備乃按成本扣除累計折舊及任何減值虧損列賬。物業、廠房及設備項目成本包括其買價及將該資產達至運作狀況及地點以作擬定用途之直接應佔費用。

於物業、廠房及設備項目投入運作後所產生之維修及保養等費用通常於產生期間於損益中扣除。倘符合確認標準，則相關重大檢查費用會於資產賬面值中撥作重置成本。倘須定期重置物業、廠房及設備的重大部分，則本集團會將該等部分確認為有特定可使用年期之個別資產，並相應地計提折舊。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Property, plant and equipment and depreciation (continued)

Depreciation is calculated on the straight-line basis to write off the cost of each item of property, plant and equipment to its residual value over its estimated useful life. The principal annual rates used for this purpose are as follows:

Buildings	3% to 10%
Leasehold improvements	10% to 33.3% or over the lease terms, whichever rate is higher
Plant and machinery	5% to 10%
Furniture, fixtures and equipment	10% to 20%
Motor vehicles	10% to 20%

Where parts of an item of property, plant and equipment have different useful lives, the cost of that item is allocated on a reasonable basis among the parts and each part is depreciated separately. Residual values, useful lives and the depreciation method are reviewed, and adjusted if appropriate, at least at each financial year end.

An item of property, plant and equipment including any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on disposal or retirement recognised in profit or loss in the year the asset is derecognised is the difference between the net sales proceeds and the carrying amount of the relevant asset.

Construction in progress is stated at cost less any impairment losses, and is not depreciated. It is reclassified to the appropriate category of property, plant and equipment when completed and ready for use.

2. 會計政策 (續)

2.4 重大會計政策 (續)

物業、廠房及設備與折舊 (續)

折舊按估計可使用年期以直線法攤銷每項物業、廠房及設備之成本至剩餘價值。採用之主要折舊年率如下：

樓宇	3%至10%
租賃物業裝修	10%至33.3%或按租期，以較高者為準
廠房及機器	5%至10%
傢俬、裝置及設備	10%至20%
汽車	10%至20%

倘物業、廠房及設備項目各部份之可使用年期不相同，則該項目之成本將按合理基礎於各部份分配，並個別計算折舊。剩餘價值、可使用年期及折舊方法至少於各財政年度結算日檢討，並在適當情況調整。

物業、廠房及設備項目（包括首次確認之任何重要部分）於出售或預期其使用或出售不會產生未來經濟利益時終止確認。於資產終止確認之年度在損益內確認之出售或廢棄資產之任何盈虧，為有關資產之出售所得款項淨額與其賬面值之差額。

在建工程按成本扣除任何減值虧損列賬，且不計算折舊，並於落成及可供使用時重列為物業、廠房及設備之適當類別。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Intangible assets (other than goodwill)

Intangible assets acquired separately are measured on initial recognition at cost. The cost of intangible assets acquired in a business combination is the fair value at the date of acquisition. The useful lives of intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are subsequently amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year end.

Intangible assets with indefinite lives are tested for impairment annually either individually or at the cash-generating unit level. Such intangible assets are not amortised. The useful life of an intangible asset with an indefinite life is reviewed annually to determine whether the indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for on a prospective basis.

Licences and permits

Purchased patents and licences are stated at cost less any impairment losses and are amortised on the straight-line basis over their estimated useful lives of 10 to 13 years.

Research and development costs

All research costs are charged to profit or loss as incurred.

Expenditure incurred on projects to develop new products is capitalised and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the project and the ability to measure reliably the expenditure during the development. Product development expenditure which does not meet these criteria is expensed when incurred.

2. 會計政策 (續)

2.4 重大會計政策 (續)

無形資產 (商譽除外)

單獨取得的無形資產於初始確認時按成本計量。通過業務合併取得的無形資產的成本為收購日期的公允價值。無形資產的可使用年期評定為有限期或無限期。有限期的無形資產隨後按可使用經濟年期攤銷，於有跡象顯示無形資產可能出現減值時評估減值。有限可使用年期的無形資產的攤銷期及攤銷方法至少於各財政年度結算日檢查一次。

年期並無限定的無形資產每年單獨或按現金產生單位進行減值測試。有關無形資產不作攤銷。每年對年期並無限定的無形資產的使用年期進行檢討，以確定年期並無限定的評估是否繼續得到支持。否則，使用年期評估由並無限定改為有限之情況將按預期適用基準入賬。

執照和許可證

購入的專利和執照按成本減任何減值虧損列賬，並以直線法在其10至13年的估計可用年期攤銷。

研究與開發成本

所有研究成本於產生時在損益中扣除。

僅當本集團可證明完成無形資產以供使用或出售在技術上屬可行，且有意完成並有能力使用或出售該資產，能明確資產產生未來經濟利益的方法及擁有足夠的資源以完成項目，並能夠可靠計量開發期間的開支時，方會將開發新產品的項目開支資本化並遞延處理。不符合上述標準的產品開發支出於產生時列作費用開支。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Intangible assets (other than goodwill) (continued)

Research and development costs (continued)

Deferred development costs are stated at cost less any impairment losses and are amortised using the straight-line basis over the commercial lives of the underlying products not exceeding ten years, commencing from the date when the products are put into commercial production.

Leases

The Group assesses at contract inception whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

(a) Right-of-use assets

Right-of-use assets are recognised at the commencement date of the lease (that is the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and any impairment losses, and adjusted for any remeasurement of lease liabilities and are separately disclosed on the consolidated statement of financial position. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on the straight-line basis over the following depreciation periods, which are the shorter of the lease terms and the estimated useful lives of the assets:

Leasehold land	Over the lease terms of 47 to 50 years
Clinics, offices and warehouses	Over the lease terms of 2 to 5 years

If ownership of the leased asset is transferred to the Group by the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

2. 會計政策 (續)

2.4 重大會計政策 (續)

無形資產 (商譽除外) (續)

研究與開發成本 (續)

遞延開發成本按成本減任何減值虧損列賬，並自產品投入商業生產當日起以直線法按相關產品不超過十年的商業年期攤銷。

租賃

本集團於合約開始時評估合約是否為或包含租賃。倘合約為換取代價而給予在一段時間內控制已識別資產使用的權利，則該合約為或包含租賃。

本集團作為承租人

本集團對所有租賃 (惟短期租賃及低價值資產租賃除外) 採取單一確認及計量方法。本集團確認租賃負債以作出租賃款項，而使用權資產指使用相關資產的權利。

(a) 使用權資產

使用權資產於租賃開始日期確認 (即相關資產可用之日期)。使用權資產按成本減任何累計折舊及任何減值虧損計量，並就租賃負債的任何重新計量作出調整以及在綜合財務狀況表內分別披露。使用權資產的成本包括已確認租賃負債金額、已發生初始直接成本及於開始日期或之前支付的租賃付款減已收取的任何租賃優惠。使用權資產按下列折舊期間即該等資產之租賃期及估計可使用年期兩者之較短者按直線基準折舊：

租賃土地	按47至50年 之租期
診所、辦公室及倉庫	按2至5年 之租期

倘租賃資產之所有權於租賃期結束前轉移至本集團或成本反映了購買選擇權之行使，則使用該資產之估計可使用年期計算折舊。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Leases (continued)

Group as a lessee (continued)

(b) Lease liabilities

Lease liabilities are recognised at the commencement date of the lease at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for termination of a lease, if the lease term reflects the Group exercising the option to terminate the lease. The variable lease payments that do not depend on an index or a rate are recognised as an expense in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses the interest rate implicit in the lease or, where that rate cannot be readily determined, the Group uses its incremental borrowing rate at the lease commencement date. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in lease payments (e.g., a change to future lease payments resulting from a change in an index or rate) or a change in assessment of an option to purchase the underlying asset.

(c) Short-term leases

The Group applies the short-term lease recognition exemption to its short-term leases of office, clinics and staff quarters (that is those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). Lease payments on short-term leases are recognised as an expense on a straight-line basis over the lease term.

2. 會計政策 (續)

2.4 重大會計政策 (續)

租賃 (續)

本集團作為承租人 (續)

(b) 租賃負債

租賃負債於租賃開始日期按於租賃期內作出的租賃付款現值確認。租賃付款包括固定付款 (包括實質固定付款) 減任何應收租賃優惠、取決於一項指數或比率的可變租賃付款及預期根據在剩餘價值擔保支付的金額。租賃付款亦包括本集團合理確定行使購買選擇權的行使價，及倘租賃期反映本集團行使終止選擇權，則須就終止租賃支付罰款。並非取決於一項指數或比率的可變租賃付款於觸發付款的事件或狀況出現期間確認為開支。

於計算租賃付款現值時，本集團使用租賃中所隱含的利率，或該利率不易釐定時，則本集團於租賃開始日期使用其增量借款利率。於開始日期後，租賃負債金額增加，以反映利息增加及就所付的租賃付款減少。此外，倘出現修改、租賃期變動、租賃付款變動 (如因指數或利率變動產生之未來租賃付款變動) 或購買相關資產的評估更改，租賃負債的賬面值將予重新計量。

(c) 短期租賃

本集團將短期租賃確認豁免應用於短期辦公室、診所及員工宿舍租賃 (即自租賃開始日期起計租期為12個月或以下，並且不包含購買選擇權的租賃)。短期租賃的租賃付款按直線法於租期內確認為開支。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Impairment of non-financial assets

Where an indication of impairment exists, or when annual impairment testing for a non-financial asset is required (other than inventories), the asset's recoverable amount is estimated. An asset's recoverable amount is the higher of the asset's or cash-generating unit's value in use and its fair value less costs of disposal, and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets, in which case the recoverable amount is determined for the cash-generating unit to which the asset belongs. In testing a cash-generating unit for impairment, a portion of the carrying amount of a corporate asset (e.g., a headquarters building) is allocated to an individual cash-generating unit if it can be allocated on a reasonable and consistent basis or, otherwise, to the smallest group of cash-generating units.

An impairment loss is recognised only if the carrying amount of an asset exceeds its recoverable amount. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. An impairment loss is charged to profit or loss in the period in which it arises in those expense categories consistent with the function of the impaired asset.

An assessment is made at the end of each reporting period as to whether there is an indication that previously recognised impairment losses may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. A previously recognised impairment loss of an asset other than goodwill is reversed only if there has been a change in the estimates used to determine the recoverable amount of that asset, but not to an amount higher than the carrying amount that would have been determined (net of any depreciation/amortisation) had no impairment loss been recognised for the asset in prior years. A reversal of such an impairment loss is credited to profit or loss in the period in which it arises.

2. 會計政策 (續)

2.4 重大會計政策 (續)

非金融資產減值

倘出現減值跡象，或須就非金融資產（不包括存貨）進行年度減值測試時，則會估計資產之可收回金額。資產之可收回金額乃按該資產或現金產生單位之使用價值及公允價值減銷售成本（以較高者為準）計算，並就個別資產予以釐定，惟倘該資產產生之現金流入不能大致獨立於其它資產或資產組合所產生之現金流入，則可收回金額按資產所屬現金產生單位釐定。於測試現金產生單位之減值時，倘公司資產（例如總部大樓）之賬面值可按合理一致基準分配至個別現金產生單位，則有關賬面值之一部分會分配至該單位，否則分配至最小現金產生單位組別。

減值虧損僅於資產賬面值超逾其可收回金額時確認。評估使用價值時，估計未來現金流量按除稅前貼現率折讓至其現值，該貼現率反映當時市場對貨幣時間價值及該項資產之特有風險之評估。減值虧損於產生期間自損益中與減值資產功能一致之支出類別中扣除。

於各報告期末會評估有否跡象顯示先前已確認減值虧損不再存在或已減少。倘出現該等跡象，則會估計可收回金額。除非用於釐定資產之可收回金額之估計有變，否則該資產（商譽除外）過往已確認減值虧損不予撥回，而撥回之減值虧損以假設過往年度並無確認減值虧損而應有之資產賬面值（經扣除任何折舊／攤銷）為限。有關減值虧損撥回於產生期間計入損益。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets

Initial recognition and measurement

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through other comprehensive income, and fair value through profit or loss.

The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Group's business model for managing them. With the exception of trade receivables that do not contain a significant financing component, the Group initially measures a financial asset at its fair value, plus in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component are measured at the transaction price determined under HKFRS 15 *Revenue from Contracts with Customers* in accordance with the policies set out for "Revenue recognition" below.

In order for a financial asset to be classified and measured at amortised cost or fair value through other comprehensive income, it needs to give rise to cash flows that are solely payments of principal and interest ("SPPI") on the principal amount outstanding. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

The Group's business model for managing financial assets refers to how it manages its financial assets in order to generate cash flows. The business model determines whether cash flows will result from collecting contractual cash flows, selling the financial assets, or both. Financial assets classified and measured at amortised cost are held within a business model with the objective to hold financial assets in order to collect contractual cash flows, while financial assets classified and measured at fair value through other comprehensive income are held within a business model with the objective of both holding to collect contractual cash flows and selling. Financial assets which are not held within the aforementioned business models are classified and measured at fair value through profit or loss.

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產

首次確認及計量

金融資產於初步確認時分類為其後按攤銷成本計量、按公允價值計入其它全面收益及按公允價值計入損益。

金融資產於初步確認時之分類視乎金融資產合約現金流量之特徵及本集團管理該等資產之業務模式。除並無重大融資成分之應收賬款外，本集團初步按其公允價值加（倘並非按公允價值計入損益之金融資產）交易成本計量金融資產。如下文「收入確認」所載政策，並無重大融資成分之應收賬款按香港財務報告準則第15號客戶合約收益釐定之交易價格計量。

為使金融資產按攤銷成本或按公允價值計入其它全面收益而分類及計量，需產生僅為支付本金及未償還本金利息（「SPPI」）之現金流量。現金流量並非為SPPI的金融資產以按公允價值計入損益分類及計量，而不論業務模式。

本集團管理金融資產之業務模式指為產生現金流量管理金融資產之方式。業務模式釐定現金流量會否來自收取合約現金流量、出售金融資產或以上兩者。按攤銷成本進行分類及計量的金融資產於旨在持有金融資產以收取合約現金流量的業務模式內持有，而按公允價值計入其它全面收入進行分類及計量的金融資產則於旨在同時持作收取合約現金流量及銷售的業務模式內持有。並非於上述業務模式內持有的金融資產按公允價值計入損益進行分類及計量。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets (continued)

Initial recognition and measurement (continued)

Purchases or sales of financial assets that require delivery of assets within the period generally established by regulation or convention in the marketplace are recognised on the trade date, that is, the date that the Group commits to purchase or sell the asset.

Subsequent measurement

The subsequent measurement of financial assets depends on their classification as follows:

(a) Financial assets at amortised cost (debt instruments)

Financial assets at amortised cost are subsequently measured using the effective interest method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified or impaired.

(b) Financial assets designated at fair value through other comprehensive income (equity investments)

Upon initial recognition, the Group can elect to classify irrevocably its equity investments as equity investments designated at fair value through other comprehensive income when they meet the definition of equity under HKAS 32 *Financial Instruments: Presentation* and are not held for trading. The classification is determined on an instrument-by-instrument basis.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognised as other income in profit or loss when the right of payment has been established except when the Group benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case such gains are recorded in other comprehensive income. Equity investments designated at fair value through other comprehensive income are not subject to impairment assessment.

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產 (續)

首次確認及計量 (續)

購買或出售需在市場規例或慣例規定之期限內交付之金融資產均於交易日 (即本集團承諾購買或出售資產之日) 確認。

其後計量

金融資產之其後計量視乎以下分類：

(a) 按攤銷成本計量之金融資產 (債務工具)

按攤銷成本計量之金融資產其後按實際利息法計量及須檢視有否減值。收益及虧損於資產終止確認、修訂或減值時在損益確認。

(b) 指定為按公允價值計入其它全面收益之金融資產 (股本投資)

於首次確認時，本集團可選擇於股本投資符合香港會計準則第32號金融工具：呈列項下之股本定義且並非持作買賣時，將其股本投資不可撤回地分類為指定按公允價值計入其它全面收益之股本投資。分類乃按個別工具基準釐定。

該等金融資產之收益及虧損概不會被轉撥至損益。當支付權確立時，股息於損益中確認為其它收入，惟當本集團於作為收回金融資產一部分成本之所得款項中獲益時則除外，於此等情況，該等收益於其它全面收益入賬。指定按公允價值計入其它全面收益之股本投資不受減值評估影響。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets (continued)

Subsequent measurement (continued)

(c) Financial assets at fair value through profit or loss

Financial assets at fair value through profit or loss are carried in the consolidated statement of financial position at fair value with net changes in fair value recognised in profit or loss. This category includes equity investments which the Group had not irrevocably elected to classify at fair value through other comprehensive income.

Impairment

The Group recognises an allowance for expected credit losses ("ECLs") for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

(a) General approach

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12 months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. When making the assessment, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information that is available without undue cost or effort, including historical and forward-looking information.

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產 (續)

其後計量 (續)

(c) 按公允價值計入損益之金融資產

按公允價值計入損益之金融資產乃於綜合財務狀況表按公允價值列賬，而公允價值變動淨額則於損益確認。該類別包括本集團已不可撤銷地選擇分類為按公允價值計入其它全面收益之股本投資。

減值

本集團就所有並非按公允價值計入損益持有之債務工具確認預期信貸虧損撥備。預期信貸虧損乃以根據合約應付之合約現金流量與本集團預期收取之所有現金流量之間之差額為基準，按原有實際利率相近之差額貼現。預期現金流量將包括來自銷售所持有抵押品或其它信用增級之現金流量，此乃合約條款不可或缺之部分。

(a) 一般方法

預期信貸虧損於兩個階段進行確認。對於自初步確認後並無顯著增加之信貸風險，預期信貸虧損就可能於未來12個月內（12個月預期信貸虧損）出現之違約事件計提撥備。對於自初步確認後有顯著增加之信貸風險，須在信貸虧損風險預期之剩餘年期計提虧損撥備，不論違約事件於何時發生（全期預期信貸虧損）。

於各報告日期，本集團於評估自初始確認後金融工具之信貸風險是否顯著增加時，本集團將於報告日期金融工具發生之違約風險與初始確認日起金融工具發生之違約風險進行比較，本集團會考慮合理且可支持之資料，包括無需付出不必要之成本或努力而可得之歷史及前瞻性資料。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets (continued)

Impairment (continued)

(a) General approach (continued)

The Group considers a financial asset in default when contractual payments are 60 to 180 days past due. The Group has rebutted the 90 days past due presumption of default based on reasonable and supportable information, including the Group's credit risk control practices and the historical recovery rate of financial assets over 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Financial assets at amortised cost are subject to impairment under the general approach and they are classified within the following stages for measurement of ECLs except for trade receivables which apply the simplified approach as detailed below.

Stage 1 – Financial instruments for which credit risk has not increased significantly since initial recognition and for which the loss allowance is measured at an amount equal to 12-month ECLs

Stage 2 – Financial instruments for which credit risk has increased significantly since initial recognition but that are not credit-impaired financial assets and for which the loss allowance is measured at an amount equal to lifetime ECLs

Stage 3 – Financial assets that are credit-impaired at the reporting date (but that are not purchased or originated credit-impaired) and for which the loss allowance is measured at an amount equal to lifetime ECLs

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產 (續)

減值 (續)

(a) 一般方法 (續)

本集團將合約付款逾期60至180天之金融資產視作違約。本集團已根據合理及可靠資料(包括本集團信貸風險控制常規及逾期90天的金融資產歷史回收率)推翻逾期90天的違約假設。然而,於若干情況,當內部或外部資料顯示本集團不可能在本集團採取任何信貸提升安排前悉數收回未償還合約金額時,本集團亦可能認為該金融資產違約。當並無收回合約現金流量之合理預期時,金融資產予以撇銷。

按攤銷成本計量之金融資產,在一般方法下可能會發生減值,並且除了採用簡化方法之應收賬款(以下詳述)外,其在以下階段分類用於預期信貸虧損計量。

第一階段 – 金融工具自初始確認以來信貸風險未顯著增加,且其虧損撥備相等於12個月預期信貸虧損

第二階段 – 金融工具自初始確認後信貸風險顯著增加,但並非信貸減值金融資產且其虧損撥備相等於全期預期信貸虧損

第三階段 – 於報告日期信貸減值之金融資產(但不是購買或原始信貸減值),其虧損撥備相等於全期預期信貸虧損

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets (continued)

Impairment (continued)

(b) Simplified approach

For trade receivables that do not contain a significant financing component or when the Group applies the practical expedient of not adjusting the effect of a significant financing component, the Group applies the simplified approach in calculating ECLs. Under the simplified approach, the Group does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has assessed the credit risk exposure that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

Derecognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognised (i.e., removed from the Group's consolidated statement of financial position) when:

- the rights to receive cash flows from the asset have expired; or
- the Group has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a "pass-through" arrangement; and either (a) the Group has transferred substantially all the risks and rewards of the asset, or (b) the Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if, and to what extent, it has retained the risk and rewards of ownership of the asset. When it has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產 (續)

減值 (續)

(b) 簡化方法

對於不包含重大融資成分之應收賬款，或本集團採用可行權宜方式，不會就重大融資成分之影響調整時，本集團採用簡化方法進行預期信貸虧損計量。根據簡化方法，本集團不會追蹤信貸風險之變化，而是於各報告日期進行全期預期信貸虧損確認虧損撥備。本集團已根據其歷史信貸虧損經驗評估面對之信貸風險，並根據債務人及經濟環境之前瞻性因素作出調整。

終止確認

金融資產 (或 (如適用) 一項金融資產的一部分或一組類似金融資產的一部分) 於下列情況首先終止確認 (即從本集團綜合財務狀況表中移除)：

- 從該資產收取現金流量的權利已屆滿；或
- 本集團已轉讓從該資產收取現金流量的權利或已根據「轉付」安排承擔向第三方全數支付 (無重大延誤) 所收取現金流量的責任；及 (a) 本集團已轉讓該資產的絕大部分風險及回報，或 (b) 本集團並無轉讓或保留該資產的絕大部分風險及回報，但已轉讓該資產的控制權。

倘本集團已轉讓從該資產收取現金流量的權利或已訂立轉付安排，則其會評估是否保留該資產所有權的風險及回報以及保留的程度。如並無轉讓或保留該資產的絕大部分風險及回報，亦無轉讓該資產的控制權，本集團繼續以其持續參與的程度確認已轉讓資產。在此情況下，本集團亦確認相關負債。已轉讓資產及相關負債按可反映本集團所保留權利及責任的基準計量。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Investments and other financial assets (continued)

Derecognition (continued)

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Group could be required to repay.

Financial liabilities

Initial recognition and measurement

Financial liabilities are recognised when the Group becomes a party to the contractual provisions of the instrument. Financial liabilities are all classified, at initial recognition, as financial liabilities at amortised cost, which are recognised initially at fair value and net of directly attributable transaction costs.

The Group classifies financial liabilities that arise from a supplier finance arrangement within trade and bills payables in the consolidated statement of financial position if they have a similar nature and function to trade payables. This is the case if the supplier finance arrangement is part of the working capital used in the Group's normal operating cycle, the level of security provided is similar to trade payables and the terms of the liabilities that are part of the supply chain finance arrangement are not substantially different from the terms of trade payables that are not part of the arrangement. Cash flows related to liabilities arising from supplier finance arrangements that are classified in trade and bills payables in the consolidated statement of financial position are included in operating activities in the consolidated statement of cash flows. Otherwise, the financial liabilities are classified in bank borrowings in the consolidated statement of financial position and the related cash flows are included in financing activities in the consolidated statement of cash flows.

2. 會計政策 (續)

2.4 重大會計政策 (續)

投資及其它金融資產 (續)

終止確認 (續)

以轉讓資產擔保形式的持續參與按資產的原賬面值與本集團可能被要求償還代價最高金額兩者間的較低者計量。

金融負債

首次確認及計量

金融負債於本集團成為工具合約條文訂約方時確認。金融負債於首次確認時均分類為按攤銷成本列賬的金融負債，首次按公允價值確認並扣除直接應佔交易成本。

倘供應商融資安排產生的金融負債具有與應付賬款相似的性質及功能，則本集團於綜合財務狀況表內將其分類至應付賬款及應付票據。倘供應商融資安排屬本集團正常營運週期所用營運資金的一部分，所提供的擔保水平與應付賬款相似，且屬於供應鏈融資安排一部分的負債條款與不屬於該安排一部分的應付賬款的條款並無重大差異，則屬此情況。於綜合財務狀況表內分類為應付賬款及應付票據的與供應商融資安排所產生的負債相關的現金流量，計入綜合現金流量表內的經營活動。否則，金融負債於綜合財務狀況表內分類為銀行借款，而相關現金流量計入綜合現金流量表內的融資活動。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Financial liabilities (continued)

Subsequent measurement

After initial recognition, financial liabilities at amortised cost are subsequently measured at amortised cost, using the effective interest method unless the effect of discounting would be immaterial, in which case they are stated at cost. Gains and losses are recognised in profit or loss when the liabilities are derecognised as well as through the effective interest rate amortisation process. Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest amortisation is included in finance costs in profit or loss.

Derecognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled, or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a derecognition of the original liability and a recognition of a new liability, and the difference between the respective carrying amounts is recognised in profit or loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the consolidated statement of financial position if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, or to realise the assets and settle the liabilities simultaneously.

2. 會計政策 (續)

2.4 重大會計政策 (續)

金融負債 (續)

其後計量

於初步確認後，按攤銷成本列賬的金融負債其後以實際利息法按攤銷成本計量，除非貼現影響為微不足道，在該情況下則按成本列賬。當負債終止確認以及按實際利率法進行攤銷程序時，其收益及虧損在損益中確認。攤銷成本於計及收購事項任何折讓或溢價及屬實際利率不可或缺一部分的費用或成本後計算。實際利息攤銷計入損益的融資成本內。

終止確認

當負債之責任解除或取消或屆滿時，終止確認金融負債。

倘現有金融負債被來自同一借款人但條款極不相同之另一項負債所取代，或對現有負債之條款進行大幅修訂，上述更替或修訂將被視作終止確認原有負債及確認新負債，而有關賬面值之差額將在損益內確認。

抵銷金融工具

當具目前可執行法定權力抵銷已確認金額及計劃以淨額結算，或同時變現資產及清償負債時，金融資產與金融負債方可互相抵銷，並於綜合財務狀況表內以淨額呈報。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined on the weighted average cost method and, in the case of work in progress and finished goods, comprises direct materials, direct labour and an appropriate proportion of overheads. Net realisable value is based on estimated selling prices less any estimated costs to be incurred to completion and disposal.

Cash and cash equivalents

Cash and cash equivalents in the consolidated statement of financial position comprise cash on hand and at banks, and short-term highly liquid deposits with a maturity of generally within three months that are readily convertible into known amounts of cash, subject to an insignificant risk of changes in value and held for the purpose of meeting short-term cash commitments.

For the purpose of the consolidated statement of cash flows, cash and cash equivalents comprise cash on hand and at banks, and short-term deposits as defined above, less bank overdrafts which are repayable on demand and form an integral part of the Group's cash management.

Provisions

A provision is recognised when a present obligation (legal or constructive) has arisen as a result of a past event and it is probable that a future outflow of resources will be required to settle the obligation, provided that a reliable estimate can be made of the amount of the obligation.

When the effect of discounting is material, the amount recognised for a provision is the present value at the end of the reporting period of the future expenditures expected to be required to settle the obligation. The increase in the discounted present value amount arising from the passage of time is included in finance costs in profit or loss.

2. 會計政策 (續)

2.4 重大會計政策 (續)

存貨

存貨按成本或可變現淨值兩者中之較低者列賬。成本按加權平均成本法釐定。在製品及製成品之成本包括直接原材料、直接勞工及應佔適當比例之間接成本。可變現淨值則根據估計售價減估計完成及出售所產生之任何成本計算。

現金及現金等值項目

就綜合財務狀況表而言，現金及現金等值項目包括庫存現金及存於銀行之現金，以及高度流通之短期存款（一般於三個月內到期，並可隨時轉換為已知現金金額，價值變動風險不大，並持作滿足短期現金承諾）。

就綜合現金流量表而言，現金及現金等值項目包括庫存現金及存於銀行之現金，以及上文界定之短期存款減須按要求償還且屬本集團現金管理部分之銀行透支。

撥備

倘因過往事件而導致本集團須承擔現時法定或推定責任，且日後大有可能因履行有關責任而導致資源流失，則須就此確認撥備，惟有關責任數額須能夠可靠估計。

倘貼現影響重大，則確認撥備的數額為預期日後履行有關責任所需開支於報告期末的現值。倘已貼現的現值隨時間而有所增加，則該等增幅將計入損益內的融資成本。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Income tax

Income tax comprises current and deferred tax. Income tax relating to items recognised outside profit or loss is recognised outside profit or loss, either in other comprehensive income or directly in equity.

Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period, taking into consideration interpretations and practices prevailing in the countries in which the Group operates.

Deferred tax is provided, using the liability method, on all temporary differences at the end of the reporting period between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred tax liabilities are recognised for all taxable temporary differences, except:

- when the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss and does not give rise to equal taxable and deductible temporary difference; and
- in respect of taxable temporary differences associated with investments in subsidiaries, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

2. 會計政策 (續)

2.4 重大會計政策 (續)

所得稅

所得稅包括即期及遞延稅項。於損益外確認之項目所得稅於損益外在其它全面收益或直接於權益確認。

即期稅項資產及負債按預期可獲稅務當局退回或支付予稅務當局之稅款，基於報告期末已頒佈或具體頒佈之稅率（及稅法），經計及本集團營運所在國家／地區現有詮釋及慣例計量。

遞延稅項乃以負債法就於報告期末資產及負債之稅基與其用作財務申報賬面值之所有暫時差額撥備。

遞延稅項負債就所有應課稅暫時差額予以確認，惟：

- 倘遞延稅項負債源於首次確認商譽或交易（並非業務合併，且於交易時不影響會計溢利亦不影響應課稅溢利或虧損，及並不會產生同等的應課稅及可扣減暫時差額）之資產及負債除外；及
- 有關於附屬公司投資之應課稅暫時差額，而可控制暫時差額之撥回時間且暫時差額於可預見未來可能不會撥回者除外。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Income tax (continued)

Deferred tax assets are recognised for all deductible temporary differences, and the carryforward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carryforward of unused tax credits and unused tax losses can be utilised, except:

- when the deferred tax asset relating to the deductible temporary differences arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss and does not give rise to equal taxable and deductible temporary difference; and
- in respect of deductible temporary differences associated with investments in subsidiaries, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. Unrecognised deferred tax assets are reassessed at the end of each reporting period and are recognised to the extent that it has become probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

2. 會計政策 (續)

2.4 重大會計政策 (續)

所得稅 (續)

遞延稅項資產就所有可扣稅暫時差額、未動用稅項抵免及未動用稅項虧損之結轉予以確認，以可能有可供動用可扣稅暫時差額、未動用稅項抵免及未動用稅項虧損之結轉的應課稅溢利為限，惟下述者除外：

- 有關可扣稅暫時差額之遞延稅項資產源於首次確認一項交易（並非業務合併，且於交易時不影響會計溢利亦不影響應課稅溢利或虧損，及並不會產生同等的應課稅及可扣減暫時差額）之資產及負債；及
- 有關於附屬公司投資之可扣稅暫時差額，遞延稅項資產僅限於在可預見未來可能撥回暫時差額及可能有應課稅溢利以動用暫時差額情況確認。

遞延稅項資產之賬面值乃於各報告期末檢討，倘不再有足夠應課稅溢利可供動用全部或部份遞延稅項資產，則予以相應扣減。未確認之遞延稅項資產於各報告期末重新評估，而限於可能有足夠應課稅溢利可供收回全部或部份遞延稅項資產予以確認。

遞延稅項資產及負債基於報告期末已頒佈或具體頒佈之稅率（及稅法）以預期適用於資產變現及負債清償期間之稅率計算。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Income tax (continued)

Deferred tax assets and deferred tax liabilities are offset if and only if the Group has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred taxes assets and deferred tax liabilities relate to income taxes levied by the same taxation authority on either the same taxable or different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

Government grants

Government grants are recognised at their fair value where there is reasonable assurance that the grant will be received and all attaching conditions will be complied with.

Where the grant relates to an expense item, it is recognised as income on a systematic basis over the periods in which the costs, for which it is intended to compensate, are expensed. Where the grant relates to an asset, the fair value is credited to a deferred income account and is released to profit or loss over the expected useful life of the relevant asset by equal annual instalments or deducted from the carrying amount of the asset and released to profit or loss by way of a reduced depreciation charge.

2. 會計政策 (續)

2.4 重大會計政策 (續)

所得稅 (續)

僅當本集團有合法執行之權利將即期稅項資產與即期稅項負債抵銷，且遞延稅項資產與遞延稅項負債與同一稅務機構對同一應課稅企業或於各未來期間預期有大額遞延稅項負債或資產需要結算或清償時，擬按淨額基準結算即期稅項負債及資產或同時變現資產及結算負債之不同稅務企業徵收之所得稅相關，則遞延稅項資產與遞延稅項負債可予對銷。

政府補助

政府補助於可合理確定將收取並會遵守其所附之一切條件時按公允價值確認。

倘補助與開支項目有關，則會按有系統的基準在預計支銷所補償的成本之期間內確認為收入。倘補貼與資產有關，則公允價值計入遞延收入賬，並按相關資產的預計可使用年期按年等額分期轉撥至損益，或自該資產的賬面值扣除相關公允價值，並透過扣減折舊開支方式計入損益。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Revenue recognition

Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of goods or services is transferred to the customers at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services.

(a) Sale of pharmaceuticals, biotechnology, healthcare and Chinese medicine products

Revenue from the sale of pharmaceuticals, biotechnology, healthcare and Chinese medicine products is recognised at the point in time when control of the asset is transferred to the customer, generally on delivery of the pharmaceuticals, biotechnology, healthcare and Chinese medicine products.

(b) Provision of Chinese medical services

Revenue from the provision of Chinese medical services is recognised over time, using an input method to measure progress towards complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits from services provided by the Group.

(c) Provision of contract development and manufacturing organisation ("CDMO") services

Revenue from the provision of CDMO services is recognised over time, using an input method to measure progress towards complete satisfaction of the service, because the customer simultaneously receives and consumes the benefits from services provided by the Group.

Interest income

Interest income is recognised on an accrual basis using the effective interest method by applying the rate that exactly discounts the estimated future cash receipts over the expected life of the financial instrument or a shorter period, when appropriate, to the net carrying amount of the financial asset.

2. 會計政策 (續)

2.4 重大會計政策 (續)

收入確認

客戶合約收入

當客戶合約收入按反映本集團預期有權獲得以交換該等貨品或服務之代價金額轉移至客戶時，確認客戶合約收入。

(a) 銷售醫藥、生物科技、保健及中醫藥產品

來自銷售醫藥、生物科技、保健及中醫藥產品之收入在資產控制權轉移至客戶時（一般為交付該等醫藥、生物科技、保健及中醫藥產品時）確認。

(b) 提供中醫服務

提供中醫服務的收入是隨時間確認，當中使用投入法以計量達致完成履行服務的進度，原因為客戶同時收取及消耗本集團提供服務的得益。

(c) 提供合同開發與生產運營（「CDMO」）服務

提供CDMO服務的收入是隨時間確認，當中使用投入法以計量達致完成履行服務的進度，原因為客戶同時收取及消耗本集團提供服務的得益。

利息收入

利用實際利率法計算按累計基準確認之利息收入，利率為在金融工具之預期有效期或更短期間（如適用）將估計未來現金收入準確折現至金融資產賬面淨值。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Contract liabilities

A contract liability is recognised when a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services. Contract liabilities are recognised as revenue when the Group performs under the contract (i.e. transfers control of the related goods or services to the customer).

Employee benefits Pension schemes

The Group operates a defined contribution Mandatory Provident Fund retirement benefit scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance for those employees who are eligible to participate in the MPF Scheme. Contributions are made based on a percentage of the employees' basic salaries and are charged to profit or loss as they become payable in accordance with the rules of the MPF Scheme. The assets of the MPF Scheme are held separately from those of the Group in an independently administered fund. The Group's employer contributions vest fully with the employees when contributed into the MPF Scheme.

The employees of the Group's subsidiaries which operate in Mainland China are required to participate in a central pension scheme operated by local municipal governments. These subsidiaries are required to contribute a certain specific percentage of their payroll costs to the central pension scheme. The contributions are charged to profit or loss as they become payable in accordance with the rules of the central pension scheme.

2. 會計政策 (續)

2.4 重大會計政策 (續)

合約負債

合約負債於本集團轉讓相關貨品或服務前向客戶收取付款或付款到期時(以較早者為準)確認。合約負債於本集團履行合約(即轉讓相關貨品或服務控制權予客戶)時確認為收益。

僱員福利 退休金計劃

本集團根據強制性公積金計劃條例為合資格參與一項強制性公積金退休福利計劃(「強積金計劃」)之僱員實施強積金計劃。供款按僱員基本薪酬百分比計算,於按強積金計劃之規則應支付時在損益內扣除。強制金計劃之資產由一項獨立管理之基金與本集團資產分開持有。本集團之僱主供款於支付予強積金計劃後即全數歸屬予僱員。

本集團中國大陸營運附屬公司之僱員須參與當地市政府運行之中央退休金計劃。此等附屬公司須按其薪酬成本之若干指定百分比向該中央退休金計劃供款。有關供款於根據該中央退休金計劃應支付時在損益內扣除。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Borrowing costs

Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, i.e., assets that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets. The capitalisation of such borrowing costs ceases when the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs capitalised. All other borrowing costs are expensed in the period in which they are incurred. Where funds have been borrowed generally, and used for the purpose of obtaining qualifying assets, a capitalisation rate of approximately 8% has been applied to the expenditure on the individual assets.

Dividends

Interim dividends are simultaneously proposed and declared, because the Company's memorandum and articles of association grant the directors the authority to declare interim dividends. Consequently, interim dividends are recognised immediately as a liability when they are proposed and declared.

Final dividends are recognised as a liability when they are approved by the shareholders in a general meeting. Proposed final dividends are disclosed in the notes to the financial statements.

2. 會計政策 (續)

2.4 重大會計政策 (續)

借款成本

借款成本包括實體就借入資金產生之利息及其它成本。

直接涉及收購、興建或生產合資格資產(即需要一段較長時間準備始能作所擬定用途之資產)之借款成本,乃撥充資本,作為該等資產之成本一部分。當資產大致可作其擬定用途或銷售時,則不再將有關借款成本撥充資本。以待作合資格資產支銷之特定借款作為臨時投資所賺取之投資收入,於撥作資本之借款成本中扣除。所有其它借款成本均於產生期間支銷。倘資金已按正常途徑借入並用於獲取合資格資產,則個別資產按資本化率約8%計算支出。

股息

由於本公司之組織章程大綱及細則賦予董事宣派中期股息之權力,故中期股息乃同時建議及宣派。因此,中期股息在建議及宣派時即時確認為負債。

末期股息於股東大會上獲股東批准及宣派時確認為負債。擬派末期股息於財務報表附註內披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Foreign currencies

These financial statements are presented in HK\$, which is different from the Company's functional currency of Renminbi ("RMB"). As the shares of the Company are listed on the Stock Exchange, for the convenience of users of the financial statements, the results and financial position of the Group are expressed in HK\$. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency. Foreign currency transactions recorded by the entities in the Group are initially recorded using their respective functional currency rates prevailing at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency rates of exchange ruling at the end of the reporting period. Differences arising on settlement or translation of monetary items are recognised in profit or loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. The gain or loss arising on translation of a non-monetary item measured at fair value is treated in line with the recognition of the gain or loss on change in fair value of the item (i.e., translation difference on the item whose fair value gain or loss is recognised in other comprehensive income or profit or loss is also recognised in other comprehensive income or profit or loss, respectively).

In determining the exchange rate on initial recognition of the related asset, expense or income on the derecognition of a non-monetary asset or non-monetary liability relating to an advance consideration, the date of initial transaction is the date on which the Group initially recognises the non-monetary asset or non-monetary liability arising from the advance consideration. If there are multiple payments or receipts in advance, the Group determines the transaction date for each payment or receipt of the advance consideration.

2. 會計政策 (續)

2.4 主要會計政策概要 (續)

外幣

該等財務報表以港元(並非本公司之功能貨幣人民幣)呈報。由於本公司股份於聯交所上市,為方便財務報表使用者,本集團業績及財務狀況均以港元列值。本集團內之企業各自決定其功能貨幣,其財務報表項目均以所定功能貨幣計量。本集團內之企業之外幣交易初步按交易日有關功能貨幣之當時匯率換算入賬。以外幣計值之貨幣資產及負債,按有關功能貨幣於報告期末之匯率換算。結算或換算貨幣項目之差額於損益確認。

按歷史成本列賬以外幣計量之非貨幣項目,採用初步交易日之匯率換算。按公允價值列賬以外幣計量之非貨幣項目,採用計量公允價值之日之匯率換算。換算按公允價值計量之非貨幣項目之盈虧與該項目之公允價值變更之盈虧確認(即公允價值盈虧於其它全面收益確認或損益亦分別於其它全面收益或損益確認之項目之換算差額)一併處理。

為釐定有關預付代價於取消確認時的非貨幣資產或非貨幣負債的有關資產、開支或收入於初步確認時的匯率,初步交易日期為本集團初步確認因預付代價而產生的非貨幣資產或非貨幣負債之日期。倘有多筆預付款或預收款,本集團應就每筆預付代價付款或收款釐定交易日期。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

2. ACCOUNTING POLICIES (continued)

2.4 MATERIAL ACCOUNTING POLICIES (continued)

Foreign currencies (continued)

The functional currencies of the Company and certain overseas subsidiaries are currencies other than HK\$. As at the end of the reporting period, the assets and liabilities of these entities are translated into HK\$ at the exchange rates prevailing at the end of the reporting period and their statements of profit or loss are translated into HK\$ at the exchange rates that approximate to those prevailing at the dates of the transactions. The resulting exchange differences are recognised in other comprehensive income and accumulated in the exchange fluctuation reserve. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognised in profit or loss.

Any goodwill arising on the acquisition of a foreign operation and any fair value adjustments to the carrying amounts of assets and liabilities arising on acquisition are treated as assets and liabilities of the foreign operation and translated at the closing rate.

For the purpose of the consolidated statement of cash flows, the cash flows of the Company and overseas subsidiaries are translated into HK\$ at the exchange rates ruling at the dates of the cash flows. Frequently recurring cash flows of these entities which arise throughout the year are translated into HK\$ at the weighted average exchange rates for the year.

Events after the reporting period

If the Group receives information after the reporting period, but prior to the date of authorisation for issue of the financial statements, about conditions that existed at the end of the reporting period, it will assess whether the information affects the amounts that it recognises in its financial statements. The Group will adjust the amounts recognised in its financial statements to reflect any adjusting events after the reporting period and update the disclosures that relate to those conditions in light of the new information. For non-adjusting events after the reporting period, the Group will not change the amounts recognised in its financial statements, but will disclose the nature of the non-adjusting events and an estimate of their financial effects, or a statement that such an estimate cannot be made, if applicable.

2. 會計政策 (續)

2.4 主要會計政策概要 (續)

外幣 (續)

本公司及若干海外附屬公司之功能貨幣為非港元貨幣。於報告期末，有關企業之資產及負債按報告期末當日匯率換算為港元，其損益表則按與交易日期的現行匯率相近的匯率換算為港元。所產生匯兌差額於其它全面收益確認並累積計入匯兌波動儲備。出售海外業務時，該海外業務相關其它全面收益在損益確認。

收購海外業務產生的任何商譽以及因收購產生的資產和負債的賬面值的任何公允價值調整均視為海外業務的資產和負債，並按收盤匯率換算。

就綜合現金流量表而言，本公司及海外附屬公司之現金流量乃按現金流量日期之匯率換算為港元。此等實體於整年內之持續現金流量則按本年度之加權平均匯率換算為港元。

報告期後事項

倘本集團於報告期後但在獲授權刊發財務報表日期之前收到有關報告期結束時存在之情況的資料，將會評估該等資料是否影響其於財務報表中確認的金額。本集團將調整其於財務報表中確認的金額，以反映報告期後的任何調整事項，並根據新資料更新與該等情況相關的披露。至於報告期後的非調整事項，本集團不會更改其於財務報表中確認的金額，但會披露非調整事項的性質及對其財務影響作出的估計，或無法做出有關估計的聲明 (如適用)。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of the Group's financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

The major judgements, key assumptions concerning the future and other key sources of estimation uncertainty at the end of the reporting period, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below:

Impairment of goodwill

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the management to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of those cash flows. The carrying amount of goodwill as at 31 December 2024 was HK\$90,391,000 (2023: HK\$95,230,000). Further details are set out in note 16 to the financial statements.

Impairment of non-financial assets (other than goodwill)

The Group assesses whether there are any indicators of impairment for all non-financial assets at the end of each reporting period. Non-financial assets are tested for impairment when there are indicators that the carrying amounts may not be recoverable. An impairment exists when the carrying value of an asset or a cash-generating unit exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The calculation of the fair value less costs of disposal is based on available data from binding sales transactions in an arm's length transaction of similar assets or observable market prices less incremental costs for disposing of the asset. When value-in-use calculations are undertaken, management must estimate the expected future cash flows from the asset or cash-generating unit using key assumptions such as forecasted growth rates and budgeted gross margins and choose a suitable discount rate in order to calculate the present value of those cash flows. The carrying amounts of non-financial assets other than goodwill are set out in notes 14, 15(a) and 17 to the financial statements.

3. 主要會計判斷及估計

本集團財務報表之編製須管理層作出會影響收入、開支、資產及負債之列報數額及其隨附披露，以及或然負債之披露之判斷、估計及假設。該等假設及估計的不確定因素或會導致日後須就受影響之資產或負債賬面值作出重大調整。

於報告期末具有重大風險導致資產及負債賬面值於下個財政年度須作出重大調整之重大判斷、未來相關重要假設及估計不確定因素之其它主要來源論述如下：

商譽減值

本集團至少於每個年度評估商譽是否發生減值。這要求對被分配商譽的現金產生單位的使用價值進行估計。估計使用價值時，管理層需要估計來自現金產生單位的預期未來現金流量，同時選擇恰當的貼現率計算該等現金流量的現值。商譽於2024年12月31日的賬面值為90,391,000港元（2023年：95,230,000港元）。進一步詳情載於財務報表附註16。

非金融資產減值（商譽除外）

本集團評估於各報告期末是否有任何跡象顯示所有非金融資產減值。非金融資產於有跡象顯示賬面值可能無法收回時作減值測試。當資產或現金產生單位的賬面值高於其可收回金額（即其公允價值減出售成本與其使用價值間的較高者）時，即出現減值。公允價值減出售成本的計算乃基於類似資產的公平交易中具有約束力的出售交易的可得數據或可觀察市價減出售資產的遞增成本。於計算使用價值時，管理層必須使用主要假設（如預測增長率及預算毛利率）估計資產或現金產生單位的預期未來現金流量及選擇適當的貼現率，以計算該等現金流量的現值。非金融資產（商譽除外）之賬面值載於財務報表附註14、15(a)及17。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

3. SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES (continued)

Provision for expected credit losses on trade and other receivables

The measurement of expected credit losses under HKFRS 9 on trade and other receivables requires judgements, in particular, for the estimations of the amount and timing of future cash flows when determining impairment losses, and the assessment of a significant increase in credit risk for other receivables. These estimates are affected by a number of factors, changes in which can result in different allowance amounts.

The Group's ECL calculations are outputs of complex models with a number of underlying assumptions regarding the choice of variable inputs and their interdependencies. The significant estimates involved in the determination of the inputs applied in the ECL models include: the Group's internal credit grading, which assigns probabilities of default to the individual grades; the segmentation of trade receivables based on risk characteristics of the customers; development of ECL models, including the various formulas and the choice of inputs over determination of loss given default of the credit exposures; determination of associations between macroeconomic scenarios and economic inputs, and the effect on probabilities of default, exposures at default and losses given default; and selection of forward-looking macroeconomic scenarios and their probability weightings, to derive the economic inputs into the ECL models. It has been the Group's policy to regularly review its models in the context of actual loss experience and adjust when necessary. Further details of the ECL provision for trade and other receivables are set out in notes 21(b) and 22 to the financial statements.

Net realisable value of inventories

Net realisable value of inventories is the estimated selling price in the ordinary course of business less estimated selling expenses. These estimates are based on the current market condition and the historical experience of selling products of a similar nature. It could change significantly as a result of changes in market demand or competitor actions. Management reassesses these estimates at each reporting date.

3. 主要會計判斷及估計 (續)

應收賬款及其它應收款的預期信貸虧損撥備

香港財務報告準則第9號項下就應收賬款及其它應收款預期信貸虧損計量均要求作出判斷，特別是，於釐定減值虧損及評估其它應收款信貸風險的顯著上升時須估計未來現金流量的數額及時間。該等估計受多項因素影響，而其變動可導致不同撥備金額。

本集團的預期信貸虧損計量為複雜模型的輸出結果，並且連同多項有關不同輸入值選擇及該等相互依賴性的相關假設。釐定預期信貸虧損模型中所應用的輸入資料所涉及的重大估計包括：本集團的內部信貸評級，其將違約機會率分配予個別等級；應收賬款依據客戶風險特性劃分；制定預期信貸虧損模型，包括釐定違約信貸風險虧損期間的不同算式及輸入資料選擇；釐定宏觀經濟情況與經濟輸入數據之間的聯繫性，以及違約可能性的影響、違約風險及違約虧損；及選出前瞻性宏觀經濟情況及彼等可能性比重，將經濟輸入數據引入預期信貸虧損模型當中。本集團的政策是根據實際虧損情況定期審閱其模型並在必要時進行調整。關於應收賬款及其它應收款預期信貸虧損撥備的進一步詳情載於財務報表附註21(b)及22。

存貨的可變現淨值

存貨的可變現淨值乃正常業務過程中的估計售價減估計銷售費用。該等估計乃基於目前的市場狀況及銷售類似性質產品的歷史經驗，可能因市場需求的變化或競爭對手的行動而發生重大變化。管理層會於各報告日期重新評估該等估計。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION

Information reported to the managing director of the Company, being the chief operating decision maker (“CODM”), for the purposes of resource allocation and assessment of segment performance, focuses on the types of goods or services delivered, being the Chinese medicine business, pharmaceuticals and medical technologies business and medical and healthcare services. The CODM monitors the results of the Group's operating segments separately for the purpose of making decisions about resource allocation and performance assessment.

Particulars of the Group's reportable operating segments are summarised as follows:

- (a) Chinese medicine business segment engages in the sale of Chinese medicine products in Mainland China;
- (b) Pharmaceuticals and medical technologies business segment engages in the sale of pharmaceutical, biotechnology and healthcare products in Mainland China, Hong Kong and Australia and provision of CDMO services in Mainland China; and
- (c) Medical and healthcare services segment engages in the sale of healthcare and Chinese medicine products as well as provision of Chinese medical services in Mainland China, Hong Kong and Australia.

Segment revenue and results

Segment performance is evaluated based on segment profit or loss, which is a measure of adjusted profit/loss before tax. The adjusted profit/loss before tax is measured consistently with the Group's profit/loss before tax except that the allocation of central administration costs, certain other income, gains and losses are excluded from such measurement.

4. 經營分部資料

本公司為分配資源及評估分部表現而向本公司董事總經理（即「主要營運決策者」）呈報之資料集中說明已交付之貨物或服務類別，即中醫藥業務、藥物和醫療科技業務以及醫療和保健服務。主要營運決策者監察本集團各經營分部之業績以作出有關資源分配及表現評估之決定。

本集團可呈報經營分部之詳情概述如下：

- (a) 中醫藥業務板塊從事於中國內地銷售中醫藥產品；
- (b) 藥物和醫療科技業務板塊從事於中國內地、香港及澳大利亞銷售醫藥、生物及保健產品，以及在中國內地提供CDMO服務；及
- (c) 醫療和保健服務板塊從事於中國內地、香港及澳大利亞銷售保健及中醫藥產品，以及提供中醫服務。

分部收益及業績

分部表現乃根據分部溢利或虧損（即經調整除稅前溢利／虧損之計量）評估。經調整除稅前溢利／虧損按與本集團除稅前溢利／虧損一致之方式計量，但此計量乃未作中央行政成本、若干其它收入以及收益及虧損之分配。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION (continued)

Segment revenue and results (continued)

Year ended 31 December 2024

4. 經營分部資料 (續)

分部收益及業績 (續)

截至2024年12月31日止年度

		Chinese medicine business 中醫藥 業務 HK\$'000 千港元	Pharmaceuticals and medical technologies business 藥物和醫療 科技業務 HK\$'000 千港元	Medical and healthcare services 醫療和 保健服務 HK\$'000 千港元	Total 總計 HK\$'000 千港元
Segment revenue	分部收入				
Sales to external customers	向外部客戶銷售	27,084	283,917	18,936	329,937
Intersegment sales	分部間銷售	2,410	1,794	114	4,318
		29,494	285,711	19,050	334,255
<i>Reconciliation:</i>	<i>對賬：</i>				
Elimination of intersegment sales	抵銷分部間銷售				(4,318)
Revenue	收入				329,937
Segment results	分部業績	(12,163)	(14,744)	(14,395)	(41,302)
<i>Reconciliation:</i>	<i>對賬：</i>				
Other income, gains and losses, net	其它收入、收益 及虧損淨額				1,241
Corporate and other unallocated expenses	企業及其它 未分配開支				(14,279)
Loss before tax	除稅前虧損				(54,340)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION (continued)

Segment revenue and results (continued)

Year ended 31 December 2024 (continued)

4. 經營分部資料 (續)

分部收益及業績 (續)

截至2024年12月31日止年度 (續)

		Pharmaceuticals			Unallocated	Total
		Chinese medicine business 中醫藥業務	and medical technologies business 藥物和醫療科技業務	Medical and healthcare services 醫療和保健服務		
		HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元
Other segment information:	其它分部資料：					
Interest income	利息收入	33	264	12	791	1,100
Depreciation and amortisation	折舊及攤銷	327	31,148	2,767	3,990	38,232
Impairment of goodwill	商譽減值	1,339	-	-	-	1,339
Reversal of impairment of trade and other receivables, net	應收賬款及其它應收款減值撥回，淨額	(1,525)	(61)	(10)	-	(1,596)
Reversal of write-down of inventories to net realisable value	撥回撇減存貨至可變現淨值	-	(406)	-	-	(406)
Finance costs	融資成本	-	4,507	228	119	4,854
Capital expenditure*	資本開支*	1,158	62,549	3,961	-	67,668

* Capital expenditure consists of additions of property, plant and equipment, right-of-use assets and intangible assets.

* 資本開支包括物業、廠房及設備、使用權資產以及無形資產之添置。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION (continued)

Segment revenue and results (continued)

Year ended 31 December 2023

4. 經營分部資料 (續)

分部收益及業績 (續)

截至2023年12月31日止年度

		Chinese medicine business 中醫藥 業務 HK\$'000 千港元	Pharmaceuticals and medical technologies business 藥物和醫療 科技業務 HK\$'000 千港元	Medical and healthcare services 醫療和 保健服務 HK\$'000 千港元	Total 總計 HK\$'000 千港元
Segment revenue	分部收入				
Sales to external customers	向外部客戶銷售	48,367	470,685	13,037	532,089
Intersegment sales	分部間銷售	3,431	511	–	3,942
		51,798	471,196	13,037	536,031
<i>Reconciliation:</i>	<i>對賬：</i>				
Elimination of intersegment sales	抵銷分部間銷售				(3,942)
Revenue	收入				532,089
Segment results	分部業績	(11,296)	16,309	(15,310)	(10,297)
<i>Reconciliation:</i>	<i>對賬：</i>				
Other income, gains and losses, net	其它收入、 收益及虧損淨額				570
Corporate and other unallocated expenses	企業及其它 未分配開支				(15,967)
Loss before tax	除稅前虧損				(25,694)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION (continued)

Segment revenue and results (continued)

Year ended 31 December 2023 (continued)

4. 經營分部資料 (續)

分部收益及業績 (續)

截至2023年12月31日止年度 (續)

		Chinese medicine business 中醫藥 業務	Pharmaceuticals and medical technologies business 藥物和醫療 科技業務	Medical and healthcare services 醫療和 保健服務	Unallocated 未分配	Total 總計
		HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元
Other segment information:	其它分部資料：					
Interest income	利息收入	59	1,359	17	1,597	3,032
Depreciation and amortisation	折舊及攤銷	714	28,881	2,811	4,001	36,407
Impairment of trade and other receivables, net	應收賬款及其它 應收款減值 ，淨額	1,637	31	9	–	1,677
Reversal of write-down of inventories to net realisable value	撥回撇減存貨至 可變現淨值	(741)	(810)	–	–	(1,551)
Finance costs	融資成本	–	4,374	245	327	4,946
Capital expenditure [#]	資本開支 [#]	188	64,674	1,419	–	66,281

[#] Capital expenditure consists of additions of property, plant and equipment and intangible assets.

[#] 資本開支包括物業、廠房及設備以及無形資產之添置。

Segment assets and liabilities

Information about segment assets and liabilities is not disclosed as it is not regularly reviewed by the CODM.

分部資產及負債

因未經主要營運決策者定期審閱，故分部資產及負債的相關資訊未予披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

4. OPERATING SEGMENT INFORMATION (continued)

Geographical information**(a) Revenue from external customers**

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Mainland China	中國大陸	320,992	524,126
Hong Kong	香港	7,743	6,473
Australia	澳大利亞	1,202	1,490
		329,937	532,089

The revenue information above is based on the locations of the customers.

(b) Non-current assets

No geographical information of non-current assets is presented as more than 90% of the non-current assets of the Group as at 31 December 2024 and 2023 were located in the PRC (including Hong Kong).

Information about major customers

During each of the years ended 31 December 2024 and 2023, no single customer contributed 10% or more of the total revenue of the Group.

4. 經營分部資料 (續)

地域資料**(a) 來自外界客戶之收入**

以上收入資料以客戶所在地為基準。

(b) 非流動資產

由於本集團於2024年及2023年12月31日的非流動資產90%以上位於中國(包括香港)，故並無呈列非流動資產的地區資料。

有關主要客戶之資料

截至2024年及2023年12月31日止年度各年，概無來自任何單一客戶的收入佔本集團總收入的10%或以上。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

5. REVENUE

Revenue of the Group for each of the years ended 31 December 2024 and 2023 wholly represented revenue from contracts with customers.

Notes:

(a) **Disaggregated revenue information**
Year ended 31 December 2024

5. 收入

本集團截至2024年及2023年12月31日止年度各年的收益全部指來自客戶合約的收入。

附註：

(a) **經分拆之收入資料**
截至2024年12月31日止年度

Segments		Pharmaceuticals and medical technologies business			Total
		Chinese medicine business	and medical technologies business	Medical and healthcare services	
分部		中醫藥業務	藥物和醫療科技業務	醫療和保健服務	總計
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
Types of goods or services	貨品或服務類別				
Sale of pharmaceutical and biotechnology products	銷售醫藥及生物科技產品	–	267,977	–	267,977
Sale of healthcare products	銷售保健產品	–	4,766	3,510	8,276
Sale of Chinese medicine products	銷售中醫藥產品	27,084	–	8,589	35,673
Chinese medical services	中醫服務	–	–	6,837	6,837
CDMO services	CDMO服務	–	11,174	–	11,174
Total revenue from contracts with customers	客戶合約收入總額	27,084	283,917	18,936	329,937
Geographical markets	地域市場				
Mainland China	中國大陸	27,084	283,605	10,303	320,992
Hong Kong	香港	–	79	7,664	7,743
Australia	澳大利亞	–	233	969	1,202
Total revenue from contracts with customers	客戶合約收入總額	27,084	283,917	18,936	329,937
Timing of revenue recognition	收入確認之時間性				
Goods transferred at a point in time	於某時點轉移之貨品	27,084	272,743	12,099	311,926
Services rendered over time	於一段時間提供之服務	–	11,174	6,837	18,011
Total revenue from contracts with customers	客戶合約收入總額	27,084	283,917	18,936	329,937

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

5. REVENUE (continued)

Notes: (continued)

(a) **Disaggregated revenue information** (continued)
Year ended 31 December 2023

Segments	Chinese medicine business	Pharmaceuticals and medical technologies business	Medical and healthcare services	Total
分部	中醫藥業務 HK\$'000 千港元	藥物和醫療科技業務 HK\$'000 千港元	醫療和保健服務 HK\$'000 千港元	總計 HK\$'000 千港元
Types of goods or services	貨品或服務類別			
Sale of pharmaceutical and biotechnology products	銷售醫藥及生物科技產品	–	453,965	453,965
Sale of healthcare products	銷售保健產品	–	11,704	11,704
Sale of Chinese medicine products	銷售中醫藥產品	48,367	–	55,931
Chinese medical services	中醫服務	–	5,473	5,473
CDMO services	CDMO服務	–	5,016	5,016
Total revenue from contracts with customers	客戶合約收入總額	48,367	470,685	532,089
Geographical markets	地域市場			
Mainland China	中國大陸	48,367	470,009	524,126
Hong Kong	香港	–	53	6,473
Australia	澳大利亞	–	623	1,490
Total revenue from contracts with customers	客戶合約收入總額	48,367	470,685	532,089
Timing of revenue recognition	收入確認之時間性			
Goods transferred at a point in time	於某時點轉移之貨品	48,367	465,669	521,600
Services rendered over time	於一段時間提供之服務	–	5,016	10,489
Total revenue from contracts with customers	客戶合約收入總額	48,367	470,685	532,089

(b) The following table shows the amounts of revenue recognised in the current reporting period that were included in the contract liabilities at the beginning of the reporting period:

附註：(續)

(a) **經分拆之收入資料** (續)
截至2023年12月31日止年度

(b) 下表顯示於本報告期間確認而已計入報告期初之合約負債之收入金額：

	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Revenue recognised that was included in contract liabilities at the beginning of the reporting period:		
Sale of products	6,559	78,241

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

5. REVENUE (continued)

Notes: (continued)

(c) **Performance obligations**

Information about the Group's performance obligations is summarised below:

Sale of pharmaceuticals, biotechnology, healthcare and Chinese medicine products

The performance obligation is satisfied upon delivery of pharmaceuticals, biotechnology, healthcare and Chinese medicine products. Payment for customers from Chinese medicine business and pharmaceutical and medical technologies business is generally due within 60 to 180 days from delivery, except for new customers, where payment in advance is normally required, while payment for sales of products in medical and healthcare services is generally due upon delivery of products.

Provision of Chinese medical services

The performance obligation is satisfied over time as services are rendered and payment is generally due upon customer acceptance.

Provision of CDMO services

The performance obligation is satisfied over time as services are rendered and payment is generally due within 30 days from the date of billing.

The Group has applied the practical expedient in HKFRS 15 to its revenue from Chinese medical services and CDMO services contracts, as the performance obligations are expected to be recognised as revenue with an original expected duration of one year or less, the transaction price allocated to these unsatisfied contracts is not disclosed as permitted under HKFRS 15.

5. 收入 (續)

附註：(續)

(c) **履約責任**

有關本集團履約責任之資料概述如下：

銷售醫藥、生物科技、保健及中醫藥產品

履約責任於交付醫藥、生物科技、保健及中醫藥產品時達成。中醫藥業務及製藥與醫療技術業務客戶的貨款一般於交付日期起計60至180天內到期，惟新客戶一般須預付款項，而醫療保健服務的產品銷售款一般於產品交付時到期。

提供中醫服務

履約責任於提供服務時隨時間達成，款項一般於客戶接納時支付。

提供CDMO服務

履約責任於提供服務時隨時間達成，款項一般於開具賬單日期起30日內支付。

本集團已將香港財務報告準則第15號之可行權宜方法應用於來自中醫藥服務及CDMO服務合約之收益，由於履約責任預期將確認為原預計期限為一年或以下的收益，根據香港財務報告準則第15號，分配至該等未完成合約的交易價格可不作披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

6. OTHER INCOME, GAINS AND LOSSES, NET

An analysis of other income, gains and losses, net, is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Other income	其它收入		
Bank interest income	銀行利息收入	1,100	3,032
Government subsidies*	政府補助*	3,157	2,641
Value-added tax refund	增值稅退稅	935	1,973
Others	其它	419	299
		5,611	7,945
Gains and losses, net	收益及虧損淨額		
Fair value gains/(losses), net:	公允價值收益／(虧損)淨額：		
Structured deposits	結構性存款	260	711
Other financial asset at fair value through profit or loss	按公允價值計入損益之其他金融資產	377	(1,000)
Impairment of goodwill	商譽減值	(1,339)	—
Foreign exchange differences, net	匯兌差額淨額	(112)	478
Gain/(loss) on disposal of property, plant and equipment, net	出售物業、廠房及設備之收益／(虧損)淨額	(103)	141
Others	其它	(31)	—
		(948)	330
		4,663	8,275

* Government subsidies were received on research and development activities and for employment stabilisation in respect of the Group's operations in Mainland China. The government grants are unconditional, except for certain grants that must be utilised for business development of the Company's subsidiaries.

6. 其它收入、收益及虧損淨額

有關其它收入、收益及虧損淨額之分析如下：

* 本集團於中國大陸的業務已就研發活動及穩定就業獲得政府補貼。除若干補助金必須用於本公司附屬公司的業務發展外，政府補助屬無條件性質。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

7. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/
(crediting):

7. 除稅前虧損

本集團之除稅前虧損經扣除／
(計入)：

	Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Cost of inventories sold	已售存貨之成本	178,319	278,108
Depreciation of property, plant and equipment	物業、廠房及設備折舊	28,746	27,642
Depreciation of right-of-use assets	使用權資產折舊	6,599	6,401
Amortisation of other intangible assets	其它無形資產攤銷	2,887	2,364
Research and development costs:	研發成本：		
Current year expenditure	本年度開支	57,550	30,108
Less: Capitalised during the year	減：本年度資本化	(44,267)	(17,003)
Net current year expenditure	本年度開支淨額	13,283	13,105
Reversal of write-down of inventories to net realisable value*	撥回撇減存貨至可變現淨值*	(406)	(1,551)
Lease payments not included in the measurement of lease liabilities	並不包括在租賃負債計量之租賃付款	2,417	1,954
Auditor's remuneration	核數師酬金	1,390	1,454
Employee benefit expenses (including directors' remuneration (note 9)):	僱員福利開支 (包括董事酬金(附註9))：		
Wages and salaries	工資及薪酬	66,851	75,646
Pension scheme contributions**	退休金計劃供款**	10,450	10,742
		77,301	86,388
Impairment of goodwill	商譽減值	1,339	—
Impairment/(reversal of impairment) of financial assets, net:	金融資產之減值／(減值撥回)，淨額：		
Trade and bills receivables	應收賬款及應收票據	(595)	785
Deposits and other receivables	按金及其它應收款	(1,001)	892
		(1,596)	1,677

* This item is included in "Cost of sales" in the consolidated statement of profit or loss and other comprehensive income.

** During each of the years ended 31 December 2024 and 2023, the Group had no forfeited contributions under the retirement benefits scheme utilised to reduce the existing levels of contributions. As at 31 December 2024 and 2023, the Group had no material forfeited contributions available to reduce the contributions in the future.

* 此項目計入綜合損益及其它全面收益表中的「銷售成本」。

** 截至2024年及2023年12月31日止年度各年，本集團並無根據退休福利計劃沒收供款，以用作減低現有供款水平。於2024年及2023年12月31日，本集團並無重大沒收供款可供日後扣減供款之用。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

8. FINANCE COSTS

An analysis of finance costs is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Interest on bank loans	銀行貸款之利息	4,507	4,754
Interest on lease liabilities	租賃負債之利息	347	572
Total interest expense	利息開支總額	4,854	5,326
Less: Interest capitalised	減：已資本化之利息	–	(380)
		4,854	4,946

8. 融資成本

融資成本之分析如下：

9. DIRECTORS' REMUNERATION

Directors' remuneration for the year, disclosed pursuant to The Rules Governing the Listing of Securities on The Stock Exchange (the "Listing Rules"), section 383(1)(a), (b), (c) and (f) of the Hong Kong Companies Ordinance and Part 2 of the Companies (Disclosure of Information about Benefits of Directors) Regulation, is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Fees	袍金	420	421

9. 董事酬金

根據聯交所證券上市規則（「上市規則」）、香港公司條例第383(1)(a)、(b)、(c)及(f)條以及公司（披露董事利益資料）規例第2部披露本年度董事酬金如下：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

9. DIRECTORS' REMUNERATION (continued)

An analysis of the directors' remuneration, on a named basis, is as follows:

9. 董事酬金 (續)

董事酬金按列名基準之分析如下：

		Fees 袍金	
		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Executive directors:	執行董事		
Mr. Fang Wen Quan (Chairman and Managing Director)	方文權先生 (董事長兼 董事總經理)	60	60
Mr. Lui Man Sang	呂文生先生	72	72
		132	132
Non-executive directors:	非執行董事		
Mr. Feng Quanming	馮全明先生	–	–
Mr. Zhong Tao (appointed on 29 August 2023)	鍾濤先生 (於2023年8月 29日獲委任)	72	25
Mr. Shen Bo (resigned on 29 August 2023)	沈波先生 (於2023年8月 29日辭任)	–	47
		72	72
Independent non-executive directors:	獨立非執行董事：		
Mr. Lam Yat Fai	林日輝先生	72	72
Mr. Chiu Sung Hong	趙崇康先生	72	72
Dr. Xian Yanfang (appointed on 27 June 2023)	冼彥芳博士 (於2023年 6月27日獲委任)	72	37
Mr. Chiu Fan Wa (resigned on 1 July 2023)	趙帆華先生 (於2023年 7月1日辭任)	–	36
		216	217
Total directors' remuneration	董事酬金總額	420	421

Notes:

- (a) There was no arrangement under which a director or the chief executive waived or agreed to waive any remuneration during the year.
- (b) There were no other emoluments payable to the independent non-executive directors during the year (2023: Nil).

附註：

- (a) 年內並無董事或主要行政人員放棄或同意放棄任何酬金之安排。
- (b) 年內並無應付予獨立非執行董事之其它酬金 (2023年：無)。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

10. FIVE HIGHEST PAID EMPLOYEES

The five highest paid employees during the year did not include any director (2023: Nil). Details of the remuneration for the year of the five (2023: five) highest paid employees who are neither a director nor chief executive of the Company are as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Salaries, allowances and benefits in kind	薪酬、津貼及實物利益	5,645	4,728
Pension scheme contributions	退休金計劃供款	196	90
		5,841	4,818

The number of non-director highest paid employees whose remuneration fell within the following bands is as follows:

年內五名最高薪酬僱員不包括任何董事(2023年：無)。年內五名(2023年：五名)並非本公司董事或主要行政人員之最高薪酬僱員之酬金詳情如下：

酬金屬於以下組別而並非董事之最高薪酬僱員之人數如下：

		2024 2024年	2023 2023年
Nil to HK\$1,000,000	無至1,000,000港元	3	3
HK\$1,000,001 to HK\$1,500,000	1,000,001港元至1,500,000港元	1	1
HK\$1,500,001 to HK\$2,000,000	1,500,001港元至2,000,000港元	1	1
		5	5

11. INCOME TAX

11. 所得稅

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Current – Mainland China	即期－中國大陸		
Charge for the year	本年度支出	222	394
Underprovision/(overprovision) in prior years	過往年度撥備不足／(超額撥備)	2,171	(738)
Deferred tax (note 28)	遞延稅項(附註28)	4,681	(345)
Total tax expenses/(credit) for the year	本年度稅項開支／(抵免)總額	7,074	(689)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

11. INCOME TAX (continued)

Notes:

- (a) No provision for Hong Kong profits tax, Macau complementary tax and Australia income tax have been made as the Group did not generate any assessable profits arising in Hong Kong, Macau and Australia during the year (2023: Nil). Tax on profits assessable in Mainland China has been calculated at the applicable Mainland China corporate income tax ("CIT") rate of 25% (2023: 25%), except for Tianda Pharmaceuticals (Zhuhai) and Tianda Pharmaceuticals (Yunnan), subsidiaries of the Group. Pursuant to the relevant laws and regulations in the PRC, Tianda Pharmaceuticals (Zhuhai) is qualified as a new and high technology company and has obtained approvals from the relevant tax authorities for a preferential tax rate of 15% for a period of 3 years up to December 2025. Tianda Pharmaceuticals (Yunnan) is established in the Kunming Economic and Technological Development Zone. Pursuant to relevant laws and regulations in the PRC, Tianda Pharmaceuticals (Yunnan) is engaged in the Western China Development Strategy and is entitled to a preferential tax rate of 15% (2023: 15%) during the year.
- (b) A reconciliation of the tax credit applicable to loss before tax at the statutory tax rates for the jurisdictions in which the majority of its subsidiaries are domiciled to the tax expense/(credit) at the effective tax rates, and a reconciliation of the applicable rates (i.e., the statutory tax rates) to the effective tax rate, are as follows:

		2024 2024年		2023 2023年	
		HK\$'000 千港元	%	HK\$'000 千港元	%
Loss before tax	除稅前虧損	(54,340)		(25,694)	
Tax credit at the statutory tax rate	按法定稅率計算之稅項抵免	(13,585)	25.0	(6,424)	25.0
Higher/(lower) tax rate(s) enacted by local authority	地方機關頒佈之較高／(低)稅率	1,123	(2.0)	(2,213)	8.6
Income not subject to tax	毋須課稅之收入	(287)	0.5	(489)	1.9
Expenses not deductible for tax	不可扣稅之支出	528	(1.0)	421	(1.6)
Tax losses utilised from previous periods	過往期間動用之稅項虧損	(542)	1.0	(72)	0.3
Tax losses not recognised	未確認之稅項虧損	17,665	(34.8)	8,826	(34.4)
Adjustments in respect of current tax of previous period	就往期稅項於即期作出調整	2,172	(4.0)	(738)	2.9
Tax expense/(credit) at the Group's effective tax rate	按本集團之有效稅率計算之稅項開支／(抵免)	7,074	(13.0)	(689)	2.7

- (c) The Group is not subject to Pillar Two income tax exposure as, in the opinion of the directors, it does not fall into the scope of Pillar Two model rules.

11. 所得稅 (續)

附註：

- (a) 由於本集團在年內並無在香港、澳門及澳大利亞產生任何應課稅溢利，故並無作出香港利得稅、澳門所得補充稅及澳大利亞利得稅撥備（2023年：無）。除本集團附屬公司天大藥業（珠海）及天大藥業（雲南）外，於中國大陸就應課稅溢利徵收之稅項，乃按照適用中國大陸企業所得稅（「企業所得稅」）稅率25%（2023年：25%）計算。根據中國之相關法律及法規，天大藥業（珠海）符合高新技術企業資格，獲得相關稅務機關批准按優惠稅率15%繳稅，為期三年，直至2025年12月為止。天大藥業（雲南）成立於昆明市經濟技術開發區。根據中國的相關法律及法規，天大藥業（雲南）從事中國西部大開發戰略，並於年內可按優惠稅率15%（2023年：15%）繳稅。
- (b) 以下為除稅前虧損之稅項抵免（採用其大部份附屬公司業務所在司法權區之法定稅率計算）與按有效稅率計算之稅項開支／（抵免）之對賬，以及適用稅率（即法定稅率）與有效稅率之對賬：

- (c) 由於董事認為本集團不屬於支柱二規則範本的範圍，故本集團並無面臨支柱二所得稅風險。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

12. DIVIDEND

The Board does not recommend the payment of a final dividend for the year ended 31 December 2024.

On 26 March 2024, the Board proposed a final dividend of HK0.26 cents per share, totalling HK\$5,590,000, for the year ended 31 December 2023, which have been approved by the shareholders at the annual general meeting held on 7 June 2024.

13. LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of the basic loss per share amount is based on the loss attributable to shareholders of the Company for the year of HK\$61,371,000 (2023: HK\$24,155,000), and the weighted average number of ordinary shares of 2,150,041,884 (2023: 2,150,041,884) outstanding during the year.

No adjustment has been made to the basic loss per share amounts presented for each of the years ended 31 December 2024 and 2023 in respect of a dilution as the Group had no dilutive potential ordinary shares outstanding during these years.

12. 股息

董事會不建議派發截至2024年12月31日止年度之末期股息。

於2024年3月26日，董事會建議派發截至2023年12月31日止年度的末期股息每股0.26港仙，合共5,590,000港元，已於2024年6月7日舉行的股東週年大會上獲股東批准。

13. 本公司股東應佔每股虧損

每股基本虧損金額乃按年內本公司股東應佔虧損 61,371,000 港元 (2023 年：24,155,000 港元) 及年內已發行普通股加權平均數 2,150,041,884 股 (2023 年：2,150,041,884 股) 計算。

由於本集團於截至 2024 年及 2023 年 12 月 31 日止各年度並無具攤薄潛力的已發行普通股，故並無就攤薄對該等年度各年呈列的每股基本虧損金額作出調整。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

14. PROPERTY, PLANT AND EQUIPMENT

14. 物業、廠房及設備

		Buildings	Leasehold improvements	Plant and machinery	Furniture, fixtures and equipment	Motor vehicles	Construction in progress	Total
		樓宇	物業裝修	廠房及機器	傢俱、裝置及設備	汽車	在建工程	總額
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元	千港元	千港元
Net carrying amount:	賬面淨值：							
At 1 January 2023	於2023年1月1日	211,289	484	104,107	6,584	998	28,980	352,442
Additions	添置	-	711	13,847	1,538	354	32,828	49,278
Depreciation provided during the year	年內折舊撥備	(10,501)	(275)	(14,959)	(1,803)	(104)	-	(27,642)
Disposals/write-off	出售／撇銷	-	-	(50)	(46)	(19)	(27)	(142)
Transfers	轉移	942	-	19,000	1,209	-	(21,151)	-
Exchange realignment	匯兌調整	(1,488)	(3)	(802)	(48)	(7)	(242)	(2,590)
At 31 December 2023 and 1 January 2024	於2023年12月31日及 2024年1月1日	200,242	917	121,143	7,434	1,222	40,388	371,346
Additions	添置	-	1,092	3,741	947	1,051	13,774	20,605
Depreciation provided during the year	年內折舊撥備	(11,891)	(430)	(14,012)	(2,238)	(175)	-	(28,746)
Disposals/write-off	出售／撇銷	-	-	(21)	(88)	(83)	-	(192)
Transfers	轉移	21,862	-	1,055	4,381	-	(27,298)	-
Exchange realignment	匯兌調整	(7,258)	(30)	(4,097)	(310)	(36)	(1,523)	(13,254)
At 31 December 2024	於2024年12月31日	202,955	1,549	107,809	10,126	1,979	25,341	349,759
At 1 January 2023:	於2023年1月1日：							
Cost	成本	229,422	4,016	147,576	24,927	6,699	28,980	441,620
Accumulated depreciation	累計折舊	(18,133)	(3,532)	(43,469)	(18,343)	(5,701)	-	(89,178)
Net carrying amount	賬面淨值	211,289	484	104,107	6,584	998	28,980	352,442
At 31 December 2023:	於2023年12月31日：							
Cost	成本	228,714	4,713	178,857	26,775	6,826	40,388	486,273
Accumulated depreciation	累計折舊	(28,472)	(3,796)	(57,714)	(19,341)	(5,604)	-	(114,927)
Net carrying amount	賬面淨值	200,242	917	121,143	7,434	1,222	40,388	371,346
At 31 December 2024:	於2024年12月31日：							
Cost	成本	242,084	5,715	177,132	30,668	6,835	25,341	487,775
Accumulated depreciation	累計折舊	(39,129)	(4,166)	(69,323)	(20,542)	(4,856)	-	(138,016)
Net carrying amount	賬面淨值	202,955	1,549	107,809	10,126	1,979	25,341	349,759

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

14. PROPERTY, PLANT AND EQUIPMENT (continued)

- (a) At 31 December 2024, certain of the Group's buildings with a total net carrying amount of HK\$228,222,000 (2023: HK\$223,195,000) were pledged to secure general banking facilities granted to the Group (note 27).

(b) **Impairment assessment of non-current non-financial assets**

The Group's operations have been loss-making for some time which indicated that the non-current non-financial assets attributable to the relevant cash-generating units ("CGUs") (collectively, the "Non-current Non-financial Assets"), including property, plant and equipment, right-of-use assets, goodwill, and other intangible assets, may be impaired. Accordingly, the Group carried out impairment assessments of these assets as at 31 December 2024 in accordance with HKAS 36 *Impairment of Assets*:

The carrying amounts of the Non-current Non-financial Assets as at 31 December 2024 which were reviewed for impairment during the year are as follows:

14. 物業、廠房及設備 (續)

- (a) 於2024年12月31日，本集團總賬面淨值為228,222,000港元（2023年：223,195,000港元）的若干樓宇已抵押作為授予本集團的一般銀行融資的擔保（附註27）。

(b) **非流動非金融資產減值評估**

本集團的業務已虧損一段時間，顯示相關現金產生單位（「現金產生單位」）應佔之非流動非金融資產（統稱「非流動非金融資產」）（包括物業、廠房及設備、使用權資產、商譽及其它無形資產）可能產生減值。因此，本集團於2024年12月31日根據香港會計準則第36號資產減值對該等資產進行減值評估：

年內對於2024年12月31日之非流動非金融資產之賬面值進行減值檢討，詳情如下：

		Tianda Pharmaceuticals (Yunnan) 天大藥業 (雲南) HK\$'000 千港元 (note (i)) (附註(i))	TCM Pharmaceuticals (China) 天大中醫藥 (中國) HK\$'000 千港元 (note (ii)) (附註(ii))	Tianda Pharmaceuticals (Zhuhai) 天大藥業 (珠海) HK\$'000 千港元 (note (iii)) (附註(iii))	Total 總計 HK\$'000 千港元
Property, plant and equipment	物業、廠房及設備	22,551	986	320,383	343,920
Right-of use assets	使用權資產	2,365	–	28,976	31,341
Other intangible assets	其它無形資產	1,844	104	39,601	41,549
Goodwill	商譽	4,426	1,339	89,415	95,180
Total	總計	31,186	2,429	478,375	511,990

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

14. PROPERTY, PLANT AND EQUIPMENT (continued)

(b) Impairment assessment of non-current non-financial assets (continued)

(i) Tianda Pharmaceuticals (Yunnan) CGU

The recoverable amount of the Tianda Pharmaceuticals (Yunnan) CGU was determined based on its fair value less costs of disposal ("FV"). In this connection, the Group had primarily made reference to a valuation report prepared by an independent professional valuer to derive the FV of the Tianda Pharmaceuticals (Yunnan) CGU, using the market approach. The fair value measurement used significant unobservable inputs (Level 3 of the fair value hierarchy).

Based on the results of the FV assessment, no impairment provision was considered necessary for the Tianda Pharmaceuticals (Yunnan) CGU (2023: Nil).

Below was a summary of the valuation technique used and the key inputs used in assessing the FV of the Tianda Pharmaceuticals (Yunnan) CGU during the year ended 31 December 2024:

	Valuation techniques	Significant unobservable inputs	Weighted average
	估值技術	重大不可觀察輸入數據	加權平均
Property, plant and equipment and right-of-use assets	Market approach	Selling land unit rate	HK\$1,100
物業、廠房及設備以及使用權資產	(per square meter)	銷售土地單位費率	1,100港元
	市場法 (每平米)	Selling building unit rate	HK\$3,380
		(per square meter)	3,380港元
		銷售樓宇單位費率	
		(每平米)	

14. 物業、廠房及設備 (續)

(b) 非流動非金融資產減值評估 (續)

(i) 天大藥業(雲南)現金產生單位

天大藥業(雲南)現金產生單位的可收回金額乃根據其公允價值減出售成本(「公允價值」)釐定。就此而言，本集團主要參考獨立專業估值師採用市場法編製的估值報告，以得出天大藥業(雲南)現金產生單位的公允價值。公允價值計量已使用重大不可觀察輸入數據(公允價值層級第三級)。

根據公允價值評估結果，天大藥業(雲南)現金產生單位毋須計提減值撥備(2023年：無)。

以下為截至2024年12月31日止年度評估天大藥業(雲南)現金產生單位的公允價值所採用的估值技術及主要輸入數據概要：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

14. PROPERTY, PLANT AND EQUIPMENT (continued)

(b) Impairment assessment of non-current non-financial assets (continued)

(ii) TCM (China) CGU

In the opinion of the directors, the recoverable amount of the TCM (China) CGU determined based on its value-in-use is minimal. Therefore, a full impairment of HK\$1,339,000 (2023: Nil) was made against the goodwill attributable to the TCM (China) CGU during the year ended 31 December 2024. No impairment loss is considered necessary with respect to the property, plant and equipment of the TCM (China) CGU as these assets can be used in the operation of the Tianda Pharmaceuticals (Zhuhai) CGU.

(iii) Tianda Pharmaceuticals (Zhuhai) CGU

The recoverable amount of the Tianda Pharmaceuticals (Zhuhai) CGU has been determined based on a value-in-use calculation using cash flow projections on a financial budget covering a five-year period approved by senior management. The growth rate used to extrapolate the cash flows beyond the five-year period is the same as the long-term average growth rate of the pharmaceutical industry.

The discount rate and the terminal growth rate applied are 11.36% and 2.3%, respectively.

Assumptions were used in the value-in-use calculation of the Tianda Pharmaceuticals (Zhuhai) CGU as at 31 December 2024. The following describes each key assumption on which management has based its cash flow projection to undertake impairment testing of goodwill:

Forecasted growth rate – The forecasted growth rate is based on industry forecasts.

Budgeted gross margin – The basis used to determine the value assigned to the budgeted gross margin is with reference to the gross margin achieved in the year immediately before the budget year.

Discount rate – The discount rate used is before tax and reflects specific risks relating to the relevant unit.

14. 物業、廠房及設備 (續)

(b) 非流動非金融資產減值評估 (續)

(ii) 天大中醫藥 (中國) 現金產生單位

董事認為，天大中醫藥 (中國) 現金產生單位根據其使用價值釐定的可收回金額為微不足道。因此，截至2024年12月31日止年度，已就天大中醫藥 (中國) 的現金產生單位應佔商譽作出全額減值1,339,000港元 (2023年：無)。由於天大中醫藥 (中國) 現金產生單位的物業、廠房及設備可用於天大藥業 (珠海) 現金產生單位的業務，故毋須對該等資產作出減值虧損。

(iii) 天大藥業 (珠海) 現金產生單位

天大藥業 (珠海) 現金產生單位的可收回金額已基於使用價值計算而釐定，其採用經高級管理層批准涵蓋五年期之財務預算之現金流量預測。推算五年期間後之現金流量採用之增長率與醫藥行業的長期平均增長率相同。

所採用的折現率和終期增長率分別為11.36%及2.3%。

假設乃用於計算2024年12月31日天大藥業 (珠海) 現金產生單位的使用價值。以下載列管理層用於現金流量預測進行商譽減值測試時的各關鍵假設：

預測增長率 – 基於行業預測的預測增長率。

預算毛利率 – 用以釐定預算毛利率價值的基準為參考緊接預算年度前一年所達致的毛利率。

貼現率 – 所用貼現率為除稅前，並反映與相關單位有關的特定風險。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

14. PROPERTY, PLANT AND EQUIPMENT (continued)

(b) Impairment assessment of non-current non-financial assets (continued)

(iii) Tianda Pharmaceuticals (Zhuhai) CGU (continued)

In the opinion of the Company's directors, a decrease in the forecasted growth rate by 3 percentage points would cause the carrying amount of the Tianda Pharmaceuticals (Zhuhai) CGU to equal to its recoverable amount, and any reasonably possible change in other key assumptions on which the recoverable amount is based would not cause the Tianda Pharmaceuticals (Zhuhai) CGU's carrying amount to exceed its recoverable amount.

15. LEASES WHERE THE GROUP AS A LESSEE

The Group has lease arrangements as a lessee for various items of leasehold land, clinics, offices and warehouses for use in its operations. Lump sum payments were made upfront to acquire the leasehold land from the owners with lease periods of 47 to 50 years, and no ongoing payments will be made under the terms of these land leases. Leases of clinics, offices and warehouses generally have lease terms between 2 and 5 years.

14. 物業、廠房及設備 (續)

(b) 非流動非金融資產減值評估 (續)

(iii) 天大藥業(珠海)現金產生單位 (續)

本公司董事認為，預計增長率下降3個百分點將導致天大藥業(珠海)現金產生單位的賬面值相等於其可收回金額，而可收回金額所依據的其它主要假設的任何合理可能變動不會導致天大藥業(珠海)現金產生單位的賬面值超出其可收回金額。

15. 本集團作為承租人之租賃

本集團作為承租人就其營運所用的租賃土地、診所、辦公室及倉庫訂有各項租賃安排。根據該等土地租賃的條款，已於向業主取得租賃土地時提前作出一次性付款，租期為47至50年，其後不會繼續支付任何款項。診所、辦公室及倉庫的租期通常為2至5年。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

15. LEASES WHERE THE GROUP AS A LESSEE (continued)

(a) Right-of-use assets

The carrying amounts of the Group's right-of-use assets and the movements during the year are as follows:

		Leasehold land 租賃土地 HK\$'000 千港元	Clinics, offices and warehouses 診所、 辦公室及倉庫 HK\$'000 千港元	Total 總計 HK\$'000 千港元
At 1 January 2023	於2023年1月1日	34,386	13,680	48,066
Depreciation provided during the year	年內折舊撥備	(829)	(5,572)	(6,401)
Exchange realignment	匯兌調整	(244)	(29)	(273)
At 31 December 2023 and 1 January 2024	於2023年12月31日及 2024年1月1日	33,313	8,079	41,392
Additions	添置	–	2,796	2,796
Depreciation provided during the year	年內折舊撥備	(813)	(5,786)	(6,599)
Exchange realignment	匯兌調整	(1,160)	(101)	(1,261)
At 31 December 2024	於2024年12月31日	31,340	4,988	36,328

At 31 December 2024, certain of the Group's leasehold land with a total net carrying amount of HK\$31,340,000 (2023: HK\$30,770,000) were pledged to secure general banking facilities granted to the Group (note 27).

The Group's operations have been loss-making for some time which indicated that the non-current non-financial assets attributable to the relevant cash-generating units, including property, plant and equipment, right-of-use assets, goodwill and other intangible assets, may be impaired. Accordingly, the Group carried out impairment assessments of these assets as at 31 December 2024 in accordance with HKAS 36 *Impairment of Assets*, further details of which are set out in note 14(b) to the financial statements.

15. 本集團作為承租人之租賃 (續)

(a) 使用權資產

本集團使用權資產之賬面值及年內變動如下：

於2024年12月31日，本集團總賬面淨值為31,340,000港元（2023年：30,770,000港元）的若干租賃土地已抵押作為授予本集團的一般銀行融資的擔保（附註27）。

本集團的業務已虧損一段時間，顯示相關現金產生單位應佔之非流動非金融資產（包括物業、廠房及設備、使用權資產、商譽及其它無形資產）可能產生減值。因此，本集團於2024年12月31日根據香港會計準則第36號資產減值對該等資產進行減值評估，進一步詳情載於財務報表附註14(b)。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

15. LEASES WHERE THE GROUP AS A LESSEE (continued)

(b) Lease liabilities

The carrying amount of the Group's lease liabilities and the movements during the year are as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
At 1 January	於1月1日	8,747	14,404
New leases	新租賃	2,796	–
Accretion of interest recognised during the year	年內確認的利息增加	347	572
Payments	付款	(6,406)	(6,198)
Exchange realignment	匯兌調整	(113)	(31)
At 31 December	於12月31日	5,371	8,747
Portion classified as current liabilities	分類為流動負債之部分	(2,192)	(5,678)
Non-current portion	非流動部分	3,179	3,069

The maturity analysis of lease liabilities is disclosed in note 36 to the financial statements.

(c) The amounts recognised in profit or loss in relation to leases are as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Interest on lease liabilities	租賃負債利息	347	572
Depreciation of right-of-use assets	使用權資產折舊	6,599	6,401
Expenses relating to short-term leases	與短期租賃相關的開支	2,417	1,954
Total amount recognised in profit or loss	損益中確認款項總額	9,363	8,927

(d) The total cash outflow for leases is disclosed in note 31(c) to the financial statements.

15. 本集團作為承租人之租賃 (續)

(b) 租賃負債

本集團租賃負債之賬面值及年內變動如下：

租賃負債之到期分析於財務報表附註36中披露。

(c) 損益中確認的租賃相關款項如下：

(d) 租賃的現金流出總額於財務報表附註31(c)披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

16. GOODWILL

16. 商譽

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
At 1 January:	於1月1日：		
Cost	成本	99,594	100,344
Accumulated impairment	累計減值	(4,364)	(4,396)
Net carrying amount	賬面淨值	95,230	95,948
Net carrying amount:	賬面淨值：		
At 1 January	於1月1日	95,230	95,948
Impairment loss recognised	已確認減值虧損	(1,339)	–
Exchange realignment	匯兌調整	(3,500)	(718)
At 31 December	於12月31日	90,391	95,230
At 31 December:	於12月31日：		
Cost	成本	95,940	99,594
Accumulated impairment	累計減值	(5,549)	(4,364)
Net carrying amount	賬面淨值	90,391	95,230

(a) Goodwill allocation

Goodwill acquired through business combinations is allocated to the following cash-generating units for impairment testing:

- Pharmaceutical products cash-generating unit for Tianda Pharmaceuticals (Yunnan)
- Chinese medicine products cash-generating unit for TCM (China)
- Chinese medicine products cash-generating unit for Zhuhai TPCHM
- Pharmaceutical products cash-generating unit for Tianda Pharmaceuticals (Zhuhai)

(a) 商譽分配

透過業務合併收購之商譽乃分配至下列現金產生單位作減值測試：

- 天大藥業（雲南）之醫藥產品現金產生單位
- 天大中醫藥（中國）之中醫藥產品現金產生單位
- 珠海天大中藥飲片之中醫藥產品現金產生單位
- 天大藥業（珠海）之醫藥產品現金產生單位

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

16. GOODWILL (continued)

(a) Goodwill allocation (continued)

The net carrying amount of goodwill allocated to each of the cash-generating units is as follows:

		Tianda Pharmaceuticals (Yunnan) 天大藥業 (雲南) HK\$'000 千港元	TCM (China) 天大中醫藥 (中國) HK\$'000 千港元	Tianda Pharmaceuticals (Zhuhai) 天大藥業 (珠海) HK\$'000 千港元	Total 總額 HK\$'000 千港元
Carrying amount of goodwill as at 31 December 2024	於2024年12月31日 之商譽賬面值	4,270	–	86,121	90,391
Carrying amount of goodwill as at 31 December 2023	於2023年12月31日 之商譽賬面值	4,426	1,388	89,416	95,230

Full impairment of HK\$1,231,000 and impairment of HK\$1,596,000 and HK\$1,384,000 were made for the goodwill attributable to the CGUs for Zhuhai TPCMH, TCM (China) and Tianda Pharmaceuticals (Yunnan) in prior years, respectively.

(b) Details of annual impairment assessment of goodwill are set out in note 14(b) to the financial statements.

16. 商譽 (續)

(a) 商譽分配 (續)

分配至各現金產生單位之商譽之賬面淨值如下：

珠海天大中醫藥片、天大中醫藥(中國)及天大藥業(雲南)的現金產生單位應佔商譽於過往年度分別被全額減值1,231,000港元及減值1,596,000港元及1,384,000港元。

(b) 商譽年度減值評估之詳情載於財務報表附註14(b)。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

17. OTHER INTANGIBLE ASSETS

17. 其它無形資產

		Technical knowhow 技術知識 HK\$'000 千港元	Licences and permits 執照及許可證 HK\$'000 千港元	Development costs 開發成本 HK\$'000 千港元	Total 總額 HK\$'000 千港元
Net carrying amount:	賬面淨值：				
At 1 January 2023	於2023年1月1日	–	1,753	4,373	6,126
Additions	增加	–	–	17,003	17,003
Amortisation provided during the year	年內攤銷撥備	–	(428)	(1,936)	(2,364)
Exchange realignment	匯兌調整	–	(11)	(77)	(88)
At 31 December 2023 and 1 January 2024	於2023年12月31日 及2024年1月1日	–	1,314	19,363	20,677
Additions	增加	27,386	–	16,881	44,267
Amortisation provided during the year	年內攤銷撥備	(517)	(419)	(1,951)	(2,887)
Exchange realignment	匯兌調整	(518)	(39)	(970)	(1,527)
At 31 December 2024	於2024年12月31日	26,351	856	33,323	60,530
At 1 January 2023:	於2023年1月1日：				
Cost	成本	–	90,567	9,071	99,638
Accumulated amortisation and impairment	累計攤銷及減值	–	(88,814)	(4,698)	(93,512)
Net carrying amount	賬面淨值	–	1,753	4,373	6,126
At 31 December 2023:	於2023年12月31日：				
Cost	成本	–	90,327	25,957	116,284
Accumulated amortisation and impairment	累計攤銷及減值	–	(89,013)	(6,594)	(95,607)
Net carrying amount	賬面淨值	–	1,314	19,363	20,677
At 31 December 2024:	於2024年12月31日：				
Cost	成本	26,858	87,225	41,597	155,680
Accumulated amortisation and impairment	累計攤銷及減值	(507)	(86,369)	(8,274)	(95,150)
Net carrying amount	賬面淨值	26,351	856	33,323	60,530

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

17. OTHER INTANGIBLE ASSETS (continued)

The Group's operations have been loss-making for some time which indicated that the non-current non-financial assets attributable to the relevant cash-generating units, including property, plant and equipment, right-of-use assets, goodwill and other intangible assets, may be impaired. Accordingly, the Group carried out impairment assessments of these assets as at 31 December 2024 in accordance with HKAS 36 *Impairment of Assets*, further details of which are set out in note 14(b) to the financial statements.

18. FINANCIAL ASSET AT FAIR VALUE THROUGH PROFIT OR LOSS

Unlisted fund investment, at fair value
非上市基金投資，
按公允價值計量

The above unlisted fund investment was mandatorily classified as a financial asset at fair value through profit or loss as its contractual cash flows are not solely payments of principal and interest.

On 19 April 2023, the Group entered into an agreement to subscribe for an investment fund in a principal amount of HK\$10,000,000. The principal objective of the fund is to maximise capital appreciation and achieve returns to investors. The fund is managed by Tianda Asset Management Limited, which is a fellow subsidiary of the Company.

On 2 December 2024, the fund investment was fully redeemed.

17. 其它無形資產 (續)

本集團的業務已虧損一段時間，顯示相關現金產生單位應佔之非流動非金融資產（包括物業、廠房及設備、使用權資產、商譽及其它無形資產）可能產生減值。因此，本集團於2024年12月31日根據香港會計準則第36號資產減值對該等資產進行減值評估，進一步詳情載於財務報表附註14(b)。

18. 按公允價值計入損益之金融資產

	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Unlisted fund investment, at fair value 非上市基金投資， 按公允價值計量	–	9,000

由於上述非上市基金投資的合約現金流量並非僅為支付本金及利息，因此強制歸類為按公允價值計入損益之金融資產。

於2023年4月19日，本集團訂立協議認購本金為10,000,000港元的投資基金。該基金的主要目標是為投資者實現最大的資本增值和回報。該基金由本公司的同系附屬公司天大資產管理有限公司管理。

於2024年12月2日，該基金投資已悉數贖回。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

19. EQUITY INVESTMENT DESIGNATED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME

19. 指定為按公允價值計入其它全面收益之股本投資

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Listed equity investment, at fair value:	上市股本投資，		
ASLAN Pharmaceuticals Limited American	按公允價值：		
Depository Shares ("ASLAN")	亞獅康股份有限公司		
	(「亞獅康」) 美國預託股份	-	216

The above equity investment was irrevocably designated at fair value through other comprehensive income as the Group considers the investment to be strategic in nature.

以上股本投資乃不可撤銷地指定為按公允價值計入其它全面收益，因為本集團認為該投資屬策略性質。

ASLAN has filed voluntary liquidation and was delisted from National Association of Securities Dealers Automated Quotations ("NASDAQ") stock market in July 2024. In the opinion of the directors, the fair value of the investment in ASLAN as at 31 December 2024 was close to zero.

亞獅康已提出自願清盤，並於2024年7月從全國證券交易商協會自動報價系統（「納斯達克」）股票市場退市。董事認為，於2024年12月31日，於亞獅康之投資之公允價值接近零。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

20. INVENTORIES

20. 存貨

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Raw materials	原材料	19,742	25,465
Work in progress	在製品	5,686	17,126
Finished goods	製成品	14,781	22,557
		40,209	65,148

21. TRADE AND BILLS RECEIVABLES

21. 應收賬款及應收票據

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Trade receivables	應收賬款	59,743	72,586
Impairment (note (b))	減值(附註(b))	(1,153)	(1,748)
		58,590	70,838
Bills receivable	應收票據	18,833	33,963
		77,423	104,801

Notes:

- (a) The Group's trading terms with its customers are mainly on credit, except for new customers where payment in advance is normally required. The credit periods range from 30 to 180 days. The Group seeks to maintain strict control over its outstanding receivables to minimise credit risk. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade and bills receivables relate to a large number of customers, there is no significant concentration of credit risk. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade and bills receivables are non-interest-bearing.

附註：

- (a) 本集團與客戶之貿易方式主要以記賬為主，惟新客戶一般需要預先付款。信貸期通常為30至180天不等。本集團對未償還應收款項維持嚴格監控，將信貸風險減至最低。高級管理層定期審閱逾期結欠。鑑於上文所述情況及本集團之應收賬款及應收票據涉及眾多客戶，故並無重大集中信貸風險。本集團並無持有關於應收賬款結餘的抵押品或其它加強信貸安排。應收賬款及應收票據為不計息。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

21. TRADE AND BILLS RECEIVABLES (continued)

Notes: (continued)

(a) (continued)

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Within 2 months	2個月內	52,849	77,582
2 to 3 months	2至3個月	10,609	6,071
Over 3 months	3個月以上	13,965	21,148
		77,423	104,801

(b) The movements in the loss allowance for impairment of trade receivables during the year are as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
At 1 January	於1月1日	1,748	963
Impairment losses/(reversal of impairment losses) recognised during the year, net	年內確認的減值虧損／ (減值虧損撥回) 淨額	(595)	785
At 31 December	於12月31日	1,153	1,748

An impairment analysis is performed at each reporting date by assigning an internal credit rating with reference to the historical records of the Group to determine the probability of default. Loss given default is estimated based on market information. The loss rate is then adjusted to reflect the current conditions and forecasts of future economic conditions, as appropriate. Generally, trade receivables are written off if past due for more than one year and are not subject to enforcement activity.

21. 應收賬款及應收票據 (續)

附註：(續)

(a) (續)

於報告期末，以發票日期為基準扣除虧損撥備的應收賬款及應收票據之賬齡分析如下：

(b) 年內應收賬款之減值虧損撥備之變動如下：

減值分析於各報告日期進行，方式為參考本集團的過往記錄給予內部信貸評級，以確定違約的可能性。違約損失乃根據市場資料估計。虧損率其後會作出調整，以反映現時情況及對未來經濟狀況的預測（如適用）。一般而言，應收賬款如逾期超過一年且不受強制執行活動影響，則會被撇銷。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

21. TRADE AND BILLS RECEIVABLES (continued)

Notes: (continued)

(b) (continued)

Set out below is the information about the credit risk exposure on the Group's trade receivables:

Class of credit rating	信貸評級類別	Expected credit loss rate 預期信貸虧損率 %	Gross carrying amount 總賬面值 HK\$'000 千港元	Expected credit losses 預期信貸虧損 HK\$'000 千港元
At 31 December 2024	於2024年12月31日			
Class 1*	第1類*	—	42,442	—
Class 2**	第2類**	0.01	2,633	1
Class 3***	第3類***	0.92	895	8
Class 4****	第4類****	1.85	12,866	237
Credit impaired receivables	已信貸減值應收賬款	100.00	907	907
Total	總計		59,743	1,153
At 31 December 2023	於2023年12月31日			
Class 1*	第1類*	—	45,577	—
Class 2**	第2類**	0.02	11,152	2
Class 3***	第3類***	1.71	9,891	169
Class 4****	第4類****	3.33	4,540	151
Credit impaired receivables	已信貸減值應收賬款	100.00	1,426	1,426
Total	總計		72,586	1,748

* Class 1 customers maintain active business with the Group and have a good repayment history. Receivables were not yet past due.

** Class 2 customers maintain active business with the Group and have a good repayment history. Certain portion of receivables from these customers were past due but the Group expects that the receivables can be recovered.

*** Class 3 customers have no recent transactions with the Group but have a good repayment history. Receivables were past due but the Group expects that the receivables can be recovered.

**** Class 4 customers have past due receivables and the Group expects high risk of irrecoverability for the receivables.

The bills receivable are due within 90 days. In respect of bills receivable, they are mostly banker's acceptance bills and there were no recent history of default for bills receivable. As at 31 December 2024 and 2023, the loss allowance on these receivables was assessed to be minimal.

21. 應收賬款及應收票據 (續)

附註：(續)

(b) (續)

下文載列本集團應收賬款之信貸風險資料：

* 第1類客戶與本集團保持活躍業務往來及還款記錄良好。應收賬款尚未逾期。

** 第2類客戶與本集團保持活躍業務往來及還款記錄良好。此等客戶的若干應收賬款已逾期，但本集團預計可收回應收賬款。

*** 第3類客戶近期並無與本集團進行交易，但還款記錄良好。應收賬款已逾期，但本集團預計可收回應收賬款。

**** 第4類客戶的應收賬款已逾期，且本集團預計應收賬款存在無法收回的高風險。

該等應收票據於90日內到期。就應收票據而言，大部分為銀行承兌匯票，且應收票據最近無違約記錄。於2024年及2023年12月31日，該等應收賬款之虧損撥備獲評估為微不足道。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

22. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

22. 預付款項、按金及其它應收款

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Non-current	非流動		
Deposits for acquisition of items of:	收購以下項目之按金：		
Property, plant and equipment	物業、廠房及設備	755	572
Other intangible assets	其它無形資產	11,383	34,650
		12,138	35,222
Current	流動		
Prepayments	預付款項	2,447	1,811
Deposits	按金	6,144	8,432
Other receivables	其它應收款	3,352	2,312
		11,943	12,555
Impairment allowance (note)	減值撥備 (附註)	(49)	(1,050)
		11,894	11,505
Total	總計	24,032	46,727

Note: The movements in the loss allowance for impairment of deposits and other receivables during the year are as follows:

附註：年內按金及其它應收款之減值虧損撥備之變動如下：

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
At 1 January	於1月1日	1,050	158
Impairment losses/(reversal of impairment losses) recognised during the year, net	年內確認的減值虧損／(減值虧損撥回) 淨額	(1,001)	892
At 31 December	於12月31日	49	1,050

The provision rates are based on an internal credit rating with reference to the historical records of the Group to determine the probability of default. Loss given default is estimated based on market information. The loss rate is then adjusted to reflect the current conditions and forecasts of future economic conditions, as appropriate.

撥備率乃基於參考本集團過往記錄之內部信貸評級以釐定違約概率。違約損失乃根據市場信息估計。損失率繼而調整以反映當前狀況及未來經濟狀況預測 (如合適)。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

22. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES (continued)

Note: (continued)

Set out below is the information about the credit risk exposure on the Group's deposits and other receivables:

At 31 December 2024	於2024年12月31日	
Expected credit loss rate	預期信貸虧損率	0.23%
Gross carrying amount (HK\$'000)	總賬面值 (千港元)	21,634
Expected credit losses (HK\$'000)	預期信貸虧損 (千港元)	49
At 31 December 2023	於2023年12月31日	
Expected credit loss rate	預期信貸虧損率	2.28%
Gross carrying amount (HK\$'000)	總賬面值 (千港元)	45,966
Expected credit losses (HK\$'000)	預期信貸虧損 (千港元)	1,050

22. 預付款項、按金及其它應收款 (續)

附註：(續)

下文載列本集團按金及其它應收款之信貸風險資料：

23. BALANCES WITH FELLOW SUBSIDIARIES

(a) Due from a fellow subsidiary

At 31 December 2024, the Group had an outstanding trade balance due from a fellow subsidiary, Tianda Group (Australia) Pty. Ltd. of HK\$87,000 (2023: HK\$312,000), which was payable on credit terms similar to those offered to the major customers of the Group.

The balance is unsecured, non-interest-bearing and with a credit term of 90 days. As at the end of the reporting period, the balance was aged within 2 months based on the invoice date.

(b) Due to fellow subsidiaries

23. 與同系附屬公司之結餘

(a) 應收一間同系附屬公司款項

於2024年12月31日，本集團應收同系附屬公司天大集團（澳大利亞）有限公司之未償還貿易結餘為87,000港元（2023年：312,000港元），該款項按類似於向本集團主要客戶提供的信貸條款支付。

該結餘為無抵押、免息及信貸期為90天。於報告期末，該結餘之賬齡為根據發票日期之兩個月內。

(b) 應付同系附屬公司款項

			2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
	Notes 附註			
Trade and bills payables	應付賬款及應付票據	(i)	10,385	11,975
Short-term lease payable	短期應付租賃	(ii)	1,274	483
			11,659	12,458

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

23. BALANCES WITH FELLOW SUBSIDIARIES (continued)

(b) Due to fellow subsidiaries (continued)

Notes:

- (i) At 31 December 2024, the Group had trade balances due to two fellow subsidiaries of the Company, namely Zhuhai S.E.Z. Cheng Cheng Printing Co. Ltd. and Tianda (China) Ltd., of HK\$10,385,000 (2023: HK\$11,810,000) and Nil (2023: HK\$165,000), respectively.

The balances are unsecured, non-interest bearing and with a credit term of 90 days. As at the end of the reporting period, the balances were aged within 2 months based on the invoice date.

- (ii) The Group had lease payables to two fellow subsidiaries of the Company, namely Zhuhai Tianda Realty Limited and Shenzhen Tianda Creative Ltd., of HK\$800,000 (2023: HK\$483,000) and HK\$474,000 (2023: Nil), respectively. The balances are unsecured, non-interest bearing and repayable on demand.

23. 與同系附屬公司之結餘 (續)

(b) 應付同系附屬公司款項 (續)

附註：

- (i) 於2024年12月31日，本集團應付本公司兩間同系附屬公司珠海經濟特區誠成印務有限公司及天大實業(中國)有限公司之未償還貿易結餘分別為10,385,000港元(2023年：11,810,000港元)及零港元(2023年：165,000港元)。

該結餘為無抵押、免息及信貸期為90天。於報告期末，該結餘之賬齡為根據發票日期之兩個月內。

- (ii) 本集團應付本公司兩間同系附屬公司珠海天大置業有限公司及深圳天大創意有限公司的租金分別為800,000港元(2023年：483,000港元)及474,000港元(2023年：無)。該結餘為無抵押、免息及按要求償還。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

24. CASH AND BANK BALANCES

At 31 December 2024, the Group's cash and bank balances denominated in RMB amounted to HK\$71,352,000 (2023: HK\$136,393,000). RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default.

25. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Within 2 months	2個月內	36,783	80,762
2 to 3 months	2至3個月	3,738	1,368
Over 3 months	3個月以上	26,917	23,888
		67,438	106,018

Trade payables are non-interest-bearing and are normally settled within terms of 30 to 60 days.

24. 現金及銀行結餘

於2024年12月31日，本集團以人民幣計值之現金及銀行結餘為71,352,000港元（2023年：136,393,000港元）。人民幣不可自由兌換為其它貨幣，然而根據中國大陸外匯管制規例及結匯、售匯及付匯管理規定，本集團可透過獲准進行外匯業務之銀行將人民幣兌換為其它貨幣。

存於銀行之現金基於每日銀行存款利率按浮動利率賺取利息。銀行結餘存放於最近並無拖欠紀錄之信譽良好的銀行。

25. 應付賬款

於報告期末，以發票日期為基準的應付賬款之賬齡分析如下：

應付賬款為不計息，一般於30至60天內清償。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

26. OTHER PAYABLES AND ACCRUALS

26. 其它應付款及應計費用

			2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
	Notes 附註			
Contract liabilities	合約負債	(a)	8,429	13,714
Other payables	其它應付款	(b)	10,319	11,342
Accruals	應計費用		28,094	63,826
Dividend payables	應付股息		43	41
			46,885	88,923

Notes:

附註：

(a) Details of contract liabilities are as follows:

(a) 合約負債詳情如下：

	31 December 2024 2024年 12月31日 HK\$'000 千港元	31 December 2023 2023年 12月31日 HK\$'000 千港元	1 January 2023 2023年 1月1日 HK\$'000 千港元
Short-term advances received from customers	已收客戶短期墊款		
Sale of pharmaceutical and Chinese medicine products	銷售醫藥及中醫藥產品	8,429	13,714
			111,733

Contract liabilities include short-term advances received from customers for the sale of pharmaceutical and Chinese medicine products. The decrease in contract liabilities in 2024 and 2023 was mainly due to the decrease in short-term advances received from customers in relation to the sale of pharmaceutical and Chinese medical products at the end of the year.

合約負債包括銷售醫藥及中醫藥產品的已收客戶短期墊款。2024年及2023年合約負債減少主要是由於年末就醫藥及中醫產品銷售之已收客戶短期墊款減少所致。

(b) Other payables are non-interest-bearing and have an average credit term of three months.

(b) 其它應付款不計利息，平均信貸為期三個月。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

27. BANK BORROWINGS

27. 銀行借款

		2024 2024年			2023 2023年		
		Effective interest rate (%) 實際利率(%)	Maturity 到期時間	HK\$'000 千港元	Effective interest rate (%) 實際利率(%)	Maturity 到期時間	HK\$'000 千港元
Current:	流動：						
Bank loans – secured (note (a))	銀行貸款－有抵押 (附註(a))	PRC Loan Prime Rate ("LPR") +1% 中國貸款市場 報價利率加1%	2025 2025年	54,741	LPR +1% 中國貸款市場 報價利率加1%	2024 2024年	53,170
Bank loans – unsecured	銀行貸款－無抵押	LPR +0.45% 中國貸款市場 報價利率加0.45%	2025 2025年	67,333	LPR +0.45% 中國貸款市場 報價利率加0.45%	2024 2024年	43,322
				122,074			96,492
Non-current:	非流動：						
Bank loan – secured (note (a))	銀行貸款－有抵押 (附註(a))			–	LPR+1% 中國貸款市場 報價利率加1%	2025 2025年	8,358
				122,074			104,850

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

27. BANK BORROWINGS (continued)

Notes:

- (a) The secured bank loans as at 31 December 2024 were secured by the pledge of certain of the Group's leasehold land and buildings with an aggregate carrying amount of HK\$259,562,000 (2023: HK\$253,965,000) (notes 14(a) and 15(a)).
- (b) The financial liabilities that are part of the Group's supplier finance arrangements are included in bank borrowings and are normally settled on 360-day term.

The Group has established supplier finance arrangements that are offered to some of the Group's key suppliers in Mainland China. Participation in the arrangements is at the suppliers' own discretion. Suppliers that participate in the supplier finance arrangements will receive early payments or payments at the original due dates on invoices sent to the Group from the Group's external finance provider. If suppliers choose to receive early payments, they bear the related expenses. In order for the finance provider to pay the invoices, the goods must have been received or supplied and the invoices must have been approved by the Group. Payments to suppliers ahead of or at the invoice due date are processed by the finance provider and, in all cases, the Group settles the original invoice by paying the finance provider in line with the original invoice maturity date or at a later date as agreed with the finance provider. Interest expenses on the bank borrowings begin to accrue when those suppliers have received the payments from the external finance provider. Payment terms with suppliers have not been renegotiated in conjunction with the arrangements. The Group provides no security to the finance provider.

All financial liabilities that are part of the supplier financial arrangements are included in the current portion of the Group's secured bank loans within bank borrowings in the consolidated statement of financial position.

27. 銀行借款(續)

附註：

- (a) 於2024年12月31日，有抵押銀行貸款以總賬面金額約為259,562,000港元（2023年：253,965,000港元）的本集團若干租賃土地及樓宇作抵押（附註14(a)及15(a)）。
- (b) 計入銀行借款作為本集團供應商融資安排一部分的金融負債一般於360日期限內結清。

本集團已制定供應商融資安排，提供予本集團在中國大陸的部分主要供應商。供應商可自行決定是否參與有關安排。參與供應商融資安排的供應商向本集團發出發票後，可獲本集團的外部融資供應商提早付款或於原定到期日付款。若供應商選擇提前收款，則須承擔有關開支。必須在已收到或提供貨物，且發票已獲本集團批准後，融資供應商方會支付發票。在發票到期日之前或之時向供應商支付的款項由融資供應商處理，在所有情況下，本集團根據原始發票到期日或與融資供應商協定的較後日期向融資供應商付款，以結清原始發票。銀行借款的利息開支自供應商收到外部融資供應商的付款後開始累計。與供應商訂立的付款條款並未就有關安排重新協商。本集團並無向融資供應商提供抵押。

所有作為供應商融資安排一部分的金融負債均計入綜合財務狀況表的銀行借款中本集團有抵押銀行貸款之流動部分。

		31 December 2024 2024年 12月31日 HK\$'000 千港元	31 December 2023 2023年 12月31日 HK\$'000 千港元	1 January 2023 2023年 1月1日 HK\$'000 千港元
Carrying amount of financial liabilities that are part of the supplier finance arrangements included in:	作為供應商融資安排一部分的金融負債賬面值，計入：			
Bank borrowings of which suppliers have received payments	供應商已收到付款的銀行借款	39,559	—	—

For financial liabilities that are part of the supplier finance arrangements included in bank borrowings, the related non-cash transaction is disclosed in note 31(a) to the financial statements.

就計入銀行借款作為供應商融資安排一部分的金融負債而言，相關非現金交易於財務報表附註31(a)披露。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

28. DEFERRED TAX LIABILITIES

The components of the deferred tax liabilities and their movements during the year are as follows:

28. 遞延稅項負債

於本年度，遞延稅項負債的組成部分及其變動如下：

		Attributable to 應佔		
		Fair value adjustment arising from acquisition of a subsidiary 收購一間 附屬公司 產生之 公允價值調整	Development costs 開發成本	Total 總額
		HK\$'000 千港元	HK\$'000 千港元	HK\$'000 千港元
At 1 January 2023	於2023年1月1日	306	656	962
Deferred tax credited to profit or loss during the year (note 11)	年內在損益計入之 遞延稅項 (附註11)	(55)	(290)	(345)
Exchange realignment	匯兌調整	(2)	(4)	(6)
At 31 December 2023 and 1 January 2024	於2023年12月31日及 2024年1月1日	249	362	611
Deferred tax charged/(credited) to profit or loss during the year (note 11)	年內在損益扣除／(計入)之 遞延稅項 (附註11)	(53)	4,734	4,681
Exchange realignment	匯兌調整	(8)	(104)	(112)
At 31 December 2024	於2024年12月31日	188	4,992	5,180

Notes:

- (a) The Group has tax losses arising in Hong Kong and Australia of HK\$211,034,000 (2023: HK\$191,870,000) that are available indefinitely for offsetting against future taxable profits of the companies in which the losses arose. The Group has tax losses arising in Macau of HK\$1,576,000 (2023: HK\$1,397,000) that will expire in one to three years for offsetting against future taxable profits. The Group also has tax losses arising in Mainland China of HK\$123,743,000 (2023: HK\$97,853,000) that will expire in one to five years for offsetting against future taxable profits.

Deferred tax assets have not been recognised in respect of these losses as they have arisen from subsidiaries that have been loss-making for some time and it is uncertain that taxable profits will be available against which the tax losses can be utilised.

附註：

- (a) 本集團有源自香港及澳大利亞而可無限期用於抵銷產生虧損之公司的未來應課稅溢利之稅項虧損211,034,000港元(2023年：191,870,000港元)。本集團有源自澳門而可用於抵銷未來應課稅溢利及將於一至三年內屆滿之稅項虧損1,576,000港元(2023年：1,397,000港元)。本集團亦有源自中國大陸而可用於抵銷未來應課稅溢利及將於一至五年內屆滿之稅項虧損123,743,000港元(2023年：97,853,000港元)。

由於該等虧損來自已虧損一段時間的附屬公司，且並不確定會有應課稅溢利以抵銷稅務虧損，故並無就該等虧損確認遞延稅項資產。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

28. DEFERRED TAX LIABILITIES (continued)

Notes: (continued)

- (b) Pursuant to the PRC Corporate Income Tax Law, a 10% withholding tax is levied on dividends declared to foreign investors from the foreign investment enterprises established in Mainland China. A lower withholding tax rate may be applied if there is a tax treaty between Mainland China and the jurisdiction of the foreign investors. For the Group, the applicable rate is 5% (31 December 2023: 5%). The Group is therefore liable to withholding taxes on dividends distributed by those subsidiaries established in Mainland China.

At 31 December 2024, there was no significant unrecognised deferred tax liability for taxes that would be payable on the unremitted earnings of the Group's subsidiaries established in the PRC that are subject to withholding taxes as it is the intention of the management to retain the earnings within these subsidiaries. (2023: Nil).

- (c) There are no income tax consequences attaching to the payment of dividend by the Company to its shareholders.

28. 遞延稅項負債 (續)

附註：(續)

- (b) 根據中國企業所得稅法，向來自於中國大陸成立的外國投資企業的外國投資者所宣派股息須繳納10%的預扣稅。倘中國大陸與外國投資者所在司法權區訂立稅務條約，適用的預扣稅率或較低。就本集團而言，適用稅率為5% (2023年12月31日：5%)。因此本集團須就中國大陸成立的該等附屬公司所分派的股息繳納預扣稅。

於2024年12月31日，本集團於中國成立並須繳納預扣稅的附屬公司未匯出盈利的應付稅項並無重大未確認遞延稅項負債，原因為管理層有意將該等盈利保留於該等附屬公司 (2023年：無)。

- (c) 本公司向其股東派付股息並無附帶所得稅後果。

29. SHARE CAPITAL

29. 股本

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Authorised:	法定：		
4,000,000,000 ordinary shares of HK\$0.1 each	4,000,000,000股每股 面值0.1港元之普通股	400,000	400,000
Issued and fully paid:	已發行及繳足：		
2,150,041,884 ordinary shares of HK\$0.1 each	2,150,041,884股每股 面值0.1港元之普通股	215,004	215,004

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

30. RESERVES

- (a) The amounts of the Group's reserves and the movements therein for the current and prior years are presented in the consolidated statement of changes in equity.
- (b) Under the Companies Act (Revised) of the Cayman Islands, the funds in the share premium account of the Company are distributable to shareholders of the Company provided that immediately following the date on which the dividend is proposed to be distributed, the Company will be in a position to pay off its debts as they fall due in the ordinary course of business.
- (c) The capital contribution reserve represents (1) the excess of the disposal consideration over the fair value of the disposal of Tinwise Investment Limited, a then wholly-owned subsidiary of the Company, and its subsidiaries in 2010 as a deemed contribution from a shareholder; (2) the excess of the disposal consideration over the fair value of the disposal of the packaging and printing business in 2012 as a deemed capital contribution from the ultimate holding company; and (3) the excess of the disposal consideration over the fair value of the disposal of mineral resources business in 2012 as a deemed capital contribution from the ultimate holding company.
- (d) The special reserve represents the difference between the nominal amount of the share capital issued by the Company and the nominal amount of the share capital of a subsidiary acquired by the Company pursuant to a corporate reorganisation in preparation for the listing of the Company's shares on the Stock Exchange in 1992.
- (e) The statutory reserve represents (1) the appropriation of certain percentages of profit after tax of the subsidiaries established in the PRC as recommended by the directors of those subsidiaries based on the PRC statutory financial statements and (2) the provision for production safety fund by a subsidiary in the PRC at fixed rates ranging from 2% to 4% based on operating revenue (the maintenance and production safety funds), which is transferred from retained profits to the statutory reserves and could be utilised when expenses and capital expenditures in production maintenance and safety measures are incurred.

30. 儲備

- (a) 本集團於本年度及過往年度之儲備數額及相關變動載於綜合權益變動表。
- (b) 根據開曼群島公司法（經修訂），本公司股份溢價賬內的資金可分派予本公司股東，惟緊隨建議分派股息日期後，本公司將有能力償還其於日常業務過程中到期的債務。
- (c) 出資儲備代表(1) 2010年出售本公司當時的全資附屬公司Tinwise Investment Limited及其附屬公司之代價高於所出售之公允價值，作為一名股東之視作出資；(2) 2012年出售包裝及印刷業務之代價高於所出售之公允價值，作為最終控股公司之視作出資；及(3) 2012年出售礦產資源業務之代價高於所出售之公允價值，作為最終控股公司之視作出資。
- (d) 特別儲備乃本公司根據一項為籌備本公司股份於1992年在聯交所上市而進行之公司重組所發行之股本面值與所收購一間附屬公司之股本面值兩者間之差額。
- (e) 法定儲備乃指(1)於中國成立之附屬公司之董事根據中國法定財務報表而建議就該等附屬公司之除稅後溢利作出若干百分比之分配及(2)一間中國附屬公司以經營收入為基準按介乎2%至4%之固定利率撥備之生產安全基金（維修及生產安全基金），由保留溢利轉撥至法定儲備，且於生產維修及安全措施產生支出及資本開支時動用。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

30. RESERVES (continued)

- (f) The capital reserve represents the difference between the consideration paid and the carrying amount of the additional interests of Tianda Pharmaceuticals (Yunnan) acquired by the Group on 30 September 2023. Details of the transaction are disclosed in note 33(b)(ii).

31. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Major non-cash transactions

During the year, the Group had non-cash additions to the right-of-use assets and lease liabilities of HK\$2,796,000 (2023: Nil) and HK\$2,796,000 (2023: Nil), respectively, in respect of lease arrangements for clinics, offices and warehouses.

During the year, the Group reclassified trade payables of HK\$40,337,000 (2023: Nil) to bank borrowings in respect of the supplier finance arrangements.

30. 儲備 (續)

- (f) 資本儲備指本集團於2023年9月30日收購的天大藥業(雲南)額外權益的已付代價與賬面值之間的差額。交易詳情於附註33(b)(ii)中披露。

31. 綜合現金流量表附註

(a) 主要非現金交易

於本年度，本集團就診所、辦公室及倉庫的租賃安排，分別有2,796,000港元(2023年：無)及2,796,000港元(2023年：無)的非現金使用權資產及租賃負債增加。

年內，本集團就供應商融資安排將貿易應付款項40,337,000港元(2023年：無)重新分類至計息銀行借款。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

31. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (continued)

31. 綜合現金流量表附註(續)

(b) Changes in liabilities arising from financing activities:

(b) 融資活動產生的負債變動：

		Lease liabilities 租賃負債 HK\$'000 千港元	Bank borrowings 銀行借款 HK\$'000 千港元	Dividend payables 應付股息 HK\$'000 千港元
At 1 January 2023	於2023年1月1日	14,404	126,646	39
Changes from financing cash flows	來自融資現金流量的變動	(5,626)	(20,952)	–
Interest expense	利息開支	(572)	(4,374)	–
Interest paid classified as operating cash flows	分類為經營現金流量之已付利息	572	4,374	–
Dividend declared	已宣派股息	–	–	5,590
Dividends paid	已付股息	–	–	(5,588)
Exchange realignment	匯兌調整	(31)	(844)	–
At 31 December 2023 and 1 January 2024	於2023年12月31日及2024年1月1日	8,747	104,850	41
Changes from financing cash flows	來自融資現金流量的變動	(6,060)	(19,001)	–
Increase arising from supplier finance arrangements	供應商融資安排所產生的增幅	–	40,337	–
New leases	新租賃	2,796	–	–
Interest expense	利息開支	(347)	(4,507)	–
Interest paid classified as operating cash flows	分類為經營現金流量之已付利息	347	4,507	–
Dividend declared	已宣派股息	–	–	5,590
Dividends paid	已付股息	–	–	(5,588)
Exchange realignment	匯兌調整	(112)	(4,112)	–
At 31 December 2024	於2024年12月31日	5,371	122,074	43

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

31. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS (continued)

(c) Total cash outflow for leases

The total cash outflow for leases included in the consolidated statement of cash flows is as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Within operating activities	於經營活動內	(2,764)	(2,526)
Within financing activities	於融資活動內	(6,060)	(5,626)
		(8,824)	(8,152)

32. CAPITAL COMMITMENTS

The Group had the following capital commitments at the end of the reporting period:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Contracted, but not provided for:	已訂約但未撥備：		
Property, plant and equipment	物業、廠房及設備	23,698	49,800
Other intangible assets	其它無形資產	19,021	14,950
		42,719	64,750

31. 綜合現金流量表附註 (續)

(c) 租賃的現金流出總額

計入綜合現金流量表的現金流出總額如下：

32. 資本承擔

本集團於報告期末有以下資本承擔：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

33. RELATED PARTY DISCLOSURES

- (a) The Group had the following transactions with related parties during the year:

		Notes 附註	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元 (Restated) (經重列)
Ultimate holding company:	最終控股公司：			
Purchases of consumer goods	購買消費品	(ii)	11	–
Fellow subsidiaries:	同系附屬公司：			
Sales of healthcare products	銷售保健產品	(i)	66	437
Sales of pharmaceuticals and medical technologies products	銷售藥品及醫療技術產品	(i)	–	16
Purchases of packaging materials and designing services*	購買包裝材料及設計服務*	(ii)	7,214	14,892
Purchases of consumer goods	購買消費品	(ii)	93	140
Short-term lease payments for office, warehouse and clinics	辦公室、倉庫及診所的短期租賃付款	(iii)	1,515	1,624

* These related party transactions also constitute continuing connected transactions as defined in Chapter 14A of the Listing Rules.

Notes:

- (i) The sales to fellow subsidiaries were made according to the published prices and conditions offered to major customers of the Group.
- (ii) The purchases from the ultimate holding company and fellow subsidiaries were made according to the published prices and conditions offered by the fellow subsidiaries to their major customers.
- (iii) The transactions were conducted in accordance with the terms and conditions mutually agreed by both parties.

33. 關連人士披露

- (a) 本集團於年內與關連人士進行以下交易：

* 該等關連人士交易亦構成上市規則第14A章所界定之持續關連交易。

附註：

- (i) 向同系附屬公司的銷售乃按公開價格及向本集團主要客戶提供的條件進行。
- (ii) 向最終控股公司及同系附屬公司採購乃按公開價格及同系附屬公司向其主要客戶提供的條件作出。
- (iii) 該等交易乃按雙方相互同意之條款及條件進行。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

33. RELATED PARTY TRANSACTIONS (continued)

(b) Other transactions with related parties:

- (i) On 19 April 2023, the Group entered into an agreement to subscribe for an investment fund in a principal amount of HK\$10,000,000. The principal objective of the fund is to maximise capital appreciation and achieve returns to investors. The fund is managed by Tianda Asset Management Limited, which is a fellow subsidiary of the Company.

This related party transaction also constituted a connected transaction as defined in Chapter 14A of the Listing Rules.

- (ii) On 1 August 2023, Yunyu Bio-Pharmaceutical Co., Limited ("Yunyu Bio-Pharmaceutical"), a wholly-owned subsidiary of the Company, entered into an equity transfer agreement (the "Agreement") with Yunnan Li Nuo Biotechnology Co., Limited ("Li Nuo"), the 45% minority shareholder of Tianda Pharmaceuticals (Yunnan), which was then 55% owned by the Group. Pursuant to the Agreement, Yunyu Bio-Pharmaceutical acquired this remaining 45% interest in Tianda Pharmaceuticals (Yunnan) held by Li Nuo at a consideration of RMB23,500,000 (equivalent to approximately HK\$25,228,000) on 30 September 2023, and Tianda Pharmaceuticals (Yunnan) has become an indirect wholly-owned subsidiary of the Company since then. The excess of the consideration paid over the carrying amount of the additional interest of Tianda Pharmaceuticals (Yunnan) acquired, amounting to HK\$336,000, was recognised as a reduction in the Group's capital reserve during the year ended 31 December 2023.

Further details of this transaction are set out in the announcement of the Company dated 1 August 2023.

33. 關連人士交易 (續)

(b) 與關連人士的其它交易：

- (i) 本集團於2023年4月19日訂立協議，認購本金額為10,000,000港元的投資基金。該基金的主要目標是為投資者實現最大的資本增值和回報。該基金由本公司的同系附屬公司天大資產管理有限公司管理。

該關連人士交易亦構成上市規則第14A章所界定之關連交易。

- (ii) 於2023年8月1日，本公司全資附屬公司雲玉生物製藥有限公司（「雲玉生物製藥」）與持有天大藥業（雲南）（由本集團當時持有55%股權）45%股權的少數股東雲南利諾生物技術有限公司（「利諾」）訂立股權轉讓協議（「協議」）。根據協議，雲玉生物製藥於2023年9月30日以人民幣23,500,000元（相當於約25,228,000港元）的代價收購利諾持有的天大藥業（雲南）剩餘45%的股權，天大藥業（雲南）自此成為本公司的間接全資附屬公司。所收購天大藥業（雲南）額外權益的已付代價高於賬面值的差額336,000港元，已於截至2023年12月31日止年度確認為本集團資本儲備減少。

有關該交易的進一步詳情，請參閱本公司日期為2023年8月1日的公告。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
綜合財務報表附註

31 December 2024 2024年12月31日

33. RELATED PARTY TRANSACTIONS (continued)

(c) Compensation of key management personnel of the Group:

33. 關連人士交易 (續)

(c) 本集團主要管理人員酬金：

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元 (Restated) (經重列)
Short-term employee benefits	短期僱員福利	5,942	5,137
Post-employment benefits	退休福利	429	481
Total compensation paid to key management personnel	已付主要管理人員酬金總額	6,371	5,618

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

34. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:

At 31 December 2024

Financial assets

		Financial assets at amortised cost 按攤銷成本 列賬之 金融資產 HK\$'000 千港元
Trade and bills receivables	應收賬款及應收票據	77,423
Financial assets included in prepayments, deposits and other receivables	計入預付款項、 按金及其它應收款之 金融資產	21,585
Due from a fellow subsidiary	應收一間同系附屬公司款項	87
Cash and bank balances	現金及銀行結餘	85,688
		184,783

Financial liabilities**金融負債**

		Financial liabilities at amortised cost 按攤銷成本列賬 之金融負債 HK\$'000 千港元
Trade payables	應付賬款	67,438
Financial liabilities included in other payables and accruals	計入其它應付款及應計費用 之金融負債	33,963
Due to fellow subsidiaries	應付同系附屬公司款項	11,659
Bank borrowings	銀行借款	122,074
Lease liabilities	租賃負債	5,371
		240,505

34. 金融工具之類別

於報告期末各類金融工具之賬面
值如下：

於2024年12月31日

金融資產**金融負債**

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

34. FINANCIAL INSTRUMENTS BY CATEGORY (continued)

The carrying amounts of each of the categories of financial instruments as at the end of the reporting period are as follows:
(continued)

At 31 December 2023
Financial assets

34. 金融工具之類別 (續)

於報告期末各類金融工具之賬面值如下：(續)

於2023年12月31日
金融資產

		Financial assets at fair value through profit or loss 按公允價值 計入損益之 金融資產 HK\$'000 千港元	Financial assets at fair value through other comprehensive income 按公允價值 計入其它全面 收益之金融資產 HK\$'000 千港元	Financial assets at amortised cost 按攤銷成本 列賬之 金融資產 HK\$'000 千港元	Total 總額 HK\$'000 千港元
Financial asset at fair value through profit or loss	按公允價值計入損益之金融資產	9,000	-	-	9,000
Equity investment designated at fair value through other comprehensive income	指定為按公允價值計入 其它全面收益之股本投資	-	216	-	216
Trade and bills receivables	應收賬款及應收票據	-	-	104,801	104,801
Financial assets included in prepayments, deposits and other receivables	計入預付款項、按金及 其它應收款之金融資產	-	-	44,916	44,916
Due from a fellow subsidiary	應收一間同系附屬公司款項	-	-	312	312
Cash and bank balances	現金及銀行結餘	-	-	162,442	162,442
		9,000	216	312,471	321,687

Financial liabilities

金融負債

		Financial liabilities at amortised cost 按攤銷成本列賬 之金融負債 HK\$'000 千港元
Trade payables	應付賬款	106,018
Financial liabilities included in other payables and accruals	計入其它應付款及應計費用 之金融負債	63,428
Due to fellow subsidiaries	應付同系附屬公司款項	12,458
Bank borrowings	銀行借款	104,850
Lease liabilities	租賃負債	8,747
		295,501

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

35. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and the fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair value, are as follows:

		Carrying amounts 賬面值		Fair values 公允價值	
		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元	2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Financial liabilities	金融負債				
Bank borrowings	銀行借款	122,074	104,850	120,693	104,676

Management has assessed that the fair values of trade and bills receivables, financial assets included in prepayments, deposits and other receivables, an amount due from a fellow subsidiary, cash and bank balances, trade payables, financial liabilities included in other payables and accruals and amounts due to fellow subsidiaries approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair value:

35. 金融工具之公允價值及公允價值等級

本集團的金融工具（經合理計算其賬面值與公允價值合理相若者除外）賬面值及公允價值如下：

管理層已評估，應收賬款及應收票據、計入預付款項、按金及其它應收款之金融資產、應收一間同系附屬公司款項、現金及銀行結餘、應付賬款、計入其它應付款及應計費用之金融負債以及應付同系附屬公司款項之公允價值與其各自之賬面值相若，主要由於該等工具於短期內到期。

金融資產及負債之公允價值按自願雙方（非強迫或清盤銷售）之間的當前交易中進行交換的工具的金額入賬。已採用下列方法及假設估計公允價值：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

35. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The fair value of the financial asset at fair value through profit or loss is based on the market values provided by the licensed corporation at the end of the reporting period.

The fair value of the equity investment at fair value through other comprehensive income is based on quoted market prices.

The fair values of bank borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The fair values of the bank borrowings are categorised in Level 2 of the fair value hierarchy.

Fair value hierarchy

The following table illustrates the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Equity investment at fair value through other comprehensive income	按公允價值計入其它全面收益之股本投資		
– Fair value measurement using quoted prices in active markets (Level 1)	– 以活躍市場報價進行公允價值計量(第1級)	–	216
Financial asset at fair value through profit or loss	按公允價值計入損益之金融資產		
– Fair value measurement using significant observable inputs (Level 2)	– 以重大可觀察輸入數據進行公允價值計量(第2級)	–	9,000

The equity investment at fair value through other comprehensive income was delisted from the NASDAQ Stock Market in July 2024.

35. 金融工具之公允價值及公允價值等級(續)

按公允價值計入損益之金融資產的公允價值為根據持牌法團於報告期末提供的市場價值釐定。

按公允價值計入其它全面收益之股本投資之公允價值乃基於市場報價。

銀行借款的公允價值乃按具有類似條款、信貸風險及剩餘到期日的工具的現行利率貼現預期未來現金流量計算。銀行借款的公允價值分類為公允價值等級內的第2級。

公允價值等級

下表說明本集團金融工具的公允價值計量等級：

按公允價值計量的資產

按公允價值計入其它全面收益之股本投資於2024年7月從納斯達克股票市場退市。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

35. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

During the year, there were no transfers of fair value measurement between Level 1 and Level 2 for both financial assets and financial liabilities (2023: Nil).

During the year, except for the transfer of fair value measurement from Level 1 into Level 3 for the equity investment designated at fair value through other comprehensive income following the delisting of the shares during the year as disclosed in note 19, there were no other transfer into or out of Level 3 for both financial assets and financial liabilities (2023: Nil).

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group's principal financial instruments comprise cash and cash equivalents. The main purpose of these financial instruments is to raise finance for the Group's operations. The Group has various other financial assets and liabilities such as trade and bills receivables, other receivables, structured deposits, trade payables, other payables and amounts due to fellow subsidiaries.

The main risks arising from the Group's financial instrument are interest rate risk, foreign currency risk, credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarised below.

35. 金融工具之公允價值及公允價值等級 (續)

年內，金融資產及金融負債並無第1級與第2級之間公允價值計量轉撥(2023年：無)。

年內，除附註19所披露於年內因股份退市而將指定為按公允價值計入其它全面收益之股本投資之公允價值計量由第1級轉入第3級外，概無其他金融資產及金融負債轉入或轉出第3級(2023年：無)。

36. 金融風險管理目標及政策

本集團的主要金融工具包括現金及現金等值項目。該等金融工具的主要目的是撥付本集團的營運。本集團擁有不同的其它金融資產及負債，如應收賬款及應收票據、其它應收款、結構性存款、應付賬款、其它應付款及應付同系附屬公司款項。

本集團金融工具產生的主要風險包括利率風險、外幣風險、信貸風險及流動資金風險。董事會審查並協定用於管理此等風險的政策，並概述如下。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Interest rate risk

The Group's exposure to the risk of changes in market interest rates relates primarily to the Group's cash and bank balances and bank borrowings with a floating interest rate. The Group has not used any interest rate derivatives to hedge its interest rate risk, and will consider hedging significant interest rate risk should the need arise.

The following table demonstrates the sensitivity to a reasonably possible change in interest rates, with all other variables held constant, of the Group's loss before tax (through the impact on floating rate of cash and cash equivalents and bank borrowings).

		Increase/ (decrease) in basis points	Increase/ (decrease) in loss before tax 除稅前虧損 增加／(減少) 2024 2024年 HK\$'000 千港元	Increase/ (decrease) in loss before tax 除稅前虧損 增加／(減少) 2023 2023年 HK\$'000 千港元
HK\$	港元	100	(134)	(248)
RMB	人民幣	100	507	(315)
HK\$	港元	(100)	134	248
RMB	人民幣	(100)	(507)	315

36. 金融風險管理目標及政策 (續)

利率風險

本集團面對市場利率變動風險主要與本集團按浮動利率計息的現金及銀行結餘以及銀行借款有關。本集團並無使用任何利率衍生工具以對沖其利率風險，並將於有需要時考慮對沖重大利率風險。

下表說明在所有其它變數保持不變的情況，利率合理可能變動對本集團除稅前虧損的敏感度（通過浮動利率對現金及現金等值項目以及銀行借款的影響）。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Foreign currency risk

The Group has transactional currency exposures. Such exposures arise from sales by operating units in currencies other than the units' functional currencies. Approximately 1.7% (2023: 1.5%) of the Group's sales were denominated in currencies other than the functional currencies of the operating units making the sale.

The following table demonstrates the sensitivity at the end of the reporting period to a reasonably possible change in the foreign currency exchange rate, with all other variables held constant, of the Group's (loss)/profit before tax.

36. 金融風險管理目標及政策 (續)

外幣風險

本集團存在交易貨幣風險。有關風險是源自經營單位的單位功能貨幣以外的貨幣之銷售。約1.7% (2023年：1.5%) 之本集團銷售是以進行銷售之經營單位的單位功能貨幣以外的貨幣為結算單位。

下表說明在所有其它變數保持不變的情況，外幣匯率合理可能變動對本集團除稅前(虧損)/溢利於報告期末的敏感度。

		Change in foreign currency rate 外幣 匯率變動 %	Increase/ (decrease) in loss before tax 除稅前虧損 增加／(減少) HK\$'000 千港元
Year ended 31 December 2024	截至2024年12月31日止年度		
If RMB weakens against HK\$	倘若人民幣兌港元匯率下跌	1	(134)
If RMB strengthens against HK\$	倘若人民幣兌港元匯率上升	(1)	134

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Foreign currency risk (continued)

		Change in foreign currency rate 外幣 匯率變動 %	Increase/ (decrease) in loss before tax 除稅前虧損 增加／(減少) HK\$'000 千港元
Year ended 31 December 2023	截至2023年12月31日止年度		
If RMB weakens against HK\$	倘若人民幣兌港元匯率下跌	1	(241)
If RMB strengthens against HK\$	倘若人民幣兌港元匯率上升	(1)	241

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group's exposure to bad debts is not significant.

36. 金融風險管理目標及政策 (續)

外幣風險 (續)

信貸風險

本集團僅與認可及信譽良好的第三方進行交易。本集團的政策是，所有冀以信貸條款進行交易的客戶均須通過信貸核査程序。此外，應收賬款餘額持續受到監控，本集團的壞賬風險不大。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Credit risk (continued)

Maximum exposure and year-end staging

The tables below show the credit quality and the maximum exposure to credit risk based on the Group's credit policy, which is mainly based on past due information unless other information is available without undue cost or effort, and year-end staging classification as at 31 December. The amounts presented are gross carrying amounts for financial assets.

At 31 December 2024

		12-month ECLs 12個月預期 信貸虧損	Lifetime ECLs 全期預期信貸虧損			
		Stage 1 第1階段 HK\$'000 千港元	Stage 2 第2階段 HK\$'000 千港元	Stage 3 第3階段 HK\$'000 千港元	Simplified approach 簡化方法 HK\$'000 千港元	Total 總計 HK\$'000 千港元
Trade receivables*	應收賬款*	–	–	–	59,743	59,743
Bills receivable	應收票據	18,833	–	–	–	18,833
Due from a fellow subsidiary	應收一間同系 附屬公司款項	87	–	–	–	87
Financial assets included in prepayments, deposits and other receivables	計入預付款項、按金 及其它應收款之 金融資產					
– Normal**	– 正常**	21,634	–	–	–	21,634
Cash and bank balances	現金及銀行結餘					
– Not yet past due	– 尚未逾期	85,688	–	–	–	85,688
		126,242	–	–	59,743	185,985

36. 金融風險管理目標及政策 (續)

信貸風險 (續)

最高風險及年結階段

下表載列基於本集團之信貸政策之信貸質素及最高信貸風險，主要基於逾期資料（除非其它資料可在無須付出不必要成本或努力之情況下獲得），以及於12月31日之年結階段分析。所呈列的金額為金融資產的總賬面值。

於2024年12月31日

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Credit risk (continued)

Maximum exposure and year-end staging (continued)

At 31 December 2023

		12-month ECLs 12個月預期 信貸虧損	Lifetime ECLs 全期預期信貸虧損			
		Stage 1 第1階段 HK\$'000 千港元	Stage 2 第2階段 HK\$'000 千港元	Stage 3 第3階段 HK\$'000 千港元	Simplified approach 簡化方法 HK\$'000 千港元	Total 總計 HK\$'000 千港元
Trade receivables*	應收賬款*	–	–	–	72,586	72,586
Bills receivable	應收票據	33,963	–	–	–	33,963
Due from a fellow subsidiary	應收一間同系附屬公司 款項	–	–	–	312	312
Financial assets included in prepayments, deposits and other receivables	計入預付款項、按金及 其它應收款之 金融資產					
– Normal**	– 正常**	45,966	–	–	–	45,966
Cash and bank balances	現金及銀行結餘					
– Not yet past due	– 尚未逾期	162,442	–	–	–	162,442
		242,371	–	–	72,898	315,269

* For trade receivables to which the Group applies the simplified approach for impairment, information based on the credit rating is disclosed in note 21 to the financial statements.

** The credit quality of bills receivables and financial assets included in prepayments, deposits and other receivables is considered to be "normal" when they are not past due and there is no information indicating that the financial assets had a significant increase in credit risk since initial recognition. Otherwise, the credit quality of the financial assets is considered to be "doubtful".

36. 金融風險管理目標及政策 (續)

信貸風險 (續)

最高風險及年結階段 (續)

於2023年12月31日

* 就本集團已為其減值應用簡化方法之應收賬款而言，基於信貸評級之資料於財務報表附註21披露。

** 計入預付款項、按金及其它應收款之應收票據及金融資產之信貸質素於有關金融資產並無逾期時被視為「正常」，並無資料顯示有關金融資產之信貸風險自首次確認以來顯著增加。否則，有關金融資產之信貸質素被視為「呆賬」。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Liquidity risk

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank loans and projected cash flows from operations.

The Group has the following bank borrowings and lease liabilities as at the end of the reporting period:

36. 金融風險管理目標及政策 (續)

流動資金風險

本集團之目標旨在透過使用銀行貸款及營運之預測現金流量以維持資金持續供應與靈活性之間的平衡。

於報告期末，本集團有以下銀行借款及租賃負債：

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Bank borrowings	銀行借款	122,074	104,850
Lease liabilities	租賃負債	5,371	8,747
		127,445	113,597
Analysed into:	分析為：		
Bank borrowings repayable:	須於以下期間償還的		
	銀行借款：		
Within one year or on demand	一年內或按要求	122,074	96,492
In the second year	第二年	–	8,358
		122,074	104,850
Other borrowings repayable:	須於以下期間償還的		
	其他借款：		
Within one year or on demand	一年內或按要求	2,192	5,678
In the second year	第二年	2,000	1,278
In the third to fifth years, inclusive	第三至第五年 (包括首尾兩年)	1,179	1,791
		5,371	8,747
Total	總計	127,445	113,597

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Liquidity risk (continued)

The maturity profile of the Group's financial liabilities as at the end of the reporting period, based on the contractual undiscounted payments, is as follows:

31 December 2024

		On demand or no later than 1 year 按要求或 一年以下 HK\$'000 千港元	1 to 5 years 一至五年 HK\$'000 千港元	Total 總額 HK\$'000 千港元
Trade payables	應付賬款	67,438	–	67,438
Other payables and accruals	其它應付款及應計費用	31,795	–	31,795
Bank borrowings	銀行借款	123,412	–	123,412
Lease liabilities	租賃負債	2,338	3,305	5,643
Due to fellow subsidiaries	應付同系附屬公司款項	11,659	–	11,659
		236,642	3,305	239,947

31 December 2023

2024年12月31日

2023年12月31日

		On demand or no later than 1 year 按要求或 一年以下 HK\$'000 千港元	1 to 5 years 一至五年 HK\$'000 千港元	Total 總額 HK\$'000 千港元
Trade payables	應付賬款	106,018	–	106,018
Other payables and accruals	其它應付款及應計費用	63,428	–	63,428
Bank borrowings	銀行借款	99,155	8,367	107,522
Lease liabilities	租賃負債	5,970	3,257	9,227
Due to fellow subsidiaries	應付同系附屬公司款項	12,458	–	12,458
		287,029	11,624	298,653

流動資金風險 (續)

根據已訂約未貼現付款，本集團金融負債於報告期末之到期情況如下：

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

36. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)

Capital management

The primary objectives of the Group's capital management are to safeguard the Group's ability to continue as a going concern and to maintain healthy capital ratios in order to support its business and maximise shareholders' value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the year ended 31 December 2024 and 2023.

The Group monitors capital using a gearing ratio, which is debt divided by the equity attributable to shareholders of the Company. Debt includes bank borrowings. Capital includes equity attributable to shareholders of the Company. The gearing ratios as at the end of the reporting periods were as follows:

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
Bank borrowings	銀行借款	122,074	104,850
Equity attributable to shareholders of the Company	本公司股東應佔權益	505,838	592,071
Gearing ratio	資本負債比率	24.1%	17.7%

37. COMPARATIVE AMOUNTS

Certain comparative amounts have been reclassified and re-presented to conform to the current year's presentation.

36. 金融風險管理目標及政策 (續)

資本管理

本集團資本管理的主要目標是保障本集團持續經營的能力，並保持穩健的資本比率，以支持其業務並實現股東價值最大化。

本集團根據經濟狀況變動及相關資產的風險特徵管理資本結構並作出調整。為維持或調整資本結構，本集團可調整向股東派付的股息、向股東返還資本或發行新股份。本集團不受任何外部施加的資本要求所限。截至2024年及2023年12月31日止年度，管理資本的目標、政策或程序並無變動。

本集團使用資本負債比率（即債務除以本公司股東應佔權益）監察資本。債務包括銀行借款。資本包括本公司股東應佔權益。截至報告期末的資本負債比率如下：

37. 比較金額

已重新分類及重列若干比較金額，以符合本年度的呈列方式。

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

38. STATEMENT OF FINANCIAL POSITION OF THE COMPANY

38. 本公司之財務狀況表

Information about the statement of financial position of the Company as at the end of the reporting period is as follows:

有關本公司於報告期末之財務狀況表之資料如下：

		2024 2024年 HK\$'000 千港元	2023 2023年 HK\$'000 千港元
NON-CURRENT ASSETS	非流動資產		
Plant and equipment	廠房及設備	28	51
Right-of-use assets	使用權資產	–	3,967
Investments in subsidiaries	於附屬公司之投資	296,281	296,281
Due from subsidiaries	應收附屬公司款項	167,773	234,056
Total non-current assets	非流動資產總值	464,082	534,355
CURRENT ASSETS	流動資產		
Deposits and other receivables	按金及其它應收款	2,324	2,218
Cash and bank balances	現金及銀行結餘	41,363	58,051
Total current assets	流動資產總值	43,687	60,269
CURRENT LIABILITIES	流動負債		
Other payables	其它應付款	2,044	2,691
Lease liabilities	租賃負債	60	4,300
Total current liabilities	流動負債總額	2,104	6,991
NET CURRENT ASSETS	流動資產淨值	41,583	53,278
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債	505,665	587,633
NON-CURRENT LIABILITIES	非流動負債		
Lease liabilities	租賃負債	–	60
NET ASSETS	資產淨值	505,665	587,573
EQUITY	權益		
Issued capital	已發行股本	215,004	215,004
Reserves (note)	儲備(附註)	290,661	372,569
TOTAL EQUITY	權益總額	505,665	587,573

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

綜合財務報表附註

31 December 2024 2024年12月31日

38. STATEMENT OF FINANCIAL POSITION OF THE COMPANY (continued)

Note: A summary of the Company's reserves is as follows:

38. 本公司之財務狀況表 (續)

附註：本公司儲備之概要如下：

		Share premium 股份溢價 HK\$'000 千港元	Capital redemption reserve 資本 贖回儲備 HK\$'000 千港元	Capital contribution reserve 資本 供款儲備 HK\$'000 千港元	Exchange fluctuation reserve 匯兌 波動儲備 HK\$'000 千港元	Retained profits/ (accumulated losses) 保留溢利/ (累計虧損) HK\$'000 千港元	Total 總額 HK\$'000 千港元
At 1 January 2023	於2023年1月1日	355,703	67	88,441	(36,523)	26,077	433,765
Loss for the year	本年度虧損	-	-	-	-	(54,129)	(54,129)
Exchange differences arising on translation of the Company's financial statements	換算本公司財務報表產生之匯兌差額	-	-	-	(1,477)	-	(1,477)
Total comprehensive loss for the year	本年度全面虧損總額	-	-	-	(1,477)	(54,129)	(55,606)
Final dividends for the nine months ended 31 December 2022 declared	已宣派截至2022年12月31日止九個月的末期股息	-	-	-	-	(5,590)	(5,590)
At 31 December 2023 and 1 January 2024	於2023年12月31日及2024年1月1日	355,703	67	88,441	(38,000)	(33,642)	372,569
Loss for the year	本年度虧損	-	-	-	-	(74,386)	(74,386)
Exchange difference arising on translation of the Company's financial statements	換算本公司財務報表產生之匯兌差額	-	-	-	(1,932)	-	(1,932)
Total comprehensive loss for the year	本年度全面虧損總額	-	-	-	(1,932)	(74,386)	(76,318)
Final dividends for the the year ended 31 December 2023 declared	已宣派截至2023年12月31日止年度的末期股息	(5,590)	-	-	-	-	(5,590)
At 31 December 2024	於2024年12月31日	350,113	67	88,441	(39,932)	(108,028)	290,661

39. APPROVAL OF THE FINANCIAL STATEMENTS

The financial statements were approved and authorised for issue by the board of directors on 28 March 2025.

39. 財務報表之批准

財務報表已於2025年3月28日獲董事會核准及批准刊發。

FINANCIAL SUMMARY

財務摘要

RESULTS

業績

		Year ended 31 March		Nine months ended 31 December	Year ended 31 December	
		截至3月31日止年度		截至12月31日止九個月	截至12月31日止年度	
		2021	2022	2022	2023	2024
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元
Revenue	收入	474,332	509,955	410,021	532,089	329,937
Loss before tax	除稅前虧損	(27,442)	(28,018)	(47,890)	(25,694)	(54,340)
Income tax credit/(expense)	所得稅抵免／(支出)	1,524	6,343	3,647	689	(7,074)
Loss for the period/year	本期間／年度虧損	(25,918)	(21,675)	(44,243)	(25,005)	(61,414)
Loss attributable to:	虧損歸屬於：					
Shareholders of the Company	本公司股東	(27,142)	(19,771)	(40,977)	(24,155)	(61,371)
Non-controlling interests	非控股權益	1,224	(1,904)	(3,266)	(850)	(43)
		(25,918)	(21,675)	(44,243)	(25,005)	(61,414)
		HK cents	HK cents	HK cents	HK cents	HK cents
		港仙	港仙	港仙	港仙	港仙
Loss per share	每股虧損	(1.26)	(0.92)	(1.91)	(1.12)	(2.85)

ASSETS AND LIABILITIES

資產及負債

		At 31 March		At 31 December		
		於3月31日		於12月31日		
		2021	2022	2022	2023	2024
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元	千港元
Total assets	資產總值	1,133,461	1,164,151	1,088,468	917,291	765,022
Total liabilities	負債總額	(342,966)	(375,076)	(434,226)	(325,350)	(259,357)
		790,495	789,075	654,242	591,941	505,665
Equity attributable to shareholders of the Company	本公司股東應佔權益	756,709	756,754	627,831	592,071	505,838
Non-controlling interests	非控股權益	33,786	32,321	26,411	(130)	(173)
		790,495	789,075	654,242	591,941	505,665

您的健康是天大的事
TIANDA FOR HEALTH

